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Mutations in the gene encoding the bone morphogenetic protein type 2 receptor (BMPR2) are 
the most common genetic cause of heritable pulmonary arterial hypertension (PAH). 
However, given the reduced penetrance of BMPR2 mutations in affected families, a major 
outstanding question is the identity of additional factors or pathways that are responsible for 
the manifestation of clinical disease. Furthermore, limited human tissue is available for study 
and usually only from patients with end-stage disease, making it difficult to understand how 
PAH is established and progresses. Alternative human models of PAH are therefore required. 
  
This thesis describes the characterisation of the first human iPSC-derived smooth muscle cell 
(iPSC-SMC) model of PAH and elucidates the role of BMPR2 deficiency in establishing 
PAH-associated phenotypes in iPSC-derived SMCs. To achieve this, I used CRISPR-Cas9 
gene editing to generate wild-type and BMPR2+/- iPSC lines with isogenic backgrounds which 
were subsequently differentiated into lineage-specific iPSC-SMCs that displayed a gene 
expression profile and responses to BMP signalling akin to those present in distal pulmonary 
artery smooth muscle cells (PASMCs).  
 
Using these cells, I found that the introduction of a single BMPR2 mutation in iPSC-SMCs 
was sufficient to recapitulate the pro-proliferative and anti-apoptotic phenotype of patient-
derived BMPR2+/- PASMCs. However, acquisition of the mitochondrial hyperpolarisation 
phenotype was enhanced by inflammatory signalling and required an interaction 
between BMPR2 mutations and environmental stimuli provided by exposure to serum over 
time. Furthermore, I showed that BMPR2+/- iPSC-SMCs had an altered differentiation state 
and were less contractile compared to wild-type iPSC-SMCs, phenotypes which have not 
been observed previously in PAH-derived PASMCs. Finally, RNA sequencing analysis 
identified genes that were differentially expressed between wild-type and BMPR2+/- iPSC-
SMCs and may hence provide further insights into PAH pathobiology. 
 
The iPSC-SMC model described in this study will be useful for identifying additional factors 
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1.1 – Pulmonary hypertension 
 
The term pulmonary hypertension (PH) describes a range of conditions that can be devastating 
and often fatal, characterised by high blood pressure in the pulmonary artery, with clinical 
symptoms including fatigue, dyspnea (shortness of breath) and presyncope/syncope 
(lightheadedness/fainting) (Lai et al., 2014). For a positive diagnosis of PH, the mean 
pulmonary arterial pressure (mPAP) at rest should be greater than or equal to 25 mm Hg as 
measured using right heart catheterisation (Hoeper et al., 2013a). 
 
1.1.1 – Classification of pulmonary hypertension 
 
Pulmonary hypertension is classified into five main categories based on the underlying cause, 
pathology and haemodynamic profile (Table 1.1): pulmonary arterial hypertension (PAH) 
(Group 1); pulmonary hypertension due to left heart disease (Group 2); pulmonary hypertension 
due to lung diseases and/or hypoxia (Group 3); chronic thromboembolic pulmonary 
hypertension (CTEPH) (Group 4); and pulmonary hypertension with unclear multifactorial 
mechanisms (Group 5) (Simonneau et al., 2013). Pulmonary veno-occlusive disease (PVOD) 
and/or pulmonary capillary hemangiomatosis (PCH), as well as persistent pulmonary 
hypertension of the newborn (PPHN), were previously classified as subcategories of PAH 
(Simonneau et al., 2009). However, because PVOD/PCH and PPHN are thought to carry more 
differences than similarities compared to other PAH subgroups, they are currently classified 
into distinct categories (Groups 1’ and 1”, respectively), although these are not completely 
separated from PAH (Simonneau et al., 2009; 2013). A modification of the existing 
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Table 1.1.  Classification of pulmonary hypertension (taken from Simonneau et al., 2013) 
 











Pulmonary arterial hypertension (PAH) 
1.1 Idiopathic PAH 
1.2 Heritable PAH 
1.2.1 BMPR2 
1.2.2 ALK1, ENG, SMAD9, CAV1, KCNK3 
1.2.3 Unknown 
1.3 Drug and toxin induced 
1.4 Associated with: 
1.4.1 Connective tissue disease 
1.4.2 HIV infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart diseases 
1.4.5 Schistosomiasis 
1’ Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis 





Pulmonary hypertension due to left heart disease 
2.1 Left ventricular systolic dysfunction 
2.2 Left ventricular diastolic dysfunction 
2.3 Valvular disease 







Pulmonary hypertension due to lung diseases and/or hypoxia 
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitude 
3.7 Developmental lung diseases 





Pulmonary hypertension with unclear multifactorial mechanisms 
5.1 Hematologic disorders: chronic haemolytic anaemia, myeloproliferative disorders, 
splenectomy 
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis 
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH  
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1.1.2 – Pulmonary arterial hypertension 
 
The term PAH describes a subgroup of PH patients characterised haemodynamically by having 
a pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg and a pulmonary vascular 
resistance (PVR) greater than 3 Wood units in the absence of left heart disease, lung diseases, 
CTEPH or other rare diseases (Hoeper et al., 2013a). PAH can be classified as being either 
idiopathic (IPAH, where the cause of the disease is unknown), heritable (HPAH, defined as 
present in at least two members of the same family or by the presence of a pathogenic mutation), 
drug- and toxin-induced, or associated with other conditions such as human immunodeficiency 
virus (HIV) infection, congenital heart disease, connective tissue disease, or schistosomiasis 
(Table 1.1) (Simonneau et al., 2013).  
 
In the Western world, IPAH is thought to be the most common form of PAH (30 – 50% of PAH 
cases), whereas HPAH patients with a family history of the disease account for approximately 
6% of PAH cases (Lane et al., 2000; Humbert et al., 2006; Badesch et al., 2010).    
The incidence of PAH is estimated to be between 2.0 and 7.6 cases per million adults per year, 
with a prevalence ranging from 11 to 26 cases per million adults (Humbert et al., 2006; Peacock 
et al., 2007; Badesch et al., 2010; Ling et al., 2012). In patient registries (Table 1.2), PAH is 
approximately twice as common in females than in males and is increasingly being diagnosed 
in older patients (Simonneau et al., 2009; Hoeper and Gibbs, 2014). Symptoms may develop at 
any age, with an estimated 5-year mortality rate of 30% (Humbert et al., 2006; Badesch et al., 
2010).  
 
Currently available therapies target three main signalling pathways which play a key role in 
regulating vascular cell proliferation and pulmonary vascular tone (Humbert et al., 2014; 
Humbert & Ghofrani, 2016; Lau et al., 2017). Prostaglandin analogues such as iloprost 
(Olschewski et al., 2002) and the prostacyclin IP receptor agonist selexipag (Sitbon et al., 2015) 
target the prostacyclin pathway, stimulating the production of cyclic adenosine monophosphate 
(cAMP) which induces vadodilation (Murray, 1990). Phosphodiesterase type V inhibitors such 
as sildenafil and the soluble guanylate cyclase stimulator riociguat target the nitric oxide 
signalling pathway, promoting vasodilation by boosting the levels of cyclic guanosine 
monophosphate (cGMP) (Galie et al., 2005; Ghofrani et al., 2013). By contrast, endothelin-1 
receptor antagonists such as bosentan reduce vasoconstriction by targeting endothelin receptors 
(Rubin et al., 2002). However, although these therapies have contributed to improved life 
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expectancy, they probably do not change the underlying pathology. Patients with end-stage 
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1.1.3 – Cellular phenotypes associated with pulmonary arterial hypertension 
 
At the cellular level, pulmonary arterial hypertension is characterised by extensive vascular 
remodelling due to abnormal proliferation, migration and apoptosis of pulmonary artery smooth 
muscle cells (PASMCs), endothelial cells (ECs), and pulmonary artery adventitial fibroblasts 
(PAAFs) (Humbert et al., 2004) (Figure 1.1). During this process, abnormal ECs may release 
factors such as fibroblast growth factor 2 (FGF-2) which promote smooth muscle cell (SMC) 
proliferation or fail to produce agents which inhibit SMC proliferation and induce vasodilation 
(Thompson & Rabinovitch, 1996; Alastalo et al., 2011; Lai et al., 2014). Increased EC apoptosis 
during the early stages of PAH is thought to lead to a loss of smaller pulmonary arteries, whilst 
SMC dedifferentiation, migration, proliferation and clonal expansion result in progressive 
muscularisation of normally non-muscularised distal pulmonary vessels (Rabinovitch, 2008; 




Figure 1.1. Vascular remodelling in pulmonary arterial hypertension. Vascular remodelling is 
characterised by increased proliferation of smooth muscle cells, endothelial cells and fibroblasts within 
the pulmonary artery which causes narrowing of the vascular lumen, thus impeding blood flow and 
resulting in elevated pulmonary arterial pressure. AEC, alveolar epithelial cell (from Schermuly et al., 
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Furthermore, PAH is associated with metabolic dysfunction such as increased glycolysis and 
mitochondrial abnormalities such hyperpolarisation of the inner mitochondrial membrane 
(Paulin & Michelakis, 2014). In addition, increased elastase and matrix metalloproteinase 
(MMP) activity lead to extracellular matrix degradation and fragmentation of the internal elastic 
lamina (Rabinovitch, 2001; Zaidi et al., 2002; Tuder et al., 2013), whilst platelet activation and 
in situ thrombus formation further obstruct blood flow within pulmonary vessels (Lannan et al., 
2014). Complex, lumen-obliterating plexiform lesions are often found in patients with end-
stage PAH (Tuder et al., 1994) (Figure 1.2). Taken together, these changes ultimately lead to 
the development of right heart failure, which may further be accelerated by increased 




Figure 1.2. Photomicrographs of lung sections from PAH patients showing the histological 
appearance of plexiform lesions. (A) Plexiform lesions immunostained for the endothelial marker 
CD31 on a single layer of cells lining endothelial channels (arrows) (B) Stromal cells stain positively 
for a-smooth muscle actin (brown). Images taken at approximately 200x magnification (from Atkinson 
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1.1.4 – The genetic basis of pulmonary arterial hypertension 
 
In the year 2000, heterozygous germline mutations in the bone morphogenetic protein receptor 
type 2 (BMPR2) gene were identified as the main genetic cause of heritable PAH (Deng et al., 
2000; Lane et al., 2000). Although mutations in several other genes have also been detected in 
PAH patients (Table 1.3), these are estimated to be present in approximately 8% of PAH cases 
(Gräf et al., 2018). Furthermore, the observation that BMPR2 protein expression is reduced in 
most PAH patients regardless of whether they have BMPR2 mutations (Atkinson et al., 2002) 
highlights the central role of BMPR2 signalling in the pathogenesis of PAH. 
 
To date, over 400 different PAH-associated BMPR2 mutations have been identified, of which 
over 75% were detected in families with PAH (Soubrier et al., 2013; Best et al., 2014; Machado 
et al., 2015). PAH-associated BMPR2 mutations have been detected in almost all exons within 
the gene, including the ligand binding domain, the serine-threonine kinase domain and the 
cytoplasmic tail (Machado et al., 2006). Approximately 70% of BMPR2 mutations are nonsense 
or frame-shift mutations which cause haploinsufficiency due to degradation of the mutant 
transcripts by nonsense-mediated mRNA decay, whereas the remaining 30% result in impaired 
BMPR2 trafficking to the plasma membrane or have reduced kinase activity (Machado et al., 
2006).  
 
Although BMPR2 mutations are present in approximately 82% of HPAH patients (Evans et al., 
2016), only approximately 20% of people carrying BMPR2 mutations go on to develop the 
disease, meaning there may be no history of disease in multiple generations within affected 
families (Lai et al., 2014). Moreover, penetrance of BMPR2 mutations is higher in females than 
in males, with 43% of female versus 14% of male BMPR2 mutation carriers developing PAH 
during their lifetime (Larkin et al., 2012). In addition, BMPR2 expression in HPAH patients is 
considerably lower than the 50% reduction expected due to haploinsufficiency alone (Atkinson 
et al., 2002). Together with the reduced penetrance of BMPR2 mutations, this suggests that 
additional environmental or genetic ‘second hits’ are required to further reduce BMPR2 
expression or signalling to a level that is sufficient to initiate the development of PAH (Morrell 
et al., 2009). However, a major unaddressed question is precisely how reduced BMPR2 
signalling, either alone or via interaction with ‘second hits’, contributes to the development and 
progression of PAH.        
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1.2 – Bone morphogenetic protein signalling 
 
1.2.1 – Bone morphogenetic proteins 
 
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor b (TGF-
b) superfamily of ligands. Originally identified as proteins that induce bone and cartilage 
formation (Urist, 1965; Wang et al., 1988), it is now evident that BMPs also play important 
roles in regulating many other biological functions including morphogenesis, cell 
differentiation, proliferation, and apoptosis (Katagiri & Watabe, 2016). To date, over twenty 
different BMP isoforms have been identified (Bragdon et al., 2011) (Table 1.4). They have 
highly conserved structures that are shared by other members of the TGF-b family, and can be 
classified into several sub-groups, including the BMP-2/4 group, BMP-5/6/7/8 group, BMP-
9/10 group and BMP12/13/14 group (Bubnoff & Cho, 2001; Mazerbourg & Hsueh, 2006). 
BMP-1 is a metalloproteinase which cleaves the C-terminus of type I collagen and is therefore 







BMP family member 
 
 
Tissue expression in humans 
 





Lung, kidney, pancreas, spleen 
 








Heart, lung, skeletal muscle, thymus, 
bone marrow, spleen, brain, spinal 
cord, liver, kidney, pancreas, prostate 
 
 
Skeletal repair and regeneration, 
kidney formation 






Heart, lung, skeletal muscle, thymus, 
bone marrow, spleen, brain, spinal 
cord, kidney, pancreas, prostate 
 
 
Bone and cartilage morphogenesis, 







Heart, lung, skeletal muscle, liver, 
kidney, thymus, bone marrow, 




Bone morphogenesis, nervous 







Heart, lung, skeletal muscle, liver, 
kidney, thymus, bone marrow, 




Skeletal repair and regeneration, 
nervous system development, 
kidney and eye formation 








Heart, lung, kidney, thymus, bone 











Heart, skeletal muscle, bone marrow, 












Bone morphogenesis, glucose 
metabolism, anti-angiogenesis, 








Heart, lung, skeletal muscle, liver, 
thymus, bone marrow, spleen, brain, 









Thymus, bone marrow, spleen, brain, 
spinal cord, pancreas 
 
 
Patterning mesodermal and neural 
tissues, dentin formation 










Ligament and tendon development, 








Skeletal morphogenesis, normal 







Heart, bone marrow, liver, kidney 
 
Skeletal repair and regeneration 







Oocyte and follicular development 





Heart, skeletal muscle, thymus, bone 




Negative regulator of bone 
morphogenesis 
 
BMP3B (GDF-10)  
 
 




Regulation of cell differentiation, 
skeletal morphogenesis 
 
Table 1.4.  Overview of bone morphogenetic proteins, their functions and expression (adapted 
from Bragdon et al., 2011) 
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Most BMPs are expressed in a variety of tissues during development, where they often play 
crucial roles, as evidenced by the embryonic lethal phenotype of knock-out animals that are 
homozygous for null mutations in BMPs 2, 4, 8b and 10 (Winnier, 1995; Zhang & Bradley, 
1996; Zhao & Hogan, 1996; Chen et al., 2004). The embryonic lethal phenotype of these 
animals therefore suggests that these bone morphogenetic proteins are necessary for 
development, including vascular development.  
 
1.2.2 – Bone morphogenetic protein receptor signalling 
 
BMPs elicit their effects by binding to type I and type II transmembrane receptors (Shi & 
Massague, 2003; de Caestecker, 2004) (Figure 1.3), which consist of a short extracellular 
domain, a single transmembrane domain, one intracellular domain with serine/threonine kinase 
activity and a C-terminal cytoplasmic tail region (Miyazono et al., 2010). Unlike TGF-b 
proteins, BMPs can bind to type I receptors in the absence of type II receptors, although their 
binding affinities are higher when both receptor types are present (Rosenzweig et al., 1995).  
 
There are three type II receptors - bone morphogenetic protein receptor type II (BMPR2), 
activin receptor type IIA (ActR-IIA) and activin receptor type IIB (ActRIIB). BMPR2 
specifically binds BMPs, whereas ActR-IIA and ActRIIB also act as receptors for activin and 
myostatin (Yu et al., 2005). Activin receptor-like kinases ALK1, ALK2, ALK3 (BMPR-1A) 
and ALK6 (BMPR-1B) serve as type I receptors for most BMPs, whereas TGF-b signals via 
ALK5 (Shi & Massague, 2003). Whilst ALK2 and ALK3 are expressed in many different cell 
types, ALK6 is less widely expressed, and ALK1 is mainly expressed in endothelial cells and 









Figure 1.3. Overview of bone morphogenetic protein receptor signalling. Activators of BMP 
signalling are listed in the blue box, whereas BMP signalling inhibitors are shown in red boxes. BMP, 
bone morphogenetic protein; ALK, activin receptor-like kinase; BMPR; bone morphogenetic protein 
receptor; ActR, activin receptor; BMPER, BMP binding endothelial regulator; BAMBI, BMP and 
activin membrane bound inhibitor; KCP, kielin/chordin-like protein.  
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BMP2 and BMP4 bind to ALK3 and ALK6, recruiting type II receptors to form an active 
receptor complex (ten Dijke et al., 1994; Macias-Silva et al., 1998). By contrast, BMP6 and 
BMP7 bind to ActR-IIA in a complex with ALK2 or ALK3 (ten Dijke et al., 1994; Yamashita 
et al., 1995; Ebisawa et al., 1999). BMP9 and BMP10 bind to BMPR2 together with ALK1 or 
ALK2 (Brown et al., 2005; David et al., 2007), but can also signal via ActR-IIA or endoglin, a 
co-receptor for TGF-b/BMP signalling (Alt et al., 2012). These signalling combinations are 





Figure 1.4. Summary of interactions between BMP and TGF-b proteins and their receptors. 
Different receptor complexes preferentially bind particular BMP ligands, with TGF-b1 and activin 
predominantly signalling via Smad2/3, whereas bone morphogenetic proteins mainly signal via 
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Upon binding of the BMP ligand, type II receptors phosphorylate and activate type I receptors. 
In turn, the activated type I receptor phosphorylates at least one of the receptor-regulated Smads 
(Smad1, Smad5 and Smad8). These BMP-specific R-Smads are then able to form a complex 
with the co-Smad, Smad4, followed by translocation of the resulting Smad complex to the 
nucleus where it can activate or inhibit gene transcription by binding to DNA and interacting 
with transcriptional co-activators (p300, CBP, Runx2, and/or GCN5) or co-repressors (c-Ski, 
SnoN, Tob or SIP1) (Shi and Massague, 2003; Massague et al., 2005; Katagiri & Watabe, 
2016). By contrast, TGF-b ligands signal via Smad2 and Smad3, although TGF-b can also 
signal via ALK1 and ALK2 to activate Smad1 and Smad5 in endothelial cells and some other 
cells (Goumans et al., 2003; Daly et al., 2008). 
 
Downstream targets of BMPR2 signalling include the inhibitor of DNA binding/differentiation 
(ID) proteins which control PASMC proliferation by inhibiting the cell cycle (Yang et al., 
2013), as well as the transcription factors Hey1 and Tcf7 which are involved in Notch and Wnt 
signalling, respectively (Miyazono et al., 2010).  
 
1.2.2.1 – Regulation of BMP signalling 
 
BMP signalling is temporally and spatially regulated at multiple levels via interactions with 
many different intracellular and extracellular signals (Shi & Massague, 2003; Guo & Wang, 
2009) (Figure 1.3). Extracellular BMP antagonists include gremlin, noggin, chordin, follistatin 
and differential screening-selected gene in neuroblastoma (DAN) family members (Katagiri & 
Watabe, 2016), some of which can be up-regulated by BMPs, thus forming negative feedback 
loops (Kameda et al., 1999; Pereira et al., 2000). By contrast, BMP1, kielin/chordin-like protein 
(KCP) and BMP binding endothelial regulator (BMPER) can potentiate BMP signalling 
(Marques et al., 1997; Piccolo et al., 1997; Moser et al., 2003). 
 
At the cell membrane, BMP signalling is inhibited by BAMBI (BMP and activin membrane-
bound inhibitor), which prevents the formation of signal receptor complexes. On the other hand, 
glycosylphosphatidylinositol (GPI)-anchored membrane proteins of the repulsive guidance 
molecule (RGM) family enhance BMP signalling by forming complexes with BMP type I 
receptors (Halbrooks et al., 2007).  
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Intracellularly, Smad6 and Smad7 act as inhibitory Smads by binding to BMP type I receptors, 
thus preventing downstream Smad1/5 activation, thereby negatively regulating BMP signalling 
(Imamura et al., 1997; Heldin & Moustakas, 2012). 
Furthermore, BMP signalling is modulated by ubiquitin-mediated proteasomal degradation of 
Smad1 and Smad5 by the E3 ubiquitin ligase Smurf1, which also interacts with Smad6 to 
mediate degradation of type I BMP receptors (Zhu et al., 1999; Murakami et al., 2003). 
Additional regulation of BMP signalling is achieved by several different microRNAs 
(miRNAs) such as miR-21 and miR-302 (Ahmed et al., 2011; Kang et al., 2012), as well as by 
proteins such as the 12-kDa FK506-binding protein (FKBP12) which binds to and inhibits the 
activation of type I BMP receptors (Spiekerkoetter et al., 2013).   
 
1.2.3 – Cross-talk of BMP signalling with other signalling pathways 
 
In addition to signalling via the Smad-dependent pathways described above, BMPs can also 
signal via mitogen-activated protein kinases (MAPKs), Akt, phosphatidylinositol 3-kinase 
(PI3K), c-Jun amino-terminal kinase (JNK), and small GTPases. These Smad-independent 
pathways interact with Smad-dependent pathways to modulate various cellular responses 
(Katagiri & Watabe, 2016). For example, interactions between TGF-b/BMP, Notch, Wnt, 
Hedgehog (Hh) and other signalling pathways (Figure 1.5) regulate stem cell maintenance, 
organogenesis, and cell fate specification during embryonic development, whilst also being 
important for modulating cell growth in adult tissues (Attisano & Labbe, 2004; Sumi et al., 
2008). Dysregulated Notch and Wnt signalling have also been implicated in pulmonary arterial 
hypertension, as discussed below. 
 





Figure 1.5. Simplified schematic summarising some of the main interactions between the Notch, 
Wnt and TGF-b/BMP signalling pathways. Cross-talk between the TGF-b and Notch signalling 
pathways most commonly occurs in the nucleus where the Smad/b-catenin-Lef protein complex 
regulates the transcription of a shared set of target genes. Multiple context-specific protein interactions 
(dashed black lines) between Notch, Wnt and TGF-b signalling also occur in the cell cytoplasm. Dvl, 
Dishevelled; GSK3b, glycogen synthase kinase-3 beta; APC, adenomatous polyposis coli; NICD, Notch 
intracellular domain; TGF-b, transforming growth factor beta; BMP, bone morphogenetic protein; Lef, 
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1.2.3.1 – Wnt signalling in pulmonary arterial hypertension 
 
Wnt proteins are secreted molecules which signal via canonical and non-canonical pathways to 
regulate a variety of biological functions. The canonical pathway involves Wnt signalling via 
cytoplasmic b-catenin, which can translocate to the nucleus to regulate the expression of genes 
involved in processes such as cell proliferation, differentiation and survival (Papkoff et al., 
1996). By contrast, the non-canonical Wnt/planar cell polarity (PCP) pathway does not require 
b-catenin accumulation and regulates more specialised functions such as cell motility and 
polarity (Shulman et al., 1998; Veeman et al., 2003). 
Several genes involved in the PCP pathway, such as those encoding ras homolog gene family 
A (RHOA), WNT11, and Dishevelled (DVL), were found to be upregulated in laser-
microdissected pulmonary arterial resistance vessels from patients with IPAH (Laumanns et 
al., 2009). Furthermore, overexpression of the soluble Wnt receptor Secreted Frizzled Related 
Protein 2 (SFRP2) was detected in HPAH patient-derived fibroblasts and lung tissue, as well 
as in the lungs of R899X Bmpr2+/- mice (West et al., 2014). Taken together, these findings 
suggest that reduced BMPR2 signalling in PAH is associated with increased Wnt signalling, 
which may contribute to increased proliferation and migration of pulmonary vascular cells in 
PAH (de Jesus Perez et al., 2009; Takahashi et al., 2016). However, whether this is indeed the 
case is yet to be confirmed.    
 
1.2.3.2 – Notch signalling in pulmonary arterial hypertension 
 
To date, four different Notch receptors (Notch1 – Notch4) and five cell-bound Notch ligands 
of the Jagged (Jag1 and Jag2) and Delta-like (Dll1, Dll3 and Dll4)) families have been 
characterised in mammals (Alva & Iruela-Arispe, 2004). Aberrant Notch signalling has also 
been implicated in the pathogenesis of PAH, although there is controversy as to whether this is 
due to changes in Notch2 or Notch3 expression (Li et al., 2009; Xiao et al., 2013; Yu et al., 
2013; Hurst et al., 2017). For example, Notch1, Notch3 and Jagged 1 were found to be highly 
expressed in animal models of PAH, whilst adenoviral transfection of soluble Jagged 1 (sJag1) 
resulted in significantly reduced proliferation and increased apoptosis of PASMCs from 
pulmonary hypertensive rats (Xiao et al., 2013). Similarly, increased Notch3 expression has 
also been detected in human patient-derived PASMCs (Li et al., 2009); however, Notch3 and 
its downstream target HES1 were found to be decreased in tumour necrosis factor-alpha 
(TNFa)-treated HPAH PASMCs (Hurst et al., 2017). Interestingly, Hurst et al. found that 
TNFa stimulation in HPAH PASMCs induced post-translational cleavage and shedding of 
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BMPR2 at the cell surface, thus diverting BMP signalling via ActR-IIA which promoted 
PASMC proliferation via downstream activation of Notch2 and Src kinases (Hurst et al., 2017). 
This suggests that Notch2 rather than Notch3 signalling contributes to the increased 
proliferation of PASMCs observed in PAH. 
 
1.2.4 – Bone morphogenetic protein signalling in vascular smooth muscle cells 
 
In the lung, BMPR2 is predominantly expressed in pulmonary artery endothelial cells (PAECs) 
and PASMCs (Atkinson et al., 2002). Under normal conditions, BMP2, BMP4 and BMP7 
inhibit the proliferation of vascular smooth muscle cells isolated from the proximal pulmonary 
artery (Farber & Loscalzo, 2004). Disruption of BMPR2 signalling in these cells results in the 
loss of the anti-proliferative effects of BMP4, reduced BMP6 and BMP7 signalling, as well as 
increased PASMC proliferation in response to TGF-b1 (Yu et al., 2005; Dewachter et al., 2009). 
Furthermore, depending on their anatomical and potentially also their developmental origin, 
adult PASMCs may have different responses to the same BMP molecules. For example, 
PASMCs in the proximal vascular branch tend to be growth-suppressed by BMPs 2, 4 and 7 
and may even undergo apoptosis in response to these ligands, whereas BMP2 and BMP4 
stimulate proliferation in PASMCs isolated from smaller pulmonary arteries in the distal 
vascular branches (Yang et al., 2005). This difference in BMP responsiveness between 
proximal and distal PASMCs is an important consideration for developing disease models and 
PAH therapies, as it is predominantly the smaller, more distal vessels that are the site of disease 
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1.3 – Molecular pathogenesis of pulmonary arterial hypertension 
 
1.3.1 – Hypoxia and PAH 
 
The acute response of the pulmonary vasculature to hypoxia involves the constriction of 
precapillary pulmonary arteries in a process known as hypoxic pulmonary vasoconstriction 
(HPV) (von Euler & Liljestrand, 1946) which increases pulmonary vascular resistance and 
pulmonary arterial pressure. By contrast, chronic exposure to hypoxia leads to vascular 
remodelling characterised by the muscularisation of previously non-muscularised pulmonary 
arteries, an increase in the extent of muscularisation of already muscularised arteries, and the 
pruning of smaller peripheral arteries (Arias-Stella & Saldana, 1963; Hislop & Reid, 1976; 
Stenmark et al., 2006). At the cellular level, these structural changes are caused by increased 
proliferation and reduced apoptosis of PASMCs which has been linked to increased expression 
of hypoxia inducible factor-1alpha (HIF-1a) (Ball et al., 2014). 
 
The amount of pulmonary vascular remodelling in response to chronic hypoxia varies both 
between and within species (Grünig et al., 2000; Zhao et al., 2001; Rhodes, 2005; Swenson, 
2013), suggesting that susceptibility to hypoxia-induced pulmonary hypertension is affected by 
genetic background. For example, Tibetan highlanders are less prone to develop pulmonary 
hypertension compared to more recent migrants to high altitude, partly due to natural selection 
of non-coding variants of the HIF pathway genes EPAS1 and EGLN1 (Beall et al., 2010; 
Simonson et al., 2010). Furthermore, Bmpr2+/- mice might be more susceptible to hypoxia-
induced PH compared to wild-type mice (Frank et al., 2008). However, previous work from our 
group has shown that Bmpr2+/- mice exposed to chronic hypoxia for 2-3 weeks display similar 
pulmonary haemodynamics and vascular morphometry compared to wild-type littermates 
(Long et al., 2006). By comparison, targeted delivery of an adenoviral vector containing the 
Bmpr2 gene to the pulmonary vascular endothelium of hypoxic rats significantly reduced 
pulmonary arterial and right ventricular (RV) pressures, RV hypertrophy and muscularisation 
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However, in most forms of human hypoxic PH [World Health Organisation (WHO) Group 3], 
the pathological changes are less severe compared to those found in PAH patients with BMPR2 
mutations (Pugliese et al., 2015). In contrast to Group 3 pulmonary hypertension in which 
hypoxia is the primary stimulus, PAH is characterised by the normoxic activation of HIF-1a 
signalling in the absence of alveolar hypoxia (Bonnet et al., 2006), although cellular hypoxia 
may contribute to pulmonary vascular remodelling as the disease progresses (Farber & 
Loscalzo, 2005). 
 
1.3.2 – Inflammation and metabolic dysfunction in PAH 
 
Immune dysfunction is a central feature of PAH associated with connective tissue diseases and 
infections, with schistosomiasis probably being the single largest cause of PAH (Graham et al., 
2010; Rabinovitch et al., 2014). In patients with pulmonary hypertension, inflammation is also 
an early consequence of exposure to hypoxia and is one of the proposed “second hits” that are 
thought to be required to trigger PAH establishment and progression (Rabinovitch et al., 2014). 
Hypoxia may promote inflammation by inducing the transcription of HIF target genes such as 
nuclear factor kappaB (NF-κB), a transcription factor which regulates the production of 
inflammatory cytokines (Cummins et al., 2016). In turn, activation of NF-κB can increase HIF 
expression (Eltzschig & Carmeliet, 2011; Fröhlich et al., 2013), thus creating a potential 













Figure 1.6. Signalling crosstalk between inflammation and hypoxia. In addition to increasing HIF 
protein expression, hypoxia also induces the production of inflammatory cytokines which activate 
nuclear factor kappaB (NF-κB), a key transcriptional regulator of cellular immune responses. In turn, 
NF-κB promotes the transcription of HIF-1a, thus creating a potential feedforward loop between 
hypoxia, HIF and inflammation. Inflammation also promotes the production of immunometabolites, 
gasotransmitters such as hydrogen sulphide (H2S) and nitric oxide (NO), and reactive oxygen species 
(ROS) which regulate HIF activity and metabolic processes in immune cells. CREB, cyclic AMP-
response element binding protein; FIH, factor inhibiting HIF; p300, histone acetyltransferase p300; 
PHD, prolyl hydroxylase domain (from Taylor & Colgan, 2017). 
 
Furthermore, HIF can also modulate inflammatory immune responses by controlling cellular 
metabolism (Corcoran & O’Neill, 2016). For example, HIF expression can promote glycolysis 
by increasing the transcription of glycolytic genes (Semenza et al., 1994), which in turn can 
activate a number of immune cell types such as macrophages, dendritic cells, T cells and B cells 
(Corcoran & O’Neill, 2016). Conversely, inflammatory cytokines and ROS influence the 
activity of the HIF pathway, resulting in complex crosstalk between hypoxia, inflammation and 
metabolism (Halligan et al., 2016).  
 
Such crosstalk is evident in pulmonary arterial hypertension, where hypoxia increases IL-6 
expression in human PASMCs (Savale et al., 2009) and a range of pro-inflammatory cytokines 
and chemokines in pulmonary adventitial fibroblasts (Li et al., 2011). Consistent with these 
observations, increased levels of IL-1b, IL-6, IL-8 and TNFa are detected in IPAH patients 
(Humbert et al., 1995; Soon et al., 2010), with increased levels of several of these cytokines 
correlating with increased mortality (Cracowski et al., 2014). 
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Furthermore, prolonged exposure to hypoxia may impair mitochondrial function (Ye et al., 
2016) and increase oxidative stress (Takahashi et al., 2006), which might further exacerbate 
inflammation. Cytokines and HIF-1a are thought to contribute to the hyperglycolytic 
phenotype of PASMCs and pulmonary artery endothelial cells (PAECs) in PAH, even in the 
absence of alveolar hypoxia (Archer et al., 2010). In support of this concept, the pyruvate 
dehydrogenase kinase inhibitor dichloroacetate (DCA) reduced glycolysis and reversed the 
activation of HIF-1a in Fawn-hooded rats which spontaneously develop pulmonary 
hypertension (Bonnet et al., 2006). Taken together, these findings suggest that hypoxic 
signalling and inflammation contribute to the metabolic dysfunction associated with PAH. 
 
The hyperglycolytic phenotype of the vasculature in PH has been compared the phenotype of 
cancer cells which display a metabolic shift from glucose oxidation to glycolysis under aerobic 
conditions (Archer et al., 2010; Tuder et al., 2013). This phenomenon, termed “the Warburg 
effect”, has been observed in SMCs, ECs and fibroblasts from PAH patients and animal models 
of PH (Freund-Michel et al., 2014; Paulin & Michelakis, 2014), and is associated with a more 
highly proliferative phenotype, apoptosis resistance, increased mitochondrial membrane 
polarisation, dysregulation of calcium dynamics and endoplasmic reticulum (ER) stress 
(Michelakis et al., 2002; Vander Heiden et al., 2009; Archer et al., 2010; Semenza, 2011; 
Stenmark et al., 2011; Fessel et al., 2013).  
 
The anti-apoptotic phenotype of PASMCs in PAH can be partially attributed to a failure of pro-
apoptotic mediators to be released from mitochondria via the mitochondrial permeability 
transition pore (MPTP), a voltage- and redox-sensitive channel that closes when the inner 
mitochondrial membrane becomes hyperpolarised (Zamzami et al., 1996; Zamzami & 
Kroemer, 2001; Pastorino et al., 2005). The glycolytic phenotype of PAH has been linked to 
increased activity of the glycolytic enzyme hexokinase 2, which inhibits a portion of the MPTP 
known as the voltage-dependent anion channel (VDAC) (Pastorino et al., 2005). Inhibition of 
the VDAC results in the accumulation of anions within the intermembrane space, thus leading 
to mitochondrial membrane hyperpolarisation, which further prevents MPTP opening and 
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Mitochondrial membrane hyperpolarisation has been reported in PASMCs from PAH patients 
and in animal models of PH (McMurtry et al., 2004; Bonnet et al., 2006; Sutendra et al., 2011; 
Dromparis et al., 2013; Pak et al., 2013), as well as in BMPR2+/- PAECs which also display 
mitochondrial fission, increased glycolysis and a pro-inflammatory state characterised by 
increased expression of IL-6 and IL-8 (Diebold et al., 2015). Under certain conditions, these 
changes may result in the increased production of reactive oxygen species (ROS) which are 
thought to promote PASMC proliferation (Sanders & Hoidal, 2007), vascular remodelling (Liu 
et al., 2006; Hoshikawa et al., 2001) and contribute to pulmonary vasoconstriction or 
vasodilation (Archer et al., 1986, 2008). However, whether mitochondrial ROS is increased or 
decreased in PAH remains controversial (Aggarwal et al., 2013; Bonnet & Boucherat, 2018). 
  
Furthermore, it is also unclear whether reduction in BMPR2 promotes inflammation directly, 
or whether inflammatory events precede the development of pulmonary hypertension. TNFa 
reduces BMPR2 expression in distal PASMCs and PAECs, stimulates the proliferation of 
BMPR2+/- PASMCs via preferential ActR-IIA signalling, and can promote endothelial cell 
apoptosis (Courboulin et al., 2011; Cracowski et al., 2014; Hurst et al., 2017). The soluble 
TNFa inhibitor etanercept reversed PH progression in rats, which was associated with restored 
Bmpr2 expression (Zhang et al., 2016; Hurst et al., 2017). Similarly, the immunosuppressant 
FK506 (Tacrolimus) restored BMPR2 signalling and reversed severe PH in rats (Spiekerkoetter 
et al., 2013). Taken together, these findings suggest that inflammation contributes to the 
pathogenesis of PAH by reducing BMPR2 expression.  
 
Currently available PAH therapies in humans have been shown to reduce inflammation by 
decreasing the expression of endothelial cell adhesion molecules (Verma et al., 2002; Zardi et 
al., 2005), inhibiting pro-inflammatory cytokine secretion (Finsnes et al., 2001; Zhou et al., 
2007) and by preventing the activation of lymphocytes and dendritic cells (Guruli et al., 2004). 
However, none of these therapeutics specifically target inflammation, and immunosuppression 
per se does not appear to be effective at treating PAH in humans, except in isolated cases where 
PAH has been linked to connective tissue diseases (Jais et al., 2008). This suggests that 
inflammation on its own is not sufficient to initiate the development of pulmonary hypertension 
and that multiple signalling pathways will need to be targeted to develop more effective 
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1.3.3 – Animal models of pulmonary hypertension 
 
Studying the role of inflammation, hypoxia and metabolic dysfunction in diseased human 
tissues from PAH patients is hampered by their limited availability. As PAH is a rare disease, 
these tissues can only be obtained from patients at the time of heart/lung transplantation. 
Furthermore, patient-derived primary cells have a limited proliferative capacity in vitro, 
meaning that repeated biopsies are often required to study individual mutations. As a result, 
several rodent models of PAH have been developed in an attempt to gain a better understanding 
of the molecular pathogenesis of PAH, as described below. 
 
1.3.3.1 – Monocrotaline injury   
 
Monocrotaline injury in rats is the most commonly used animal model of Group 1 pulmonary 
arterial hypertension (Sztuka & Jasinska-Stroschein, 2017). A single subcutaneous or 
intraperitoneal injection (typically 60 mg/kg) of the pyrrolizidine alkaloid monocrotaline 
(MCT) is sufficient to trigger progressive development of severe PH in rats (Lalich & Mercow, 
1961; Kay et al., 1967). Although the exact mechanism through which MCT triggers PH 
development is poorly understood, it is thought to involve direct damage to the endothelium 
(Jasmin et al., 2001). Rats appear normal during the first two weeks after MCT injection, but 
subsequently develop muscularisation of previously non-muscularised arteries and adventitial 
remodelling which leads to an increase in pulmonary vascular resistance (Pak et al., 2010). 
Furthermore, metabolomic profiling of rat lungs after 14 days of exposure to monocrotaline 
revealed metabolic changes similar to those associated with human PH (Rafikova et al., 2016). 
Taken together, monocrotaline causes right ventricular systolic pressure (RVSP) to increase 
from approximately 25 to 80 mm Hg, with rats dying due to right heart failure after 6-8 weeks 
(Schermuly et al., 2005; Pak et al., 2010).    
 
The MCT model of PH is associated with the accumulation of many inflammatory cell types 
and is therefore useful for studying the contribution of inflammation to pulmonary vascular 
remodelling (West & Hemnes, 2011). Furthermore, MCT-induced PH has been widely used as 
a preclinical model of PAH to test potential therapeutic agents, with over 30 compounds shown 
to be effective at preventing or reversing monocrotaline-induced pulmonary hypertension 
(Stenmark et al., 2009). However, only a few of these experimental agents went on to be tested 
in human subjects (Hill et al., 2017).  
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There are multiple reasons why the MCT model of PH is poor at predicting treatment outcomes 
in any human form of pulmonary hypertension. For example, monocrotaline injury does not 
recapitulate the neointima formation and vascular obliteration of small pulmonary arterioles 
that is observed in human PAH (Yi et al., 2000). Furthermore, PAH is not caused by a single 
trigger and develops more slowly compared to the rapid disease progression observed in MCT-
induced PH (Hill et al., 2017). In addition, monocrotaline may cause off-targets effects such as 
myocarditis, which is not normally observed in human PAH, thus potentially confounding the 
study of right ventricular hypertrophy commonly associated with end-stage disease (Miyauchi 
et al., 1993). Monocrotaline can also have different effects in different species, strains and even 
individual animals due to differences in its hepatic metabolism by cytochrome P450 enzymes 
(reviewed in Stenmark et al., 2009). Futhermore, monocrotaline may damage the liver by 
causing hepatic veno-occlusive disease which is not normally observed in PAH and may hence 
confound the study of PAH-associated phenotypes in MCT rats (Roth et al., 1981; DeLeve et 
al., 1999).  
 
1.3.3.2 – Chronic hypoxia 
 
Unlike monocrotaline, chronic hypoxia is a physiological stimulus that can lead to or accelerate 
the development of pulmonary hypertension in humans (Vender, 1994). Chronic hypoxia is a 
model of Group 3 pulmonary hypertension and usually involves exposing mice and rats to 
normobaric or hypobaric hypoxia for 2 to 4 weeks (West & Hemnes, 2011). The response to 
chronic hypoxia is very predictable and reproducible within a specific animal strain, with most 
of these changes occurring within the first 3 to 4 weeks before stabilising (West & Hemnes, 
2011). Whilst mice display only modest vascular remodelling following exposure to chronic 
hypoxia, exposure to chronic hypoxia in rats causes several PH-associated phenotypes such as 
muscularisation of previously non-muscularised arteries, medial thickening, and increased 
proliferation of PASMCs and adventitial fibroblasts (Stenmark et al., 2009; Pak et al., 2010).  
 
However, there is minimal evidence of vascular obstruction or plexiform lesions, with most 
hypoxia-induced structural changes gradually reversing following removal of the hypoxic 
stimulus (Meyrick & Reid, 1980). Furthermore, it is unclear whether the loss of smaller 
pulmonary vessels that is thought to be associated with human PAH is also present in hypoxic 
rats (Stenmark et al., 2009). There is also a lot of variation in the response to hypoxia with age 
and sex, as well as between and within species (Aguirre et al., 2000). In addition, hypoxic 
pulmonary vasoconstriction is weaker in humans than in rats (Reeves et al., 1979). Therefore, 
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the chronic hypoxia model of PH is more representative of less severe PH, whereas the MCT 
model may have more relevance to advanced stages of PH.    
 
1.3.3.3 – Refinement of the MCT and chronic hypoxia models of pulmonary hypertension 
 
A systematic review and meta-analysis of studies reporting the use of animal models of PH 
revealed that nearly all (94.6%) of the studies reviewed used the MCT and chronic hypoxia 
models (Sztuka & Jasinska-Stroschein, 2017). However, these models do not recapitulate more 
complex phenotypes such as neointimal and plexiform lesions that are often associated with 
advanced PAH in humans (Stenmark et al., 2009). As a result, attempts have been made to 
refine these animal models of PH in order to more closely model the human disease state. 
 
For example, monocrotaline injury in combination with one-sided pneumonectomy in rats 
induces intimal remodelling in distal pulmonary arteries, which is not observed following MCT 
injection alone (Yi et al., 2000), although this model still could not recapitulate the complex 
plexiform lesions found in humans.  
 
Furthermore, unlike exposure to chronic hypoxia alone, the vascular endothelial growth factor 
(VEGF) receptor inhibitor Sugen-5416 in combination with chronic hypoxia causes severe PH 
in rats which persists and progresses after removal of the hypoxic stimulus (Taraseviciene-
Stewart et al., 2001). In addition, Sugen/hypoxic rats display minimal responses to vasodilators 
such as iloprost (Oka et al., 2007) and sometimes develop complex plexiform-like lesions (Abe 
et al., 2010). As a result, whilst the chronic hypoxia model is more representative of Group 3 
PH, the Sugen-5416/hypoxia model is considered to more closely resemble the irreversible 
nature of severe Group 1 PAH in humans. In addition, unlike MCT, Sugen-5416 only affects 
the lungs, where it promotes the selection of apoptosis-resistant ECs which subsequently 
proliferate (Sakao et al., 2005). Moreover, the Sugen-hypoxia model is associated with an 
inflammatory cytokine profile that is similar to that of PAH patients (Taraseviciene-Stewart et 
al., 2001).  
 
1.3.3.4 – Transgenic mouse models of pulmonary hypertension 
 
In addition to the MCT and the Sugen/hypoxia models of PH, gene overexpression, knockout 
and knock-in strategies in mice have led to the development of several transgenic mouse models 
of pulmonary hypertension. For example, whilst heterozygous Bmpr2 knockout (Bmpr2+/-) 
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mice (Beppu et al., 2005) do not develop pulmonary hypertension in the absence of additional 
triggers, chronic administration of the bacterial endotoxin lipopolysaccharide (LPS) induced 
pulmonary hypertension in Bmpr2+/- mice, where it was associated with increased IL-6 and KC 
(an analogue of IL-8) expression in PASMCs (Soon et al., 2015). Bmpr2 deficiency in these 
mice was also linked to reduced expression of extracellular superoxide dismutase (SOD3) 
which scavenges superoxide radicals by converting them into the diffusible second messenger 
hydrogen peroxide (H2O2) (Soon et al., 2015). In line with these findings, the superoxide 
dismutase mimetic tempol reduced inflammation and prevented PH development in Bmpr2+/- 
mice (Soon et al., 2015), whereas lung-specific SOD3 overexpression attenuated pulmonary 
hypertension in hypoxic mice (Nozik-Grayck et al., 2008).   
 
Another Bmpr2+/- mouse model of Group 1 PH was developed by West et al. (2008), who 
generated doxycycline-inducible transgenic mice in which a known, pathogenic heterozygous 
R899X mutation in BMPR2 was placed under the control of the smooth muscle-specific SM22 
promoter. Smooth muscle-specific overexpression of the R899X mutation in these mice 
resulted in the infiltration of inflammatory cells into the perivascular region but only elevated 
RVSPs in about one-third of animals, with some mice developing complex vascular lesions 
(West et al., 2008). By comparison, similar histological changes were observed when West et 
al. used the universal Rosa26 promoter to drive expression of the R899X mutation in all cell 
types, but this time 75% of mice developed increased RVSP after 8 weeks (West & Hemnes, 
2011). By contrast, Bmpr2+/R899X knock-in mice harbouring a heterozygous R899X mutation in 
exon 12 of the endogenous Bmpr2 locus did not display increased RVSP at 3 months of age 
(Long et al., 2015). However, these mice developed elevated RVSP and displayed increased 
muscularisation of distal pulmonary arteries by 6 months of age, although no right ventricular 
hypertrophy was observed (Long et al., 2015). 
 
Furthermore, lung-specific overexpression of the pro-inflammatory cytokine IL-6 in mice 
promoted inflammatory events in distal pulmonary vessels together with the formation of 
neointimal lesions after exposure to chronic hypoxia (Steiner et al., 2009). Conversely, Il-6-/- 
mice exposed to hypoxia for two weeks displayed reduced recruitment of inflammatory cells 
as well as reduced RVSP, RV hypertrophy and medial thickness of muscular pulmonary vessels 
in comparison to wild-type littermates (Savale et al., 2009). Moreover, lung-specific 
overexpression of TNFa, achieved by placing TNFa under the control of the surfactant protein 
C (SP-C) promoter, stimulated the development of severe PH and RV hypertrophy in mice 
(Fujita et al., 2001).  
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Other transgenic mouse models of PH include (i) Tie2 Cre-mediated disruption of Egln1 which 
results in the spontaneous development of progressive PH (Dai et al., 2016), (ii) overexpression 
of the serotonin plasma membrane transporter 5-HTT (Guignabert et al., 2006) and (iii) 
vasoactive intestinal peptide (VIP) knockout (Said et al., 2007). However, these models also do 
not recapitulate the diverse aetiology and complex pathology of human forms of pulmonary 
hypertension.  
 
1.3.3.5 – Other animal models of pulmonary hypertension 
 
Attempts have also been made to generate a mouse model of schistosomiasis infection, which 
is thought to be the single largest cause of PAH worldwide (Graham et al., 2010; Rabinovitch 
et al., 2014). Chronic infection of female C57BL/6 mice with Schistosoma mansoni resulted in 
profound pulmonary vascular remodelling, infiltration of inflammatory cells into the 
perivascular region, severe thickening of the media of small pulmonary arteries, and the 
formation of plexiform-like lesions (Crosby et al., 2010). Furthermore, these mice developed 
significantly increased RVSP and right ventricular hypertrophy at 25 weeks after infection 
(Crosby et al., 2011). 
 
Other animal models of PH include the use of fawn-hooded rats which spontaneously develop 
PH (Sato et al., 1992), as well as ligation of the ductus arteriosus or graft placement between 
the ascending aorta and the main pulmonary artery in fetal lambs (Morin, 1989; Abman et al., 
1989; Belik et al., 1993; Black et al., 1998) to model the development of persistent pulmonary 
hypertension of the newborn (PPHN). 
 
By contrast, there are no animal models of PH secondary to left heart disease (Group 2), and 
there are also no rodent models of CTEPH (Group 4). Although several large animal models of 
chronic CTEPH have been described, they are difficult to create, requiring repetitive 
embolisation of venous thrombi in addition to the use of fibrinolytic inhibitors (Mercier & 
Fadel, 2013). Similarly, animal models of pulmonary hypertension due to multifactorial reasons 
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1.3.4 – Challenges associated with studying pulmonary arterial hypertension  
 
Our understanding of PAH is hampered by the limited availability of human tissue which can 
only be obtained from patients with end-stage disease, thus making it difficult to determine how 
PAH is established and how it progresses. Furthermore, these cells have a limited proliferative 
capacity, meaning that repeated biopsies are required to study individual BMPR2 mutations. 
Moreover, as described above, currently available animal models of PAH are associated with 
several limitations and are unable to recapitulate the complex aetiology and pathology observed 
in patients with pulmonary hypertension.  
 
Therefore, alternative human disease models of PAH are required to gain a better understanding 
of PAH establishment and progression. One way in which this could be achieved is through the 
use of induced pluripotent stem cells (iPSCs), which have been used to model a number of 
human diseases, including PAH (West et al., 2014; Sa et al., 2017; Gu et al., 2017; Kiskin et 
al., 2018), as described below. 
 
1.4 – Disease modelling using induced pluripotent stem cells 
 
1.4.1 – Introduction to induced pluripotent stem cells 
 
Embryonic stem cells (ESCs) are derived from the inner cell mass of blastocyst stage embryos 
and are able to limitlessly self-renew whilst having the potential to differentiate into any cell 
type within the human body (Thomson et al., 1998; Kiskinis & Eggan, 2010). However, the 
expansion and differentiation of human ESCs is associated with ethical concerns (Grskovic et 
al., 2011). By contrast, induced pluripotent stem cells are highly similar to ESCs, but are 
generated by reprogramming the nuclei of somatic cells via the ectopic expression of a select 
group of transcription factors (Takahashi & Yamanaka, 2006). 
 
The first iPSCs were generated by retroviral vector-mediated delivery of the transcription 
factors Oct4, Sox2, Klf4 and c-Myc (OKSM) into mouse skin fibroblasts (Takahashi & 
Yamanaka, 2006). This was soon followed by the generation of human iPSCs from skin 
fibroblasts (Takahashi et al., 2007; Yu et al., 2007; Lowry et al., 2008), human peripheral blood 
(Loh et al., 2009; Loh et al., 2010), and other somatic cell types. 
 
Although skin fibroblasts are the most common cell type used for generating iPSCs, the 
genomes of many fibroblast-derived iPSC lines carry copy number variations (CNVs) which 
                                                                                                                            Chapter 1 - Introduction 
 
 31 
could potentially affect their phenotypic behaviour (Hussein et al., 2011; Yusa et al., 2011; 
Martins-Taylor & Xu, 2012). By contrast, previous work in our laboratory has shown that 
human iPSC lines generated by retroviral-based reprogramming of human blood outgrowth 
endothelial cells [BOECs, also known as late-outgrowth endothelial progenitor cells (L-EPCs)] 
display normal karyotypes compared to the genomes of donor-matched circulating monocytes 
(Geti et al., 2012). The majority (>80%) of these BOEC-derived iPSC lines did not acquire any 
CNVs during reprogramming and displayed a reprogramming efficiency that was 
approximately 10-fold higher compared to the two fibroblast lines tested (Geti et al., 2012). 
Furthermore, BOECs are isolated from human peripheral blood (Lin et al., 2000; Medina et al., 
2010) which is less invasive than performing skin biopsies to isolate skin fibroblasts. Taken 
together, these observations highlight some of the advantages of using BOECs to generate 
human iPSC lines.  
 
iPSCs are characterised by their ability to differentiate into the three embryonic germ layers 
(ectoderm, mesoderm and endoderm) (Figure 1.7) and form teratomas after subcutaneous or 
intramuscular injection into immunodeficient mice (Lensch et al., 2007; Takahashi et al., 2007; 
Yu et al., 2007; Park et al., 2008). At the molecular level, iPSCs must (i) express key 
pluripotency genes including OCT4, SOX2 and NANOG (Stadtfeld et al., 2008), (ii) stain 
positively for the embryonic antigens SSEA3, TRA-1-60, and TRA-1-81 (Chan et al., 2009), 
(iii) display functional telomerase expression (Wolf & Goff, 2007), and (iv) lack expression of 
the delivered reprogramming factors with concomitant downregulation of lineage-specific 
genes associated with the adult cell that the iPSCs were derived from (Robinton & Daley, 2012). 
In culture, iPSC colonies can be identified by their cobblestone morphology, prominent nucleoli 
and well-defined individual cell borders (Robinton & Daley, 2012). 
 
 





Figure 1.7. Differentiation potential of pluripotent stem cells. Embryonic stem cells (ESCs) and 
induced pluripotent stem cells (iPSCs) are able to limitlessly self-renew and differentiate into all cell 
types of the three embryonic germ layers (ectoderm, mesoderm and endoderm). ESCs are derived from 
the inner cell mass of blastocyst stage embryos, whereas iPSCs are derived by nuclear reprogramming 
of somatic cells via the ectopic expression of a select group of transcription factors, typically Oct4, 
Sox2, Klf4 and c-Myc. HPSC, haematopoietic stem cell; MSC, mesenchymal stem cell (from Kaebisch 
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Figure 1.8. Disease modelling using induced pluripotent stem cells. iPSC-based disease modelling 
typically involves isolating patient-derived iPSCs, introducing disease-associated mutations into control 
iPSCs using CRISPR-Cas9 gene editing to generate cells with isogenic backgrounds, and differentiating 
these cells into the cell types implicated in the disease being modelled. The iPSC-derived cells are then 
used to study mechanisms contributing to the establishment of disease-associated cellular phenotypes 
and identify molecular targets that could be used for drug screening and personalised medicine (from 
Shi et al., 2017). 
 
 
Human induced pluripotent stem cells offer an invaluable model system for studying the 
molecular pathogenesis of human diseases which have strong genetic components. Unlike non-
human animal models, patient-derived iPSCs are genetically matched to the individual they 
were derived from. Furthermore, whilst patient-derived primary cells are difficult to isolate and 
are of limited supply, iPSCs can be differentiated into virtually any disease-relevant cell type, 
thus providing a potentially limitless supply of patient-specific cells which can be used for drug 
screening and personalised medicine (Figure 1.8). 
 
Since their discovery, iPSCs have been successfully differentiated into a number of different 
cell types, including neurons (Dimos et al., 2008; Ebert et al., 2009; Soldner et al., 2009), blood 
cells (Choi et al., 2009; Ye et al., 2009), adipocytes (Taura et al., 2009), fibroblasts 
(Hockemeyer et al., 2008; Maherali et al., 2008), endothelial cells (Choi et al., 2009; Patsch et 
al., 2015; Sa et al., 2017, Kiskin et al., 2018), and smooth muscle cells (Cheung et al., 2012; 
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Patsch et al., 2015; Kiskin et al., 2018). iPSCs have also been isolated from individuals with 
different diseases and were shown to retain the genetic characteristics of their donor cells (Park 
et al., 2008). This makes patient-specific iPSCs especially useful for studying monogenic 
diseases or diseases with strong genetic components such as HPAH (Ebert et al., 2009; Lee et 
al., 2009). Furthermore, patient-specific iPSCs can be differentiated into large numbers of 
disease-relevant cells which were previously difficult to obtain, such as neurons and 
cardiomyocytes (Shi et al., 2017). This approach would therefore be extremely useful for 
generating pulmonary vascular-like cells to model PAH, as pulmonary artery smooth muscle 
and endothelial cells can only be obtained from patients at the time of transplantation or death. 
 
Another advantage of using iPSCs for disease modelling is their amenability to genetic 
manipulation (Hockemeyer & Jaenisch, 2016). Gene editing efficiency can be improved by 
using zinc-finger nucleases (ZFN) (Hockemeyer et al., 2009; Zou et al., 2009), transcription 
activator-like effector nucleases (TALENs) (Christian et al., 2010; Hockemeyer et al., 2011; 
Sanjana et al., 2012) and the CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic 
Repeats CRISPR-associated protein 9) system (Jinek et al., 2012; Cong et al., 2013; Perez-
Pinera et al., 2013; Shalem et al., 2014) to induce double-stranded DNA breaks at sites of gene 
modification. 
 
Owing to its relatively low cost and ease of use, the CRISPR-Cas9 system has become the most 
commonly used gene editing strategy. CRISPR-Cas9 gene editing has been used to introduce 
disease-associated mutations into wild-type iPSCs (Wen et al., 2014; Murai et al., 2016) and to 
correct such mutations in patient-derived iPSCs (Hotta & Yamanaka, 2015; Seah et al., 2015; 
Deleidi & Yu, 2016; Orqueda et al., 2016; Gu et al., 2017), thus allowing comparisons to be 
made between isogenic lines that are genetically identical apart from the introduced mutation. 
This approach avoids potential confounding effects of inter-line variability on the phenotypes 
being studied and has great utility in investigating the contributions of specific mutations to the 
establishment of disease-associated phenotypes. Given the reduced penetrance of BMPR2 
mutations in PAH (Machado et al., 2009), genetically matched wild-type iPSCs and their gene-
edited counterparts could therefore be very useful for studying the precise role of BMPR2 
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1.4.3 – Developing induced pluripotent stem cell models of pulmonary arterial 
hypertension 
 
Owing to the limited availability of diseased pulmonary vascular cells from PAH patients, 
attempts have been made to generate iPSC-derived cells that could serve as surrogates for adult 
cells and be used to study PAH. 
  
West et al. (2014) differentiated two wild-type and two PAH patient-derived iPSC lines 
(derived from skin fibroblasts) into vascular mesenchymal stromal cells (iPSC-MSC) and 
subsequently into EC-like cells (iPSC-ECL), using microarrays to compare their gene 
expression profiles with control and IPAH patient-derived PAECs, as well as with skin 
fibroblasts from IPAH and HPAH patients (West et al., 2014). The authors looked at the effect 
of decreased BMPR2 signalling on gene expression at various stages of differentiation of iPSC-
MSCs and iPSC-ECLs and identified 33 developmental genes and 18 genes related to cell death 
that were specifically upregulated in BMPR2 mutants during differentiation. Among these, the 
Wnt receptors FZD4 and FZD5 and secreted Wnt modulators SFRP1 and SFRP2 were 
upregulated in BMPR2 mutants compared to controls, leading the authors to conclude that 
aberrant BMPR2 signalling may result in increased canonical Wnt/b-catenin signalling in PAH 
(West et al., 2014). In support of these observations, increased expression of the Wnt pathway 
genes FZD4, FZD10 and AXIN2 was detected in lung tissue samples from 22 IPAH patients 
compared to 22 control subjects (Wu et al., 2016), although none of these IPAH patients carried 
BMPR2 mutations. Furthermore, non-canonical Wnt signalling has been associated with 
vasoconstriction and vascular remodelling in IPAH patients (Laumanns et al., 2009).  
 
However, the iPSC model of PAH developed by West et al. (2014) was limited to the analysis 
of just two iPSC-ECL and iPSC-MSC lines that were not genetically matched, and the authors 
also did not characterise iPSC-ECLs in terms of their proliferative and apoptotic responses. 
Furthermore, although BMPR2 mutant iPSC-MSCs were less apoptotic compared to control 
iPSC-MSCs, they were not more proliferative (West et al., 2014). Therefore, further work will 
be required to clarify whether reduced BMPR2 signalling contributes to increased Wnt 
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In addition to the iPSC model of PAH developed by West and colleagues, iPSC-derived 
endothelial cells were used in two subsequent studies as surrogates for PAECs to model PAH 
(Sa et al., 2017; Gu et al., 2017). Sa et al. (2017) derived iPSCs from skin fibroblasts of HPAH 
and IPAH patients, differentiated these into iPSC-ECs and compared these iPSC-ECs to PAECs 
obtained from the same patients in terms of their ability to recapitulate several PAH-associated 
disease phenotypes (Sa et al., 2017). However, the iPSC-ECs generated by Sa et al. did not 
recapitulate increased proliferation, mitochondrial hyperpolarisation and DNA damage that 
have previously been reported in IPAH and HPAH-derived PAECs (Diebold et al., 2015; Sa et 
al., 2017). 
 
Nevertheless, Sa et al. showed that matched patient-derived iPSC-ECs and PAECs displayed 
similar susceptibility to apoptosis and reduction in BMPR2 signalling, cell adhesion and tube 
formation compared to iPSC-ECs and PAECs from control individuals (Sa et al., 2017). RNA-
Seq analysis of these cells suggested that impaired migration and survival were attributed to 
increased expression of kisspeptin 1 (KISS1) and downregulation of carboxylesterase 1 (CES1), 
respectively (Sa et al., 2017). Furthermore, IPAH/HPAH-derived PAECs and iPSC-ECs 
displayed similar responses to the immunosuppressant FK506 and the neutrophil elastase 
inhibitor, elafin, both of which improved angiogenesis in two patient-derived iPSC-EC and 
PAEC lines. In addition, the authors showed that the lack of a response to FK506 and elafin in 
the other five cell lines was at least partly due to increased expression of the anti-migratory 
factor split guidance ligand 3 (SLIT3), suggesting that SLIT3 might act as a potential genetic 
modifier in PAH (Sa et al., 2017). 
 
The same group subsequently went on to look for other possible genetic modifiers in three 
families with FPAH patients and unaffected mutation carriers (UMCs) (Gu et al., 2017). UMC 
iPSC-ECs displayed increased cell adhesion and survival compared to FPAH-derived iPSC-
ECs harbouring the same BMPR2 mutation, which the authors attributed to increased 
expression of BMPR2 activators and a reduced expression of BMPR2 inhibitors in UMC iPSC-
ECs relative to FPAH iPSC-ECs (Gu et al., 2017). However, preserved UMC iPSC–EC survival 
was not found to be regulated by the BMPR2 pathway (Gu et al., 2017). Instead, baculoviral 
IAP repeat containing 3 (BIRC3), a gene encoding a protein that is thought to protect ECs 
against apoptosis, was upregulated in UMC- relative to FPAH-derived iPSC-ECs in all three 
families. Whilst CRISPR-Cas9-mediated repair of the C118W BMPR2 mutation in FPAH 
iPSC-ECs restored cell adhesion, cell survival and the expression of BMPR2 target genes to 
control levels, BIRC3 expression remained upregulated, suggesting that BIRC3 expression is 
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not regulated by BMPR2 signalling (Gu et al., 2017). siRNA-mediated knock-down of BIRC3 
increased apoptosis in UMC iPSC-ECs, leading the authors to conclude that BIRC3 is 
responsible for the preserved cell survival in UMC iPSC-ECs and may hence act as a protective 
genetic modifier in PAH (Gu et al., 2017). These findings agree with previous work showing 
that reduced BMPR2 signalling in PAECs is associated with increased apoptosis in response to 
injury (de Jesus Perez et al., 2009) and with impaired adhesion and migration (de Jesus Perez 
et al., 2012; Rhodes et al., 2015).  
 
1.4.4 – Limitations of currently available iPSC models of pulmonary arterial 
hypertension 
 
Whilst the studies described above successfully generated iPSC-derived ECs and MSCs that 
could recapitulate several PAH-associated disease phenotypes and could be used to gain insight 
into some of the genes which may be dysregulated in PAH, these studies are associated with 
several limitations. For instance, neither BMPR2 mutant iPSC-MSCs or iPSC-ECs were able 
to recapitulate the hallmark pro-proliferative phenotype of patient-derived BMPR2+/- PASMCs 
and PAECs. Furthermore, most cells used in these studies did not have isogenic backgrounds, 
thus making it very difficult to discern whether the introduction of a specific BMPR2 mutation 
is sufficient to result in the acquisition of PAH-associated cellular phenotypes. Finally, whilst 
Sa et al. (2017), Gu et al. (2017) and West et al. (2014) showed that iPSC-ECs can be used as 
surrogates for PAECs for studying PAH, no iPSC-derived SMCs have yet been described that 
recapitulate PAH-associated PASMC phenotypes.  
 
Therefore, developing protocols for differentiating iPSCs into vascular smooth muscle-like 
cells which could be used as surrogates for PASMCs would provide another critical source of 
cells that could further aid the study of the molecular mechanisms implicated in PAH 
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1.5 – Vascular smooth muscle cell differentiation 
 
1.5.1 – Embryonic origins of vascular smooth muscle cells 
 
When developing protocols for differentiating iPSCs into vascular smooth muscle-like cells, 
the ultimate goal is to generate cells that are akin to the adult cell types being modelled or at 
least that these display functional responses akin to the specific type of primary cell they are 
trying to mimic.  
 
Vascular smooth muscle is a mosaic tissue, with specific vascular beds being derived from one 
or more possible embryonic origins (reviewed in Majesky, 2007). Furthermore, individual 
vessels or even vessel segments may consist of multiple SMC populations that arise from 
distinct progenitor populations which themselves have unique developmental histories 
(Majesky, 2007). For example, lineage tracing has shown that four major embryonic lineages 
contribute to the pulmonary vasculature: (i) Wnt1+ neural crest, which contributes to the SMCs 
at the root of the pulmonary artery (Jiang et al., 2000), (ii) cardiopulmonary progenitors (CPPs), 
which contribute ECs and SMCs to the proximal pulmonary artery and vein (Peng et al., 2013), 
(iii) Wilms’ tumour 1-positive (WT1+) mesothelium, which surrounds the lung and contributes 
widely to both ECs and SMCs throughout the vasculature (Que et al., 2008), and (iv) lateral 
plate mesoderm, which contributes to the PASMCs in peripheral pulmonary arteries (Hall et 
al., 2000).  
 
The ability to recapitulate specific lineages and their vascular derivatives is likely to be critical 
for generating a high-fidelity model of PAH. This is because these SMC populations may 
display distinct, lineage-specific responses to the same stimuli, even under identical 
experimental conditions (Rosenquist et al., 1989; Topouzis & Majesky, 1996). Specific SMC 
subpopulations may also respond to injury in unique ways and may therefore contribute 
differently to the vascular remodelling process (Frid et al., 1997). Furthermore, depending on 
their anatomical origin, SMCs may display opposite responses to hypoxia. Systemic arteries 
relax in response to tissue hypoxia in order to improve blood flow and oxygen supply in hypoxic 
tissues (Detar, 1980; Gupte & Wolin, 2008). By contrast, pulmonary arteries respond by 
contracting, thereby diverting blood flow from poorly ventilated regions towards the more 
oxygenated areas of the lungs – a process termed hypoxic pulmonary vasoconstriction (HPV) 
(von Euler & Liljestrand, 1946). 
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Mammalian lung development begins with the ventral budding of the primordium from the 
foregut to form the lung bud (Perl & Whitsett, 1999). Pulmonary SMCs develop from local 
mesenchymal cells at the distal end of the growing lung bud, with the mesenchymal precursor 
cells gradually migrating in a distal to proximal fashion along the bronchial tree, whereas 
bronchial smooth muscle cells migrate in the opposite direction (Badri et al., 2008). As lung 
development proceeds, BMP4 becomes most highly expressed at the tips of the distal buds, 
suggesting that it plays a role in bronchial branching (Bellusci et al., 1996). Moreover, BMP4 
differentially affects the proliferation and apoptosis of PASMCs depending on their location 
along the bronchial tree. For example, proximal PASMCs are growth-suppressed by BMP4, 
whereas distal PASMCs are not growth-suppressed by BMP4 (Yang et al., 2005). This is an 
important consideration in developing iPSC-SMC models of PAH, as it is the distal PASMCs 
that are thought to be predominantly affected in this disease (Humbert et al., 2004). 
 
1.5.2 – Arterial and venous smooth muscle cells have different functions and identities  
 
In addition to embryonic origin, it is important to consider arteriovenous (AV) specification 
when developing protocols for differentiating iPSCs into distal PASMC-like cells. This is 
because PAH predominantly affects arteries, with arterial and venous SMCs having distinct 
functions and identities (Wong et al., 2005; Deng et al., 2006). For example, arterial SMCs 
isolated from carotid arteries of male rabbits displayed elevated levels of the inhibitory 
proteoglycan decorin compared to SMCs isolated from the jugular vein (Wong et al., 2005). By 
contrast, jugular vein SMCs are more dedifferentiated, displaying reduced adhesion to collagen 
and fibronectin, and are associated with increased activity of the matrix metalloproteases 
MMP2 and MMP9 (Wong et al., 2005). 
Furthermore, Notch3 expression in mice was shown to be required for the maturation of arterial 
SMCs, with vascular smooth muscle cells (VSMCs) from Notch3-/- mice potentially being more 
venous in nature (Domenga et al., 2004). In addition, Li et al. (2011) showed that human arterial 
and venous SMCs differed in terms of their proliferative responses to the platelet-derived 
growth factor (PDGF) isoforms PDGF-AA and PDGF-BB (Li et al., 2011). The authors showed 
that PDGF-AA stimulated the proliferation of arterial but not venous SMCs, whilst human 
saphenous vein SMCs were more proliferative compared to arterial SMCs following 
stimulation with PDGF-BB (Li et al., 2011). Other genes that have been shown to be 
upregulated in arterial versus venous SMCs include regulator of G-protein synthesis 5 (RGS5), 
elastin and vimentin (Adams et al., 2000).  
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However, our current understanding of AV identity in SMCs, unlike in ECs, is very limited and 
modelling AV identity is a major challenge.   
 
1.5.3 – Phenotypic plasticity of vascular smooth muscle cells 
 
Another challenge of developing iPSC-SMC differentiation protocols is the ability to produce 
mature, fully differentiated SMCs.  This is important because unlike skeletal or cardiac muscle, 
VSMCs are not terminally differentiated and are able to undergo transient changes between 
contractile, synthetic and intermediate phenotypic states in response to changes in signalling 
within their local environment (Wolinsky & Glagov, 1967; Owens, 1995). Mature, fully 
developed VSMCs are normally quiescent and have a contractile phenotype characterised by 
an elongated, spindle-shaped morphology, the presence of contractile filaments and the 
expression of contractile protein markers myosin heavy chain 11 (MYH11) and smoothelin 
(SMTN) (Sobue et al., 1999; Owens et al., 2004). However, in response to vascular injury, 
contractile VSMCs undergo phenotypic switching by becoming more proliferative and starting 
to secrete components of the extracellular matrix (ECM) such as collagen, elastin, fibronectin, 
laminin and proteoglycans (Stiemer et al., 1993; Kane et al., 2011). These dedifferentiated 
VSMCs have a ‘synthetic’ phenotype characterised by increased expression of proteolytic 
enzymes such as matrix metalloproteinases (MMPs) and serine elastases (Chelladurai et al., 
2012), reduced MYH11 expression (Owens, 1995) and a less elongated, cobblestone-like 
morphology referred to as an epithelioid (Chamley-Campbell et al., 1979; Hao et al., 2003).  
Phenotypic switching plays an important role in pulmonary arterial hypertension, where 
increased degradation and reduced synthesis of the ECM contributes to vascular remodelling 
(Stenmark & Mecham, 1997; Vieillard-Baron et al., 2003).  For example, the matrix-degrading 
enzymes MMP2 and MMP9 were found to be upregulated in PAH-derived PASMCs and 
patient-derived plasma samples, respectively (Lepetit et al., 2005). Furthermore, increased 
MMP expression has also been detected in the lungs of MCT rats (Schermuly et al., 2004; 
Pullamsetti et al., 2005), as well in cultured SMCs in response to TNFa treatment (Rajavashisth 
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1.5.4 – Developing differentiation protocols for generating iPSC-derived SMCs 
 
The directed in vitro differentiation of iPSCs into different cell types can be achieved by using 
specific concentrations, combinations and sequences of agonists and antagonists of a number 
of different signalling pathways to mimic the signalling events which occur during embryonic 
development (Murry & Keller, 2008; Cheung et al., 2012).  
 
For example, Patsch et al. (2015) developed a chemically-defined differentiation protocol 
which involved using BMP4 treatment and glycogen synthase kinase 3 (GSK3) inhibition to 
differentiate pluripotent cells into mesoderm and subsequently into iPSC-derived ECs or SMCs 
via exposure to vascular endothelial growth factor A (VEGF-A) or PDGF-BB, respectively 
(Patsch et al., 2015). However, although metabolomic and transcriptome-wide expression 
analysis showed that these iPSC-derived ECs and VSMCs displayed a high degree of similarity 
to their respective primary cells (Patsch et al., 2015), these cells were not embryonic lineage-
specific. Therefore, these cells are limited in terms of their ability to model specific SMC 
populations in distinct vascular regions which may display different signalling responses and 
disease susceptibility compared to SMC populations derived from other lineages (Haimovici & 
Maier, 1964; VanderLaan et al., 2004; Yang et al., 2005). 
 
By contrast, by exploiting the principle that a posterior-anterior BMP concentration gradient 
along the primitive streak determines lateral plate mesoderm (LM) and paraxial mesoderm 
(PM) specification during embryogenesis (Dosch et al., 1997), Cheung et al. (2012) used 
varying concentrations of BMP4 to show that origin-specific smooth muscle cells can be 
generated from iPSCs via these two intermediate lineages (Cheung et al., 2012). Using this 
lineage-specific approach together with chemically-defined conditions, the authors showed that 
high BMP4 concentrations inhibit the development of paraxial mesoderm but promote LM 
specification. Once formed, the LM cells could subsequently be stimulated to differentiate into 
iPSC-SMCs by culturing the cells for 12 days in chemically defined medium containing PDGF-
BB and TGF-b1. At the end of the differentiation protocol, over 80% of iPSC-SMCs derived 
from these intermediate populations expressed smooth muscle myosin heavy chain (MYH11), 
a marker which is only thought to be selectively expressed in mature, fully differentiated SMCs 
(Owens et al., 2004). Furthermore, these iPSC-SMCs displayed contractility and calcium 
transients when stimulated with carbachol, thus suggesting that these cells exhibit functional 
responses that are characteristic of adult vascular smooth muscle cells in general (Cheung et 
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al., 2012). However, it was not shown whether these iPSC-SMCs display functional responses 
akin to more specific types of VSMCs such as distal PASMCs.  
 
1.6 – Aims and hypothesis 
 
1.6.1. – Aims and objectives 
 
The overarching aim of this thesis is to develop a human induced pluripotent stem cell-derived 
smooth muscle cell model of PAH associated with mutations in BMPR2.  
 
To achieve this, the specific aims and objectives of this thesis are as follows:  
 
1) To use CRISPR-Cas9 gene editing to introduce a known disease-associated BMPR2 
mutation into a human control iPSC line to generate wild-type and BMPR2+/- iPSCs 
with an isogenic background  
  
2) To differentiate control and BMPR2+/- iPSCs into lineage-specific iPSC-derived smooth 
muscle-like cells and show that these iPSC-SMCs can be used as surrogates for distal 
PASMCs for studying PAH establishment and progression.  
 
3) To determine the extent to which BMPR2+/- iPSC-SMCs recapitulate PAH-associated 
disease phenotypes observed in PASMCs and thus whether the introduction of a single 
BMPR2 mutation is necessary and sufficient to establish PAH-associated cellular 
phenotypes in iPSC-SMCs 
 
1.6.2. – Hypothesis 
 
My hypothesis is that the introduction of a single BMPR2 mutation is necessary but not 
sufficient to establish PAH-associated cellular phenotypes in iPSC-SMCs, with additional 
factors being required to fully recapitulate PAH-associated cellular phenotypes observed in 



































2.1 – Characteristics of human iPSC and PASMC lines 
 
The characteristics of the human induced pluripotent stem cell (iPSC) and pulmonary artery 
smooth muscle cell (PASMC) lines used in this investigation are summarised in Table 2.1 and 
Table 2.2 below. Prior to the start of this study, human iPSC lines were generated by 
reprogramming late blood outgrowth endothelial cells (BOECs) isolated from human peripheral 
blood as previously described (Geti et al., 2012; Ormiston et al., 2015). All blood donors 
provided informed written consent in accordance with human study 07/H0306/134 
(Cambridgeshire 3 Research Ethics Committee, UK). For PASMC isolation, the Papworth 
Hospital ethical review committee (Papworth Everard, Cambridge, UK) approved the study, 











Table 2.1. Characteristics of human iPSC lines. Prior to the start of this thesis project, human iPSC 
lines were generated from late blood outgrowth endothelial cells from three control subjects (C2, C6 
and C10), three heterozygous BMPR2 mutation carriers (B3, B4 and B11) and one idiopathic PAH 
patient (IPAH1), as described in Geti et al. (2012). The isogenic C2 W9X+/- and C2 ∆Exon1 iPSC lines 







iPSC line Sex Age Disease 
status 
BMPR2 status 
C2 M 20 No disease Wild-type 
C6 F 40 No disease Wild-type 
C10 M 28 No disease Wild-type 
     
C2 W9X+/- M 20 No disease W9X 
C2 ∆Exon1 M 20 No disease Deletion of 
BMPR2 Exon 1 
B3 M 27 No disease C347R 
B4 F 37 Hereditary 
PAH 
W9X 
B11 M 32 Hereditary 
PAH 
Del in 5’UTR 
     
IPAH1 M 62 Idiopathic PAH Wild-type 











Table 2.2. Characteristics of human pulmonary artery smooth muscle cell lines 
 
2.2 – Non-commercial cell culture media recipes 
 
All cell culture media were supplemented with antibiotic-antimycotic solution (Thermo Fisher 
Scientific) (1% v/v) containing penicillin (10,000 Units/mL), streptomycin (10,000 µg/mL) and 
amphotericin B (25 µg/mL). Where non-sterile components were added, media were sterile-
filtered through a polyethersulfone (PES) membrane with a pore size of 0.2 µm. 
 
Chemically-defined medium (CDM): IMDM (49.5% v/v), Ham’s F-12 Nutrient Mixture 
(49.5% v/v), chemically defined lipid concentrate (1% v/v) (all from Thermo Fisher Scientific), 
transferrin from human serum (15 µg/ml, Roche), recombinant human insulin (7 µg/ml, Roche), 
and 1-thioglycerol (450 µM, Sigma) (Vallier et al., 2009)  
 
CDM-BSA: Chemically-defined medium (CDM) supplemented with bovine serum albumin 
(BSA) Cohn fraction V (5 mg/ml, Europa Bioproducts) (Brons et al., 2007) 
 
CDM-PVA: Chemically-defined medium (CDM) supplemented with polyvinyl alcohol (1.2 
mg/ml, Sigma) 
 
KnockOut Serum Replacement (KSR) medium: DMEM/F12 (79.5% v/v), Gibco KnockOut 
Serum Replacement (KOSR) (19.5% v/v), MEM Non-Essential Amino Acids Solution (1% 
v/v), L-glutamine (2 mM) (all from Thermo Fisher Scientific) and fibroblast growth factor 2 




Sex Age Disease status BMPR2 
status 
32 MP F 58 Centrilobular 
emphysema 
Wild-type 
79 MP M 60 Squamous cell 
carcinoma 
Wild-type 
82 MP F 71 Adenocarcinoma Wild-type 
83 MP F 56 Unknown donor 
control 
Wild-type 
84 MP F 59 Differential 
adenocarcinoma 
Wild-type 
     
56 MP M 58 Hereditary PAH C347R 
67 MP M 22 Hereditary PAH W9X 
73 MP F 30 Hereditary PAH R899X 
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CDM-BSA/KSR (‘BK’) feeder-free iPSC culture medium: CDM-BSA (50% v/v), KSR 
(50% v/v), activin A (12.5 ng/ml), FGF-2 (15 ng/ml) (Wellcome Trust – MRC Cambridge Stem 
Cell Institute, Cambridge, UK) and L-ascorbic acid (50 ng/ml, Sigma). 
 
Feeder-dependent iPSC culture medium: CDM-BSA (25% v/v), KSR (50% v/v) and filtered 
conditioned medium (25% v/v) from irradiated, mitotically inactive mouse embryonic 
fibroblasts (iMEFs) (Wellcome Trust – MRC Cambridge Stem Cell Institute, Cambridge, UK) 
cultured for 24 hours in CDM-BSA + FGF-2 (4 ng/ml). Feeder-dependent iPSC culture medium 
also contains activin A (12.5 ng/ml), FGF-2 (15 ng/ml) and L-ascorbic acid (50 ng/ml).          
 
2.3 – Human pluripotent stem cell and PASMC culture 
 
To aid attachment of human pluripotent stem cells (hPSCs), empty cell culture plates were 
incubated for one hour at 37°C in a 0.2% w/v solution of porcine gelatine (Sigma) in HyClone 
cell culture grade water (GE Healthcare Life Sciences) followed by incubation in DMEM 
supplemented with 10% FBS and 2-mercaptoethanol (55 µM, Sigma) for at least 2 hours at 
37°C. Prior to laying down cells, this medium was aspirated and the plates washed once with 
PBS before laying down cells in their respective cell culture media.  
 
Feeder-free human iPSCs were cultured in BK medium, whereas feeder-dependent iPSCs 
growing on top of a 25% confluent layer of irradiated mouse embryonic fibroblasts (iMEFs) 
were cultured in feeder-dependent iPSC culture medium (See Section 2.2). Feeder-free H9 
human embryonic stem cells (hESCs) were cultured in CDM-BSA supplemented with activin 
A (10 ng/ml) and FGF-2 (12 ng/ml) (Vallier et al., 2009).  
 
Human pulmonary artery smooth muscle cells (PASMCs) from PAH patients carrying 
heterozygous BMPR2 mutations, or from unaffected donor control subjects at the time of 
heart/lung transplantation (Table 2.2), were cultured in high glucose (4.5 g/L) DMEM (Thermo 
Fisher Scientific) supplemented with 10% heat-inactivated foetal bovine serum (FBS) (Sigma) 
and antibiotic-antimycotic solution (1% v/v) (Thermo Fisher Scientific). All cells were 
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2.4 – Generation of BMPR2+/- iPSC lines with isogenic backgrounds 
 
2.4.1 – Site-directed mutagenesis 
 
The generation of the W9X targeting construct and the CRISPR-Cas9 targeting strategy used 
to introduce the W9X mutation into exon 1 of the BMPR2 gene are described in Section 3.1 in 
Chapter 3. The W9X mutation was created by site-directed mutagenesis by following the 
QuikChange II Site-Directed Mutagenesis (SDM) kit protocol (Agilent Technologies). The 
polymerase chain reaction (PCR) cycling parameters used for site-directed mutagenesis are 
shown in Table 2.3.  
 
Stage Number of Cycles Temperature Time 





95°C 30 seconds 
55°C 1 minute 
68°C 5 minutes 30 seconds 
 
Table 2.3. PCR cycling parameters used for site-directed mutagenesis to insert the W9X BMPR2 
mutation into the targeting construct.  
 
2.4.2 – Generation of the ∆Exon1 targeting construct 
 
The targeting strategy used to delete exon1 of the BMPR2 gene is presented in Figure 3.3 in 
Chapter 3. Genomic DNA, extracted from C2 iPSCs using the DNeasy Blood and Tissue kit 
(Qiagen), was used to PCR amplify the left and right homology arms using Pfx50 DNA 
polymerase (Thermo Fisher Scientific) and the primers listed in Table 2.6. The 5’ homology 
arm spans the region chr2: 202,376,583-202,377,403, 883 base pairs upstream of BMPR2 exon 
1, and the 3’ homology arms spans the region chr2: 202,377,511-202,378,844. Each PCR-
amplified product was then TOPO cloned using Zero Blunt TOPO PCR cloning kit according 
to the manufacturer’s instructions (Thermo Fisher Scientific) and used to finalise the construct. 
Using the QuikChange II Site-Directed Mutagenesis kit (Agilent Technologies) protocol, a 
point base pair mutation changing a Sty1 restriction endonuclease site to a PvuI site was created 
285bp downstream of the region where the left homology starts. The GeneArt® CRISPR 
Nuclease Vector (Thermo Fisher Scientific) used for W9X targeting was also used for ∆Exon1 
targeting, and successful introduction of the ∆Exon1 mutation into C2 iPSCs was confirmed by 
Sanger sequencing (performed by Source Bioscience, Cambridge, UK).   
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2.4.3 – Cell electroporation 
 
The W9X and ∆Exon1 DNA targeting vectors (see Section 3.1) were linearised by digestion 
with NotI-HF restriction enzyme (New England Biolabs) at 37°C overnight, followed by DNA 
precipitation to purify DNA from the reaction mixture. DNA precipitation was performed by 
adding 10% by volume of sodium acetate (3M, pH 5.2) to the digestion reaction, vortexing for 
1 minute, adding 2x volume of ice-cold (-20°C) absolute molecular biology grade ethanol 
(Sigma), vortexing for a further 2 minutes and then placing the sample in a -80°C freezer for at 
least 1 hour. Subsequently, the sample was centrifuged at maximum speed (≤17,000 x g) for 20 
minutes at 4°C before discarding the supernatant, washing the pellet with 70% ethanol, 
centrifuging at full speed for 5 minutes, air drying the pellet and finally re-suspending the pellet 
in 12 µl of EB elution buffer (Qiagen).    
    
The linearised targeting vector (2 μg) and CRISPR vector (2 μg) were subsequently co-
transfected into C2 wild-type iPSCs by electroporation using Human Stem Cell Nucleofector 
Kit 1 according to the manufacturer’s guidelines (Lonza). To achieve this, C2 iPSCs growing 
in 6-well plates were washed with 1.5 ml of PBS, trypsinised for 5 minutes at 37 °C using 0.5 
ml of 1x TrypLE Select (Thermo Fisher Scientific) supplemented with 2 mM EDTA (Thermo 
Fisher Scientific) and neutralised using 1 ml of BK medium per well. Cells in the resulting cell 
suspension were then counted before transferring 8 x 105 cells to a separate 1.5 ml centrifuge 
tube and centrifuging these cells at 150 x g for 3 minutes at room temperature prior to gently 
re-suspending the cell pellet in 100 µl of Nucleofector® Solution (Lonza). 2 μg of linearised 
targeting vector and 2 μg of CRISPR vector were then added prior to transferring the cell/DNA 
suspension to a cuvette without introducing any bubbles. The cuvette containing the cell/DNA 
suspension was subsequently inserted into the Amaxa Nuleofector machine (Lonza) and 
electroporated using Nucleofector Program B-016. A separate set of C2 iPSCs were 
electroporated with 2 μg of pmaxGFP vector (Lonza) as a positive control. Subsequently, 500 
µl of warm BK culture medium supplemented with Rho-associated protein kinase (ROCK) 
inhibitor Y-27632 dihydrochloride (1 µM, Tocris Bioscience) was gently added to the cuvette 
before using a supplied pipette (Lonza) to gently transfer the sample into a gelatine-coated 24-
well plate containing 500 µl of warm BK culture medium per well (to achieve a final volume 
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2.4.4 – Analysis of electroporation efficiency 
 
To determine whether electroporation was successful, the cells were assessed for orange 
fluorescence [indicative of orange fluorescent protein (OFP) expression] and/or green 
fluorescence (indicative of pmaxGFP expression) by flow cytometry approximately 24 hours 
post-transfection. Flow cytometric analysis of OFP and pmaxGFP expression was performed 
by staff at the NIHR Cambridge BRC Cell Phenotyping Hub at the Department of Medicine, 
University of Cambridge using a BD FACSCanto flow cytometer and BD FACSDiva software 
(version 6.1.3).  In addition, transfection efficiency was visually assessed 48 hours after 
electroporation using a Leica DMI3000 B manual inverted microscope equipped with a Leica 
EL6000 external light source for fluorescence excitation.    
 
2.4.5 – Genomic cleavage detection 
 
The efficiency with which the CRISPR construct produced targeted double strand breaks at the 
locus of interest after electroporation was determined using the GeneArt® Genomic Cleavage 
Detection Kit according to manufacturer’s guidelines (Thermo Fisher Scientific). Loci at which 
CRISPR/Cas9 produced targeted double-strand breaks and resulted in insertions/deletions 
(indels) being created by cellular repair mechanisms were amplified by PCR using the CRISPR 
cleavage detection primers listed in Table 2.6. The PCR product was then denatured and re-
annealed in order to enable strands with indels to re-anneal with strands without indels or with 
different indels, thus creating mismatches. These mismatches were subsequently detected and 
cleaved by Detection Enzyme (Thermo Fisher Scientific), with the resultant bands being 
analysed by running a 2% agarose gel with a 2-log DNA ladder (0.1 – 10 kb, New England 
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2.4.6 – Geneticin selection of electroporated iPSCs 
 
Wild-type C2 iPSCs co-transfected with the CRISPR vector and the W9X or ∆Exon1 targeting 
construct were trypsinised 48 hours after electroporation, plated in gelatine-coated 6-cm 
diameter cell culture dishes (Corning) and cultured for at least 5 days in BK medium containing 
Geneticin (G418) (50 ng/ml, Thermo Fisher Scientific). Individual Geneticin-resistant iPSC 
colonies were manually picked using a P1000 pipette tip, trypsinised using 50 µl of 1x TrypLE 
Select (Thermo Fisher Scientific) supplemented with 2 mM EDTA (Thermo Fisher Scientific), 
neutralised with 100 µl of BK medium and laid down in separate wells of a gelatine-coated 24-
well plate containing 400 µl BK medium supplemented with Y-27632 dihydrochloride (1 µM, 
Tocris Bioscience). When confluent, cells in each well were trypsinised and passaged, with a 
proportion of the cells from each passage being pelleted for subsequent genotyping. 
 
2.4.7 – Genotyping 
 
To assess whether the CRISPR targeting strategy resulted in the creation of the desired BMPR2 
mutation, and if so, whether the mutation was heterozygous or homozygous, a pair of 
genotyping primers (Table 2.6) were designed to amplify the homology arm containing the 
W9X or ∆Exon1 site by PCR using the cycling parameters shown in Table 2.4. To determine 
whether targeting was successful, 300 ng of the amplified PCR product was digested for 1 hour 
at 37°C by AatII (for W9X) or PvuI (for ∆Exon1) restriction enzyme (New England Biolabs) 
and subsequently run on a 2% agarose gel with a 2-log DNA ladder. Successful targeting should 
yield 750 bp and 350 bp bands for W9X, or 547 bp and 293 bp bands for ∆Exon1 and was 
further verified by sending the samples off for Sanger sequencing (Source Bioscience, 
Cambridge, UK). 
 
Stage Number of Cycles Temperature Time 





95°C 15 seconds 
60°C 30 seconds 
68°C 1 minute 15 seconds 
3 1 68°C 5 minutes 
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2.5 – Generation of lineage-specific iPSC-derived smooth muscle-like cells 
 
Human iPSCs were differentiated into iPSC-derived smooth muscle-like cells (iPSC-SMCs) 
via lateral plate mesoderm (LM), paraxial mesoderm (PM) or neural ectoderm (NE) 
intermediate populations, as previously described (Cheung et al., 2012), with modifications. To 
generate LM- and PM-iPSC-SMCs, early mesoderm formation was induced by culturing iPSCs 
in gelatine-coated T-25 flasks for 36 hours in CDM-PVA supplemented with FGF-2 (20 ng/ml, 
Wellcome Trust - MRC Centre for Stem Cell Research, Cambridge, UK), LY294002 (10 ng/ml, 
Sigma) and BMP4 (10 ng/ml, Thermo Fisher Scientific). Subsequently, lateral plate mesoderm 
formation was induced by culturing the early mesoderm cell population for a further 3.5 days 
in CDM-PVA + FGF-2 (20 ng/ml) and BMP4 (50 ng/ml), whereas paraxial mesoderm 
formation was induced by culturing the early mesoderm cell population for 3.5 days in CDM-
PVA supplemented with FGF-2 (20ng/ml) and LY294002 (10 ng/ml).  By contrast, 
neuroectoderm specification was induced by culturing iPSCs for 7 days in CDM-PVA 
supplemented with FGF-2 (12 ng/ml) and the ALK4/5/7 inhibitor SB-431542 (10 µM, Tocris 
Bioscience).   
Upon formation of these three intermediate lineages, the cells were subsequently trypsinised 
and SMC differentiation was induced by culturing the cells for at least 12 days in gelatine-
coated T-25 flasks containing CDM-PVA supplemented with PDGF-BB (10 ng/ml, Thermo 
Fisher Scientific) and TGF-b1 (2 ng/ml, Thermo Fisher Scientific) (hereafter referred to as 
‘PT’). In addition to differentiation in PT, lateral plate mesoderm-derived iPSC-SMCs (LM-
iPSC-SMCs) were also differentiated in PT medium supplemented with BMP4 (50 ng/ml) 
(hereafter referred to as ‘PTB’). Where relevant, the iPSC-SMCs at the end of the serum-free 
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2.6 – Microarray hybridisation and analysis 
 
RNA isolated from PASMCs, LM-SMCs, PM-SMCs, NE-SMCs and cDNA libraries were 
hybridised to the Illumina Human HT-12 BeadChip (Illumina Inc., San Diego, 
http://www.illumina.com). All data processing and analysis were performed using the 
algorithms included with the Bioconductor packages beadarray and lumi implemented in R 
software environment for statistical computing and graphics (R Foundation for Statistical 
Computing, Vienna, Austria, http://www.r-project.org). Principal component analysis (PCA) 
and hierarchical clustering was performed and plotted with Perseus software, which used 
complete linkage and Euclidean distance metric to generate the heat maps. 
 
2.7 – RNA extraction 
 
Cell pellets for RNA extraction were either frozen directly or stored in TRIzol Reagent (Thermo 
Fisher Scientific) at -80°C. After homogenisation of the cell pellet, RNA was extracted from 
TRIzol suspension or using the RNeasy Plus Mini Kit (Qiagen) as per the manufacturers’ 
instructions. 
 
2.8 – Reverse Transcription and Real-Time Quantitative Polymerase Chain 
Reaction (RT-qPCR) 
 
1 µg of total RNA per sample, quantified using a NanoDrop Lite UV spectrophotometer, was 
treated with DNase I (Amplification Grade) and subsequently reverse transcribed into cDNA 
using the High-Capacity cDNA Reverse Transcription Kit and a Veriti 96-Well Thermal Cycler 
(all from Thermo Fisher Scientific) by following the manufacturer’s protocol. The PCR 
thermocycler settings were: 25˚C for 10 min, followed by 37˚C for 2 hours and then 85˚C for 
5 min. qPCR reactions were set up in triplicates in MicroAmp Optical 384-Well Reaction Plate 
with Barcode (Thermo Fisher Scientific) PCR plates using SYBR® Green JumpStart™ Taq 
ReadyMix™ (5 µl per well, Sigma), ROX Reference Dye (0.2 µl per well, Thermo Fisher 
Scientific), cDNA made from 10 ng of total RNA, as well as 167 nM of sense and antisense 
primers (sequences listed in Table 2.6). Primers were tested for amplification efficiency by 
assessing cDNA amplification over a 4-log scale using 10-fold serial dilutions of cDNA (from 
1:10 to 1:10,000). Primer efficiencies were calculated from a linear regression line plotted for 
cycle threshold (Ct) against the DNA dilution. Only primers with amplification efficiencies 
between 90% and 110% were used. 
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Quantitative PCR (qPCR) amplification was performed using a QuantStudio 6 Flex Real-time 
PCR System (Thermo Fisher Scientific) using the following thermal cycling parameters: initial 
denaturation at 95°C for 2 minutes, 50 cycles of denaturation at 95°C for 30 seconds, annealing 
at 55°C for 30 seconds, extension at 72°C for 30 seconds, followed by a step at 55°C for 2 
minutes, and then 95°C for 15 seconds, 55°C for 60 seconds, followed by 95°C for 15 seconds 
to generate a melt curve, with a ramp rate of ±1.6°C/s between each step. Data were analysed 
using Life Technologies QuantStudio Software V1.1 and Microsoft Excel by the comparative 
2-(∆∆Ct) method (Livak & Schmittgen, 2001), with gene expression normalised to HPRT or 
HMBS (PBGD) as the internal housekeeping reference gene. 
 
2.9 – Immunocytochemistry 
 
iPSC-SMCs cultured in 24-well cell culture plates were washed with phosphate-buffered saline 
(PBS) (0.5 ml/well) at room temperature and fixed at 4°C overnight with 4% paraformaldehyde 
(PFA, Sigma) in PBS. Cells were subsequently washed for 3 × 5 min in PBS, permeabilised for 
3 × 10 minutes with 0.2% Tween-20 (Sigma) in PBS and blocked for at least 1 hour at room 
temperature with 10% FBS in PBS. Cells were then stained at 4°C overnight with the following 
primary antibodies diluted in 0.1% BSA (Sigma) in PBS: monoclonal mouse anti-myosin 
(smooth) (1:200, M7786, Sigma), monoclonal mouse anti-smooth muscle myosin heavy chain 
11 (1:400, ab683, Abcam), mouse anti-human smooth muscle actin (1:300, M0851, Dako), 
monoclonal mouse anti-calponin (1:5000, C2687, Sigma). Subsequently, cells were washed for 
5 × 5 minutes in PBS at room temperature prior to incubation for 1 hour at room temperature 
with donkey anti-mouse Alexa Fluor 488 fluorochrome-conjugated secondary antibody (1:300, 
Thermo Fisher Scientific). Cells were then washed with PBS for 5 × 5 minutes, incubated with 
4′,6-diamidino-2-phenylindole (DAPI) (1 µg/ml, D9542, Sigma) for 5 minutes at room 
temperature, and washed for 3 × 5 minutes in PBS prior to imaging using a Leica DMI3000 B 
manual inverted microscope with a Leica EL6000 external light source for fluorescence 
excitation. Uncompressed TIFF colour images were captured with a Pixera Penguin 600CL 
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2.10 – Western blotting 
 
Western blotting for Smad1/5 was performed by Dr Liam Hurst prior to the start of this thesis 
project. Proteins were separated by sodium dodecyl sulphate polyacrylamide agarose gel 
electrophoresis (SDS-PAGE) and transferred electrophoretically from the gel to an Amersham 
Hybond P polyvinylidene difluoride (PVDF) membrane (GE Healthcare) via semi-dry 
transfer. After transfer, membranes were blocked in 5% non-fat milk powder (Marvel) in TBS-
Tween 20 for 1 hour and then incubated at 4ºC overnight with primary antibodies directed 
against pSmad1/5 or total Smad1 (1:1000, Cell Signaling Technology) in 5% BSA 
(Sigma). The next day, membranes were washed and then incubated for 1 hour at room 
temperature with secondary antibody (anti-rabbit horseradish peroxidase (HRP), 1:2000) in 5% 
milk. Membranes were visualised by chemiluminescence using Amersham ECL Western 
Blotting Detection Reagent (GE Healthcare). 
 
2.11 – Cell proliferation assays  
 
2.11.1 – Assessing iPSC-SMC proliferation using cell counts 
 
iPSC-SMCs were laid down in triplicates in gelatine-coated 24-well plates at a density of 2 x 
104 cells per well and cultured for 7 days in either CDM-PVA + PT, CDM-PVA + PTB, DMEM 
+ 5% FBS, DMEM + 2% FBS or DMEM + 2% FBS + BMP4 (50 ng/ml). On Day 7, the cells 
in each well were trypsinised for 5 minutes at 37 ºC with 200 µl of TrypLE Select + EDTA (2 
mM), neutralised with 100 µl of PBS + EDTA (2 mM) and counted manually using disposable 
haemocytometer counting grids (Kova International). Proliferation rates were assessed by 
calculating and comparing fold changes in cell number after 7 days in culture for each cell line.  
  
2.11.2 – Assessing proliferation by measuring cellular DNA content   
 
LM-iPSC-SMCs were laid down in triplicates in gelatine-coated 6-well plates at a density of 5 
x 105 cells per well and cultured for 48 hours in CDM-PVA + PT or CDM-PVA + PTB. The 
cells in each well were then trypsinised for 5 minutes at 37 ºC using 0.5 ml of 1x TrypLE Select 
+ EDTA (2 mM), neutralised with 1 ml of CDM-PVA and counted manually using disposable 
haemocytometer counting grids. 2 x 105 cells from each suspension were then transferred into 
separate 5 ml round-bottom polystyrene tubes (BD Biosciences), centrifuged at 300 x g for 5 
minutes and re-suspended in 400 µl of CDM-PVA. 0.8 µl of Vybrant DyeCycle Ruby Stain 
(ThermoFisher Scientific) was then added to the re-suspended cells in each sample before 
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incubating the cells in the dark for 15 minutes at 37ºC and subsequently measuring the 
percentage of cells in each sample which displayed red fluorescence by running the samples on 
a BD Accuri C6 flow cytometer (BD Biosciences) using 488 nm excitation and >670 nm 
emission. An unstained sample containing 2 x 105 C2 control LM-iPSC-SMCs served as a 
negative control.  
 
2.11.3 – Somatostatin proliferation assays   
 
PAH patient-derived BMPR2+/- PASMCs and isogenic iPSC-SMCs differentiated in PTB were 
laid down in triplicates in gelatine-coated 24-well plates at a density of 2 x 104 cells per well 
and cultured for 7 days in CDM-PVA + 5% FBS (for iPSC-SMCs) or DMEM + 5% FBS (for 
PASMCs) in the presence or absence of somatostatin-14 (1 µM, Sigma) or the somatostatin 
analogues lanreotide (1 µM, Sigma), octreotide (100 nM – 1 µM, Sigma) or CH-275 (100 nM 
– 1 µM, Tocris Bioscience). After 7 days in culture, the cells in each well were trypsinised for 
5 minutes at 37 ºC with 200 µl of TrypLE Select + EDTA (2 mM), neutralised with 100 µl of 
PBS + EDTA (2 mM) and counted manually using disposable haemocytometer counting grids 
(Kova International).  
  
2.12 – Apoptosis assays  
 
2.12.1 – Annexin-V-FITC/propidium iodide apoptosis assay 
 
Serum-free LM-iPSC-SMCs were laid down in triplicates in 6-well plates at a density of 2 x 
105 cells per well and cultured for 48 hours in CDM-PVA + PT or CDM-PVA + PTB. 
Subsequently, cells were washed once with PBS and apoptosis was induced for 2.5 hours by 
replacing the growth medium with serum-free DMEM. For the unstained negative control, the 
medium was replaced with fresh CDM-PVA + PT or CDM-PVA + PTB. As a positive control 
for apoptosis, wild-type iPSC-SMCs were treated with staurosporine (50 nM, Enzo Life 
Sciences) during the 2.5-hour serum-free incubation period. Subsequently, all cell samples were 
washed once with PBS, trypsinised for 5 minutes at 37 ºC using 0.5 ml of 1x TrypLE Select + 
EDTA (2 mM), neutralised with 1 ml of CDM-PVA and collected in 5 ml round-bottom 
polystyrene tubes (BD Biosciences). The cells were then centrifuged at room temperature for 5 
minutes at 300 x g before removing the supernatant, adding 1.5 ml of PBS to each cell pellet 
and centrifuging the samples again for 5 minutes at 300 x g. The cells in each tube were then 
re-suspended in 100 µl of Annexin V Binding Buffer (BD Biosciences) before adding 5 µl of 
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fluorescein isothiocyanate (FITC)-conjugated annexin V and 5 µl of propidium iodide (PI) 
(supplied as part of the BD Biosciences FITC Annexin V Apoptosis Detection Kit I) to each 
sample, gently vortexing and then incubating the cells in the dark for 15 minutes at room 
temperature. 400 µl of Annexin V Binding Buffer was then added to each sample to quench the 
reaction before measuring the percentage of cells that were positive for FITC Annexin V 
staining whilst being negative for PI staining by running the samples on a BD Accuri C6 flow 
cytometer. FITC fluorescence was detected in the FL1 channel (533/30 band pass filter), 
whereas PI fluorescence was detected in the FL2 channel (585/40 band pass filter). Unstained 
C2 iPSC-SMCs and C2 iPSC-SMCs stained with either FITC Annexin V or PI (single-stained 
controls) were used for fluorescence compensation and gating.   
 
2.12.2 – Caspase 3/7 cleavage assay 
 
Serum-free LM-iPSC-SMCs were laid down in triplicates in a gelatine-coated 96-well tissue 
culture plate (CELLSTAR, Greiner Bio-one) at a density of 2 x 104 cells per well and cultured 
for 48 hours in 100 µl of CDM-PVA + PT (for cells differentiated in PT) or CDM-PVA + PTB 
(for cells differentiated in PTB) per well. The cells were then cultured for a further 1 hour in 
100 µl of their respective media (to assess basal apoptosis) or switched to 100 µl of serum-free 
DMEM or serum-free DMEM supplemented with staurosporine (50 nM) (to assess induced 
apoptosis). Subsequently, 100 µl of Caspase-Glo 3/7 reagent (Promega) was added to each well 
before mixing the contents of the wells using a plate shaker at 400 rpm for 30 seconds and 
incubating the plate at room temperature in the dark for 1 hour. The contents of each well were 
then transferred to a 96-well white polystyrene microplate (BRAND) and the luminescence of 
each sample measured using a Centro LB 960 microplate luminometer (Berthold 
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2.13 – iPSC-SMC and PASMC contractility assay 
 
Wild-type and BMPR2+/- LM-iPSC-SMCs matured for 7 days in DMEM + 10% FBS post-
differentiation in PTB, and human wild-type and BMPR2+/- PASMCs, were laid down in 
triplicates at a density of 5 x 104 cells per well in 12-well plates and cultured for 48 hours in 
DMEM + 10% FBS. The cells were then washed for 2 x 3 minutes with warm PBS containing 
0.1% w/v bovine serum albumin (BSA), and subsequently incubated at 37°C for 15 minutes in 
0.1% w/v BSA + carbachol (300 µM, Sigma) in PBS. Carbachol-induced cell contraction was 
assessed by taking time-lapse images of the cells every 30 seconds over a period of 15 minutes 
and using ImageJ software (https://imagej.nih.gov/ij/) to measure percentage changes in 
individual cell surface areas (for n = 10-11 cells per cell line) between t = 0 and t = 15 minutes. 
 
2.14 – Mitochondrial membrane potential assay 
 
The polarisation state of the inner mitochondrial membrane in wild-type and BMPR2+/- LM-
iPSC-SMCs was assessed at three different time points – immediately after the cells finished 
differentiating in serum-free conditions, after the cells had been cultured for one week in 
DMEM + 10% FBS in the presence or absence of exogenous recombinant human TNFα (1 
ng/ml, R&D Systems), as well as after these untreated and TNFα-treated iPSC-SMCs were 
cultured for a further week in DMEM + 10% FBS only (i.e. after a total of two weeks in serum).  
At the end of each time-point, iPSC-SMCs were plated in triplicates at a density of 5 x 104 cells 
per well in gelatine-coated 12-well cell culture plates and cultured at 37°C for 48 hours in their 
respective media, after which the cells were loaded for 30 minutes with tetramethylrhodamine 
ethyl ester (TMRE) (30 nM, Enzo Life Sciences). Subsequently, the cells were incubated for 
30 minutes at 37°C in fresh cell culture medium containing 30 nM TMRE, washed with PBS, 
trypsinised for 5 minutes at 37 ºC using 0.25 ml of 1x TrypLE Select + EDTA (2 mM), 
neutralised with 0.5 ml of CDM-PVA and collected in 5 ml round-bottom polystyrene tubes 
(BD Biosciences) prior to measuring the mean fluorescence intensity of the stained cell 
population in the FL2 channel (585/40 band pass filter) on a BD Accuri C6 flow cytometer (BD 
Biosciences).  
 
To confirm that changes in TMRE staining intensity correctly reflected changes in 
mitochondrial membrane potential, wild-type iPSC-SMCs and PASMCs were incubated for 20 
minutes in DMEM + 10% FBS in the presence or absence of carbonyl cyanide 4-
trifluoromethoxyphenylhydrazone (FCCP, 5 µM), after which the cells were loaded for 30 
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minutes with TMRE (30 nM) in the continuing presence or absence of FCCP (5 µM) prior to 
analysis by flow cytometry. 
 
2.15 – Mitochondrial superoxide staining 
 
Isogenic C2 and C2 W9X+/- LM-iPSC-SMCs were differentiated in PT and laid down in 
triplicates in gelatine-coated 24-well cell culture plates at a density of 7.5 x 104 cells per well 
(for C2 iPSC-SMCs) or 1 x 105 cells per well (for C2 W9X+/- LM-iPSC-SMCs). The cells in 
each well were then cultured for 48 hours in DMEM supplemented with 10% FBS, washed 
with 0.5 ml of Hank’s balanced salt solution containing calcium and magnesium 
(HBSS/Ca/Mg, Thermo Fisher Scientific) and incubated for 30 min at 37 ºC in 500 µl of 
HBSS/Ca/Mg containing MitoSOX Red mitochondrial superoxide indicator (5 µM, Thermo 
Fisher Scientific). Unstained C2 LM-iPSC-SMCs were incubated in HBSS/Ca/Mg as a negative 
control. The cells were then washed three times with warm HBSS/Ca/Mg (500 µl/well) before 
taking representative immunofluorescence images of the cells in each well at 200x 
magnification using a Leica DMI3000 B manual inverted microscope equipped with a Leica 
EL6000 external light source for fluorescence excitation. The level of MitoSOX staining was 
assessed by measuring average image intensities using the “Measure” tool in ImageJ. 
        
2.16 – Seahorse XF glycolysis stress test assay 
 
Glucose-stimulated glycolytic rates in wild-type and BMPR2+/- iPSC-SMCs were assessed 
using the Seahorse XF Glycolysis Stress Test assay according to the manufacturer’s guidelines 
(Agilent Technologies), with modifications. To determine optimal cell densities for plating 
LM-iPSC-SMCs, wild-type and BMPR2+/- iPSC-SMCs were plated in triplicates at cell 
densities of 1 x 104, 2 x 104 or 3 x 104 cells per well in 96-well XF96 V3 PS cell culture 
microplates (Agilent Technologies), and cultured for 14 hours overnight in DMEM 
supplemented with 10% FBS. Cell confluency was then visually assessed by inspecting the 
cells under an inverted light microscope, after which the cells in each well were trypsinised 
using 50 µl of 1x TrypLE Select + EDTA (2 mM), neutralised with 100 µl of DMEM 
supplemented with 10% FBS and counted manually using disposable haemocytometer counting 
grids to assess cell attachment. A plating density of 3 x 104 cells per well resulted in optimal 
(95-99%) cell confluency for wild-type iPSC-SMCs, and the percentage of BMPR2+/- iPSC-
SMCs which attached was found to be approximately 50% lower relative to wild-type iPSC-
SMCs across the plating densities trialled. As a result, plating densities of 3 x 104 cells/well for 
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C2 iPSC-SMCs and 6 x 104 cells/well for isogenic BMPR2+/- iPSC-SMCs were chosen to 
ensure that the glycolysis stress test assay was performed on approximately equal numbers of 
confluent wild-type and BMPR2+/- iPSC-SMCs. 
On the day of the assay, XF Base Medium (Agilent Technologies) was supplemented with L-
glutamine (1 mM, Thermo Fisher Scientific), adjusted to pH 7.4, sterile-filtered through a 0.2 
µm PES membrane and then used to wash the attached iPSC-SMCs two times (200 µl per well 
per wash) prior to incubating the iPSC-SMCs in 180 µl of this XF assay medium at 37 ºC in a 
non-CO2 buffered incubator for 1 hour. During this time, the XF sensor cartridge, previously 
hydrated overnight according to the manufacturer’s guidelines (Agilent Technologies), was 
loaded with the injection compounds (all dissolved in XF assay medium, pH-adjusted to pH 7.4 
































































    
Table 2.5. Compounds used for loading Seahorse XF sensor cartridge ports  
        
The hydrated sensor cartridge with the added compounds was then loaded into a Seahorse XF96 
analyser (Agilent Technologies). After automated calibration, the utility plate used for 
calibration was replaced with the XF96 V3 PS cell culture microplate containing the iPSC-
SMCs immediately prior to the start of the glycolysis stress test assay.  
Glycolysis was assessed by measuring the extracellular acidification rate (ECAR), which was 
automatically performed by the XF96 analyser four times for 3 minutes (with a 3-minute mixing 
step between each ECAR measurement) both before and after sequential injection of glucose 
(10 mM, Sigma) to stimulate glycolysis, oligomycin A (1 µM, Tocris Bioscience) to maximise 
the glycolytic rate, and 2-deoxy-D-glucose (50 mM, Thermo Fisher Scientific) to inhibit 
glycolysis. The rate of glycolysis was calculated by subtracting the last rate measurement taken 
prior to glucose injection from the maximum rate measurement before oligomycin injection. 
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2.17 – RNA sequencing (RNA-Seq)  
 
2.17.1 – RNA-Seq library preparation 
 
Three wild-type (C2, C6 and C10) and five BMPR2+/- (C2 W9X+/-, C2 ∆Exon1, B3, B4 and 
B11) LM-iPSC-SMC lines (see Table 2.1 for characteristics) were submitted for RNA 
sequencing immediately after being differentiated under serum-free, chemically defined 
conditions in PTB. 
 
After harvesting and extracting RNA from these cells using the RNeasy Plus Mini Kit (Qiagen), 
the RNA concentration of each sample was determined using a Qubit Fluorometer (Thermo 
Fisher Scientific) and RNA integrity was assessed by running each RNA sample on a 
Bioanalyzer (Agilent Technologies) (performed by Dr Frances Burden, Department of 
Haematology, University of Cambridge, UK).   
 
RNA-Seq libraries were generated by Dr Frances Burden and Dr Mattia Frontini as previously 
described (Petersen et al., 2017) by using 1 µg of DNase-treated RNA to generate ribosomal 
RNA-depleted libraries with a TruSeq Stranded Total RNA Library Prep Kit (with Ribo-Zero 
Human/Mouse/Rat, RS-122-2201, Illumina). Libraries were quantified using a qPCR Library 
Quantification Kit (Kapa Biosystems), pooled and sequenced using paired-end 76 bp 
sequencing on a HiSeq 2000 Sequencing System (Illumina). 
 
2.17.2 – RNA-Seq analysis 
 
RNA-Seq analysis was performed by Dr Matthias Haimel and Dr Marta Bleda in Dr Stefan 
Gräf’s group in the Department of Medicine, University of Cambridge. Trim Galore 0.3.7 
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) with parameters ‘-q 15 --
stringency 3 --paired’ was used to trim PCR and sequencing adapters. Trimmed reads were 
aligned to the Ensembl v70 (Flicek et al., 2013) human transcriptome with Bowtie 1.0.1 
(Langmead et al., 2009), with parameters ‘-a --best --strata -S -m 100 -X 500 --chunkmbs 256 
--nofw -fr’. MMSEQ 1.0.8a (Turro et al., 2011; Turro et al., 2014) was used with default 
parameters to calculate fragment counts and DESeq2 (Love et al., 2014) was applied with 
regularised log transformation to quantify gene expression. Genes with an adjusted false 
discovery rate (FDR) P value < 0.05 were considered differentially expressed. 
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2.18 – Isolation of Bmpr2+/R899X mouse lung tissue 
 
Lung tissue was isolated from Bmpr2+/R899X mice by Dr Xudong Yang and Dr Lu Long as 
previously described (Long et al., 2015). Animal work was conducted in accordance with the 
UK Animals (Scientific Procedures) Act 1986 and approved under Home Office project licence 
number PPL 70/8850.  
 
2.19 - Statistical analysis 
 
Statistical analysis was performed using GraphPad Prism 6 software. Statistical analysis of 
iPSC-SMC data was based on either (i) the number of technical replicates (independent 
experiments performed on the same cells from the same iPSC-SMC differentiation), or (ii) on 
the number of experimental replicates where each experiment was performed using cells from 
independent iPSC-SMC differentiations. When the results from n independent iPSC-SMC 
differentiations were analysed, statistical tests were based on a sample size of n. Similarly, 
when data from n technical replicates were tested for statistical significance, the sample size 
was n. Where statistical analysis was performed, the type of statistical analysis used is stated in 
the corresponding figure legends. 
 
Data were tested for statistical significance using an unpaired two-tailed Student’s t-test, by 
one-way or two-way analysis of variance (ANOVA), or by performing false discovery rate 
(FDR) analysis (for RNA-Seq data). When performing ANOVA analysis, multiple comparisons 
were corrected for using Tukey’s, Dunnett’s or Sidak’s post-hoc tests. Results were deemed 
statistically significant when the Probability (P) value was less than 0.05. For FDR analysis, 
genes were deemed to be differentially expressed when the adjusted P value (Padj) was less than 
0.05.   
 
2.20 – PCR primer sequences 
 
The nucleotide sequences and sources of the PCR primers used in this thesis project are listed 













Forward primer (5’ – 3’) Reverse primer (5’ – 3’) Source/ 
Reference 




















































































Mouse qPCR primers 
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Human qPCR primers 
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CHAPTER 3 – RESULTS (I) 
 
Generating the tools to model PAH using 
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3.1 – Generation of BMPR2+/- iPSC lines with isogenic backgrounds 
 
Reduced BMPR2 signalling is central to the pathobiology of pulmonary arterial hypertension. 
However, an important observation in heritable PAH is that BMPR2 mutations exhibit reduced 
penetrance (Rosenzweig et al., 2008; van der Bruggen et al., 2016; Gu et al., 2017). Clinically, 
unaffected BMPR2 mutation carriers appear healthy and yet have a massively increased risk of 
developing PAH (Sztrymf et al., 2008). Furthermore, penetrance is higher in females (45%) 
than in males (15%) (Evans et al., 2016). These observations suggest a requirement for 
additional environmental or genetic triggers for disease initiation and progression. To date, it 
has proved difficult to elucidate these factors due to the lack of appropriate models. Therefore, 
alternative human disease models of PAH are required to gain a better understanding of PAH 
establishment and progression.  
 
Patient-specific iPSCs can be differentiated into disease-relevant cell types and have been used 
to model a number of human diseases, including PAH (West et al., 2014; Sa et al., 2017; Gu et 
al., 2017). However, previous studies have predominantly focused on using patient-derived 
iPSCs with different genetic backgrounds, thus making it difficult to delineate the precise 
contribution of individual BMPR2 mutations to the establishment of PAH-associated cellular 
phenotypes.    
 
To remove the effects that different genetic modifiers may have on the penetrance of cellular 
phenotypes, I therefore commenced this thesis project by generating wild-type and BMPR2+/- 
iPSC lines with an isogenic background. To achieve this, I used CRISPR-Cas9-mediated 
homologous recombination (Cong et al., 2013) to introduce a single pathogenic BMPR2 
mutation (W9X) into a control iPSC line (C2) which was previously derived from a disease-
free individual with no family history of PAH or cardiovascular disease (see Table 2.1 for 
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3.1.1 – CRISPR design 
 
CRISPR-Cas9 genome editing was used to artificially introduce a known, disease-associated 
BMPR2 mutation (W9X) into the C2 iPSC line originating from a wild-type individual with no 
family history of PAH (see Table 2.1). 
 
Prior to the start of this thesis project, a CRISPR-Cas9 system was designed by Dr Amer Rana 
so that the protospacer adjacent motif (PAM) sequence, fused to the 3’ end of a 20 bp guide 
RNA sequence, recognises the PAM sequence constituting the arginine (R7) position within 
exon 1 of the BMPR2 gene. The resulting CRISPR-Cas9 complex is therefore able to introduce 
a double-strand DNA break 2-3 bp upstream of the PAM sequence, resulting in the disruption 












          





Figure 3.1. CRISPR-Cas9 genome editing strategy used to introduce a heterozygous W9X 
mutation into the BMPR2 gene in the C2 control iPSC line. The engineered CRISPR-Cas9 complex 
contains a synthetic guide RNA (gRNA) which recognises a sequence of three nucleotides known as the 
protospacer adjacent motif (PAM) sequence (underlined in green) and interacts with the adjacent 20 
bases immediately upstream of this sequence (underlined in magenta). The Cas9 nuclease introduces a 
double-strand DNA break just upstream of the PAM sequence, thus increasing the efficiency of 
homologous recombination of the W9X targeting construct with the genomic locus. Successful targeting 
would result in the destruction of an endogenous PstI restriction enzyme site and introduction of a new 
AatII site (highlighted in dark blue). Furthermore, a total of 4 silent mutations (lower case nucleotides 
highlighted in red), in addition to the single point mutation (upper case nucleotide highlighted in red) 
required to generate the W9X mutation, were introduced to prevent the CRISPR from directing the 
cutting of the targeting construct and to aid the genotyping of correctly targeted clones. The completed 
targeting vector contains a 2 kilobase pair phosphoglycerate kinase promoter-driven neomycin 
resistance (PGK-Neo) and MC1-DTA (diphtheria toxin A) cassettes to enable positive and negative 
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To create this CRISPR-Cas9 complex, prior to the start of this thesis project, double-stranded 
DNA sequences encoding the desired CRISPR RNA targets (5’-
GGATGACTTCCTCGCTGCAGgtttt-3’ and 3’-gtggcCCTACTGAAGGAGCGACGTC-5’) 
were cloned into the GeneArt® CRISPR Nuclease Vector (Thermo Fisher Scientific) (Figure 




Figure 3.2. GeneArt® CRISPR Nuclease Vector map. The GeneArt® CRISPR Nuclease Vector with 
orange fluorescent protein (OFP) is 9219 bp in size. Double-stranded oligonucleotide sequences 
encoding the desired CRISPR RNA targets are cloned into the vector where the 3’ overhangs are located. 
The auxiliary trans-activating CRISPR RNA (tracrRNA) allows the Cas9 nuclease to be loaded onto the 
guide RNA, the expression of which is driven by the human U6 promoter. Cas9 nuclease and OFP 
expression are driven by the cytomegalovirus (CMV) promoter. The vector also contains a TK pA 
polyadenylation signal, a self-cleaving 2A peptide linker, F1 and pUC origins of replication, an 
ampicillin resistance gene and a Pol III terminator that helps to stop RNA Polymerase III-mediated 
transcription.  Image reproduced from the GeneArt® CRISPR Nuclease Vector kit manual (Thermo 




          
                                                                                                                               Chapter 3 – Results (I) 
 
 69 
3.1.2 – Generation of the W9X targeting construct 
 
To insert a W9X mutation into exon 1 of BMPR2 by CRISPR-mediated homologous 
recombination, a 1 kb genomic fragment including exon 1 (Chromosome 2: 202,376,889 - 
202,377,848) was cloned from the iPSC line C2 using the BMPR2 W9X left and right homology 
arm primer sequences listed in Table 2.6 and by following the Zero Blunt TOPO PCR cloning 
kit protocol (Thermo Fisher Scientific). The W9X mutation was introduced into exon 1 by site-
directed mutagenesis by using 50 ng of genomic DNA (gDNA) template to replace the TGG 
sequence encoding the tryptophan at position 9 in the coding region with a TGA sequence 
encoding a stop codon (Figure 3.1). The SDM primers (sequences listed in Table 2.6) were 
designed in a way that would enable an AatII restriction site to be introduced 22 bp upstream 
of the W9X site within the left homology arm of the targeting construct. Introduction of this 
AatII restriction site would destroy an endogenous PstI site after homologous recombination 
with the targeted allele. Furthermore, a total of 4 silent mutations, in addition to the single point 
mutation required to generate the W9X mutation, were introduced to prevent the CRISPR from 
directing the cutting of the targeting construct and to aid the genotyping of correctly targeted 
clones.  
 
To complete the targeting construct, this engineered 1 kb fragment was cloned into a vector 
upstream of a 2 kb phosphoglycerate kinase promoter-driven neomycin resistance (PGK-Neo) 
positive selection cassette, a second 1.3 kb homology arm corresponding to intron 1 of BMPR2 
(Chromosome 2: 202,377,863 - 202,379,154), and an MC1-DTA (diphtheria toxin A) negative 
selection cassette). In addition to performing test digestion reactions using PstI and AatII 
restriction enzymes, samples were sent for Sanger sequencing (Source Bioscience, Cambridge, 
UK) to verify that the W9X mutation was successfully introduced and that the targeting 










          
                                                                                                                               Chapter 3 – Results (I) 
 
 70 
3.1.3 – Generation of the ∆Exon1 targeting construct 
 
The targeting vector used to generate the W9X targeting construct was also used to generate a 
targeting vector that would result in the deletion of exon 1 of the BMPR2 gene (∆Exon1) 
(Figure 3.3). This work was performed by Dr C-Hong Chang and is described in Section 2.4.2.  
 
 
Figure 3.3. Targeting strategy used to delete exon 1 of the BMPR2 gene. The targeting construct 
consists of a 1.1 kb homology region containing a single PvuI restriction enzyme site, a 2 kb 
phosphoglycerate kinase promoter-driven neomycin resistance (PGK-Neo) positive selection cassette, 
a second 1.3 kb homology arm corresponding to intron 1 of BMPR2, and an MC1-DTA (diphtheria toxin 
A) negative selection cassette. Successful CRISPR-Cas9-mediated homologous recombination would 
result in the introduction of the PvuI site and the insertion of the PGK-Neo cassette into the targeted 
BMPR2 locus. The MC1-DTA expression cassette contains a constitutively active hybrid polyoma virus 
enhancer/herpes simplex virus thymidine kinase (HSVtk) promoter and prevents the survival of cells in 


















          
                                                                                                                               Chapter 3 – Results (I) 
 
 71 
3.1.4 – CRISPR validation 
 
Having generated the W9X and ∆Exon1 targeting constructs, I next set out to confirm whether 
the CRISPR nuclease vector containing double-stranded DNA sequences encoding the desired 
CRISPR RNA targets and an orange fluorescent protein (OFP) reporter (Figure 3.2) can be 
successfully introduced into control C2 iPSCs by electroporation. Transfected C2 iPSCs 
displayed orange fluorescence when visualised under a fluorescence microscope 48 hours post-
transfection (Figure 3.4 A), indicating successful expression of the transfected CRISPR vector. 
Furthermore, flow cytometric analysis of C2 iPSCs 24 hours post-transfection (performed by 
staff at the NIHR Cambridge BRC Cell Phenotyping Hub) revealed that 86.3% of cells transfected 
with the pmaxGFP control vector displayed green fluorescence (Figure 3.4 B) and that 22.5% 
of the iPSCs transfected with the CRISPR vector displayed orange fluorescence indicative of 
OFP expression (Figure 3.4 C). 
 
          




Figure 3.4. Functional expression of the CRISPR nuclease vector in control C2 iPSCs. (A) 
Representative immunofluorescence images (100x magnification) of control C2 iPSCs transfected by 
electroporation with a GeneArt CRISPR Nuclease Vector containing the desired CRISPR target 
sequences and an orange fluorescent protein (OFP) reporter. Transfection with pmaxGFP vector served 
as a positive control. Transfected C2 iPSCs displayed orange fluorescence, indicating successful 
expression of the transfected CRISPR vector, albeit with a lower transfection efficiency compared to 
the pmaxGFP control vector. (B and C) Flow cytometric analysis of C2 iPSCs approximately 24 hours 
post-transfection revealed that 86.3% of cells were successfully transfected with the pmaxGFP control 
plasmid (B), whereas 22.5% of cells transfected with the CRISPR vector displayed orange fluorescence 
indicative of OFP expression (C). Flow cytometric analysis was performed by staff at the NIHR 
Cambridge BRC Cell Phenotyping Hub at the Department of Medicine, University of Cambridge. PE-
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In addition, I followed the GeneArt Genomic Cleavage Detection Kit protocol (Thermo Fisher 
Scientific) to estimate the efficiency with which the CRISPR construct cleaved genomic DNA 
at the BMPR2 locus in transfected C2 iPSCs. To do this, loci at which CRISPR-Cas9 produced 
targeted double-strand breaks and resulted in insertions/deletions (indels) being created by 
cellular repair mechanisms were amplified by PCR. The PCR product was then denatured and 
re-annealed in order to enable strands with indels to re-anneal with strands without indels or 
with different indels, thus creating mismatches. These mismatches were subsequently detected 
and cleaved by Detection Enzyme, with the resultant bands being analysed on a 2% agarose gel 
(Figure 3.5). CRISPR cleavage efficiency was calculated by performing band densitometry 
and inputting the calculated band intensities into the following formulae: 
 
Cleavage Efficiency = 1 – [(1-fraction cleaved)1/2] 
where 
Fraction Cleaved = Sum of cleaved band intensities/(sum of cleaved and parental band intensities) 
 
Band densitometry revealed that the CRISPR-Cas9 nuclease cleaved approximately 71% of the 
amplified PCR product with an efficiency of 46%. Taken together, these findings suggest that 








          





Figure 3.5. Analysis of CRISPR cleavage efficiency. The efficiency with which the CRISPR construct 
produced targeted double-strand breaks at the locus of interest after electroporation was determined 
using the GeneArt® Genomic Cleavage Detection Kit (Thermo Fisher Scientific). Loci at which 
CRISPR-Cas9 produced targeted double-strand breaks and resulted in insertions/deletions (indels) being 
created by cellular repair mechanisms were amplified by PCR. The PCR product was then denatured 
and re-annealed in order to enable strands with indels to re-anneal with strands without indels or with 
different indels, thus creating mismatches. These mismatches were subsequently detected and cleaved 
by Detection Enzyme, with the resultant bands being analysed on a 2% agarose gel. Band densitometry 
using ImageJ software revealed that the CRISPR-Cas9 nuclease cleaved approximately 71% of the 
amplified PCR product with an efficiency of 46%. The formulae used to calculate CRISPR cleavage 
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3.1.5 – Introduction of BMPR2 mutations into a control iPSC line 
 
The W9X targeting DNA construct was designed in such a way that successful CRISPR-Cas9-
mediated homologous recombination would confer neomycin resistance to the targeted iPSCs 
and result in the disruption of an endogenous PstI restriction enzyme site whilst creating a new 
AatII site within the targeted allele (Figure 3.1).  
 
Having successfully generated the W9X targeting vector, I co-transfected wild-type C2 iPSCs 
with the linearised W9X targeting construct and the CRISPR vector. After 5 days of culturing 
the transfected cells in cell culture medium containing the neomycin sulphate analogue 
Geneticin (G418, 50 ng/ml), over fifty geneticin-resistant iPSC colonies emerged from a 
starting population of 2.4 x 106 transfected cells. Twenty-two of these colonies were picked and 
genotyped by PCR to amplify a 1.1 kb region containing the W9X site. When genotyped, three 
of these picked colonies gave rise to PCR products which were digested by AatII restriction 
enzyme but were not digested by PstI. If homologous recombination is successful, AatII should 
cut the DNA at a single site within the 1.1 kb homology region to produce 750 bp and 350 bp 
bands on an agarose gel, which is what I observed (Figure 3.6 A). Taken together, these results 
suggest that these three iPSC colonies were successfully and correctly targeted.  
 
By contrast, successful CRISPR-Cas9-mediated homologous recombination of the ∆Exon1 
targeting construct would confer neomycin resistance and result in the introduction of a new 
PvuI restriction site within the targeted allele (see Figure 3.3). When genotyped, successfully 
targeted colonies gave rise to PCR products which were digested by PvuI to produce the 
expected 547 bp and 293 bp bands on an agarose gel (Figure 3.6 B). 
 
In iPSCs targeted with the W9X targeting construct, one of the targeted colonies was 
heterozygous for the W9X mutation (C2 W9X+/-), whereas the other two were homozygous (C2 
W9X-/-). By contrast, in iPSCs targeted with the ∆Exon1 targeting construct, two heterozygous 
iPSC colonies (C2 ∆Exon1) were obtained. Successful introduction of the W9X and ∆Exon1 
mutations into C2 iPSCs was confirmed by Sanger sequencing (performed by Source 
Bioscience, Cambridge, UK, and shown for the W9X mutation in Figure 3.6 C). qPCR analysis 
revealed that BMPR2 mRNA expression was significantly lower in C2 W9X+/-, C2 W9X-/- and 
C2 ∆Exon1 iPSCs relative to the C2 control iPSC line (Figures 3.6 D-E), thus further 
suggesting that successful targeting had been achieved. 
          




Figure 3.6. Generation of two types of BMPR2 mutations in a human control iPSC line. (A) 
Genotyping to reveal W9X heterozygous and homozygous alleles. Geneticin-resistant iPSC colonies 
were picked and genotyped by PCR to amplify the 1.1 kb homology region containing the W9X site, 
giving rise to PCR products that were not digested by PstI restriction enzyme but were digested by AatII 
to produce the predicted 750 bp and 350 bp band sizes on a 2% agarose gel. (B) Genotyping to reveal 
the ∆Exon1 heterozygous allele (performed by Dr C-Hong Chang). Geneticin-resistant iPSC colonies 
transfected with the ∆Exon1 targeting construct gave rise to PCR products which were digested by PvuI 
to produce the predicted 547 bp and 293 bp band sizes on a 2% agarose gel. (C) Sanger sequencing 
confirmed the introduction of a heterozygous or homozygous W9X mutation into C2 iPSCs. The 
sequence is shown as a reverse complement, with start methionine indicated by an arrow showing the 
direction of the reading frame. (D and E) qPCR analysis showed that the newly generated heterozygous 
(C2 W9X+/- and C2 ∆Exon1) and homozygous (C2 W9X-/-) BMPR2 mutant iPSC lines displayed 
reduced BMPR2 mRNA expression relative to control C2 iPSCs. Data in D and E presented as mean ± 
s.e.m. of n=2-3 independent qPCR analyses performed on cells from the same differentiation (** P < 
0.01, *** P < 0.001, one-way ANOVA with Tukey’s post hoc test (D) and unpaired two-tailed Student’s 
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In addition, to check that transfection of the CRISPR vector did not have any confounding 
effects on cell phenotypes being studied, I also carried out a control transfection which involved 
transfecting C2 iPSCs with the CRISPR vector and a pmaxGFP control plasmid (Lonza) only. 
Successfully transfected cells were selected by fluorescence-activated cell sorting (FACS), with 
the resulting C2 pmaxGFP iPSC line displaying a similar proliferation rate compared to the 
wild-type C2 iPSC line (data not shown). 
 
3.2 – Generation of lineage-specific iPSC-derived smooth muscle-like 
cells that can be used as surrogates for distal PASMCs 
 
Previous work has shown that PAH patient-derived iPSCs can be differentiated into 
endothelial-like cells (iPSC-ECs) that recapitulate some PAH-associated cellular phenotypes 
and can be used as surrogates for PAECs (Sa et al., 2017). However, no iPSC-SMC model of 
PAH has yet been described and the derivation of iPSC-SMCs that perfectly represent adult 
PASMCs is yet to be achieved.  
 
When developing protocols for differentiating iPSCs into vascular smooth muscle-like cells, it 
is important to ensure that the right types of cells are being produced and that these display 
functional responses akin to the specific type of primary cell they are trying to mimic. As it is 
the distal PASMCs that are predominantly affected in PAH, I therefore aimed to generate iPSC-
derived smooth muscle-like cells (iPSC-SMCs) with functional responses to BMP4 signalling 
akin to those observed in distal PASMCs (Yang et al., 2005). 
 
Distal PASMCs arise from lateral plate mesoderm, whereas the most proximal PASMCs arise 
from neural crest (Jiang et al., 2000). I thus used previously published lineage-specific, serum-
free and chemically defined SMC differentiation protocols (Cheung et al., 2012) to generate 
iPSC-SMCs from the lateral plate mesoderm (LM-SMCs) and neural ectoderm (NE-SMCs) 
lineages. In addition, I also differentiated iPSCs from the paraxial mesoderm lineage as a further 
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3.2.1 – Lineage-specific iPSC-SMCs express several SMC markers 
 
After differentiating wild-type and BMPR2+/- iPSCs into iPSC-SMCs from lateral plate 
mesoderm, paraxial mesoderm and neuroectoderm, I performed immunostaining to show that 
these cells expressed the smooth muscle markers calponin and smooth muscle actin (SMA) 
(Figure 3.7). Furthermore, I also differentiated isogenic C2 and C2 W9X+/- iPSCs into LM-
iPSC-SMCs and showed that these cells stained positively for smooth muscle myosin heavy 
chain (MYH11) (Figure 3.8), which is considered to be the most robust marker of mature 
vascular smooth muscle cells (Owens et al., 2004). In addition, wild-type C2 LM-iPSC-SMCs 
displayed contractile responses to stimulation with carbachol (300 µM) (see Section 4.3.2). 
Taken together, these findings show that our iPSCs can be differentiated into SMCs using these 
lineage-specific differentiation protocols (Cheung et al., 2012). 
 
          





Figure 3.7. Lineage-specific iPSC-SMCs express the SMC markers smooth muscle actin and 
calponin. Representative immunofluorescence images of wild-type and BMPR2+/- iPSCs differentiated 
into iPSC-SMCs from lateral plate mesoderm (LM), paraxial mesoderm (PM) and neuroectoderm (NE), 
and immunostained for smooth muscle actin (SMA) and calponin (green). Nuclei were visualised using 
DAPI staining (blue). Scale bars are 20 µm. 
 
 
          





Figure 3.8. LM-iPSC-SMCs express the SMC marker smooth muscle myosin heavy chain. 
Representative immunofluorescence images of C2 wild-type and C2 W9X+/- LM-iPSC-SMCs 
immunostained for smooth muscle myosin heavy chain (MYH11, green). Nuclei were visualised using 
DAPI staining (blue). Scale bars are 100 µm. 
 
 
3.2.2 – Lateral plate mesoderm-derived iPSC-SMCs most closely resemble the gene 
expression profile of distal PASMCs  
 
Having successfully generated iPSC-SMCs from LM, PM and NE lineages, I collaborated with 
Dr Felipe Serrano from Dr Sanjay Sinha’s group to determine which of the three iPSC-SMC 
lineages most closely resembles the gene expression profile of distal PASMCs. To achieve this, 
I also collaborated with Dr Benjamin Dunmore who isolated RNA from PASMCs and with Dr 
Christine Cheung who isolated RNA from LM-, PM- and NE-iPSC-SMCs. Dr Serrano and his 
colleagues then used Illumina Human HT-12 v4 Expression BeadChip microarrays to perform 
a global microarray gene expression analysis, comparing adult proximal and distal PASMCs to 
LM-SMCs, PM-SMCs and NE-SMCs. Since the neural crest is one of the origins of pulmonary 
artery SMCs, a two-dimensional principal component analysis based on differential gene 
expression restricted to 171 neural crest- and SMC-specific genes (Chi et al., 2007; Betancur et 
al., 2010) was also carried out.  
 
In both of these analyses, distal PASMCs were more similar to LM-SMCs compared with NE-
SMCs and PM-SMCs based on the first principal component (Figure 3.9 A). These results 
suggest that, among these three different lineages, LM-SMCs might be the most appropriate 
surrogate for distal PASMCs in terms of gene expression profile.      
 
 
C2 C2 W9X+/- 
          
                                                                                                                               Chapter 3 – Results (I) 
 
 81 
3.2.3 – Lateral plate mesoderm-derived iPSC-SMCs mimic the BMP4 responsiveness 
of distal PASMCs 
 
To further characterise which lineage might serve as a surrogate for adult PASMCs, I examined 
the effect of BMP4 (50 ng/ml) on the growth responses of wild-type iPSC-SMCs from each 
lineage (Figure 3.9 B). After 1 week of exposure to 2% serum and BMP4 (50 ng/ml), SMCs 
from neural ectoderm and paraxial mesoderm origins were growth-inhibited by BMP4, 
consistent with the phenotype of adult-derived proximal PASMCs (Yang et al., 2005). By 
contrast, SMCs from the LM lineage were not growth-suppressed, consistent with responses 
reported in distal PASMCs derived from adults. Since iPSCs from different individuals varied 
in the absolute numbers of SMCs produced during the differentiation process, growth responses 
are presented as fold changes rather than absolute numbers of cells. 
 
Furthermore, I also showed that BMP4-treated wild-type LM-iPSC-SMCs were significantly 
less apoptotic compared to untreated wild-type LM-iPSC-SMCs (Figure 3.9 C), which is in 





          





Figure 3.9. LM-iPSC-SMCs display a gene expression profile and responses to BMP4 stimulation 
akin to distal PASMCs. (A) Gene expression patterns of proximal and distal human PASMCs, as well 
as iPSC-SMCs derived from paraxial mesoderm (PM-SMCs), neuroectoderm (NE-SMCs), and lateral 
plate mesoderm (LM-SMCs), were analysed using Illumina HumanHT-12 v4 Expression BeadChip 
microarrays. Gene expression patterns of samples were sorted based on similarity by hierarchical 
clustering. For this analysis, 171 SMC-specific genes were selected based on the wikipathway database 
(WikiPathway WP2064 revision 47071) and were subjected to two-dimensional principal component 
analysis of differential gene expression. (B) LM-SMCs are not growth-suppressed after being cultured 
for one week in cell culture medium supplemented with 2% FBS and BMP4 (50 ng/ml), unlike PM- and 
NE-SMCs. (C) Serum starvation-induced apoptosis in wild-type LM-SMCs, assessed using flow 
cytometric analysis of cells stained with annexin-V-FITC and propidium iodide, is significantly reduced 
in the presence of exogenous BMP4 (50 ng/ml), as previously described for distal PASMCs. Data in (B) 
and (C) presented as mean ± s.e.m. of 3 different iPSC-SMC lines (biological replicates) per group (* 
P < 0.05, *** P < 0.001, one-way ANOVA with Dunnett’s post hoc test (B) and unpaired two-tailed 
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3.2.4 – BMPR2+/- lateral plate mesoderm-derived iPSC-SMCs display reduced BMP 
signalling relative to wild-type iPSC-SMCs  
 
As further validation of the iPSC-SMC model of PAH, I performed qPCR analysis to confirm 
that the mRNA expression of BMPR2 and its downstream target genes ID1 and ID2 was 
significantly reduced in C2 W9X+/- LM-iPSC-SMCs relative to isogenic wild-type C2 LM-
iPSC-SMCs (Figure 3.10 A-C). In addition, similar to what has previously been described in 
adult distal PASMCs (Upton et al., 2013), previous work performed by Dr Liam Hurst in our 
group showed that PAH patient-derived BMPR2+/- LM-iPSC-SMCs display reduced Smad1/5 
phosphorylation in response to BMP4 stimulation (Figure 3.10 D-E). Taken together, these 
findings suggest that lateral plate mesoderm-derived iPSC-SMCs might be suitable surrogates 











          





Figure 3.10. BMPR2+/- LM-iPSC-SMCs display reduced BMP signalling (A-C) qPCR analysis of 
BMPR2 (A), ID1 (B) and ID2 (C) mRNA expression in isogenic C2 and C2 W9X+/- LM-iPSC-SMCs 
cultured for one week in 10% FBS post-differentiation. Data presented as mean ± s.e.m. of the results 
from two (A) or three (B and C) independent differentiations (* P < 0.05, ** P < 0.01, *** P < 0.001, 
unpaired two-tailed Student’s t test). (D) PAH patient-derived LM-iPSC-SMCs display reduced 
Smad1/5 phosphorylation following BMP4 (10 ng/ml) treatment, shown by a representative Western 
blot for phospho-Smad1/5 and total Smad1 (loading control: α-tubulin) in untreated and BMP4-treated 
wild-type (C2 and C10), BMPR2+/- (B3 and B11) and non-BMPR2+/- idiopathic pulmonary arterial 
hypertension (IPAH) (P3) patient-derived iPSC-SMCs, with the corresponding densitometry analysis 
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3.3 – Discussion 
 
In addition to developing the first iPSC-SMC model of PAH associated with mutations in 
BMPR2, one of the main aims of this study was to examine the impact of BMPR2 mutation on 
the establishment of PAH-associated cellular phenotypes without the confounding effects of 
other genetic differences between cell lines. In this chapter, CRISPR-Cas9 genome editing was 
used to either introduce a known causal BMPR2 mutation (W9X) or delete exon 1 of the BMPR2 
gene (∆Exon1) in a wild-type iPSC line from a healthy individual with no family history of 
PAH or cardiovascular disease. This approach resulted in the generation of wild-type and 
BMPR2+/- iPSCs with an otherwise isogenic background, thus removing the effects that 
different genetic modifiers (Gu et al., 2017) may have on the penetrance of cellular phenotypes. 
As a result, any difference in phenotype between the wild-type and genome-edited BMPR2+/- 
iPSC lines can then be attributed to the introduction of the BMPR2 mutation. Although the 
possibility of CRISPR-mediated off-target effects cannot be excluded because these iPSC lines 
were not submitted to whole-genome sequencing, numerous studies have shown that such off-
target effects are rare (Smith et al., 2014; Suzuki et al., 2014; Veres et al., 2014; Chang et al., 
2015; Park et al., 2015; Li et al., 2016) and are thus unlikely to confound the phenotypes being 
studied.  
 
Another important new finding presented in this chapter is that wild-type and BMPR2+/- iPSCs 
differentiated into iPSC-SMCs via lateral plate mesoderm (LM), but not via paraxial mesoderm 
(PM) or neuroectoderm (NE), display a gene expression profile and functional responses to 
BMP4 signalling akin to distal PASMCs. This suggests that LM-iPSC-SMCs might be suitable 
surrogates for distal PASMCs when developing a human iPSC model of PAH. By comparison, 
a recent study using these three lineage-specific iPSC-SMC differentiation protocols (Granata 
et al., 2017) showed that neural crest-derived iPSC-SMCs are the most suitable surrogates for 
SMCs of the aortic root, ascending aorta and arch for studying the development of aortic 
aneurysms in Marfan syndrome. Taken together, these observations highlight the importance 
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It is important to note that the LM-iPSC-SMCs described in this thesis do not perfectly represent 
adult PASMCs. For example, although the gene expression profile of LM-iPSC-SMCs was 
similar to that of PASMCs in terms of the first principal component, it differed in the second 
principal component. Furthermore, because the generation of iPSC-SMCs that distinctly 
represent pulmonary as opposed to systemic smooth muscle cells is yet to be achieved, 
phenotypes that are only present in pulmonary vascular cells cannot be directly studied in this 
model. Nevertheless, because phenotypes such as aberrant proliferation, apoptosis and 
mitochondrial membrane polarisation are not unique to the pulmonary vasculature, this does 
not preclude LM-iPSC-SMCs from being used to develop an iPSC model of PAH. 
 
It is also worth noting that the iPSC-SMCs generated in this investigation might not be 
composed of a single homogenous SMC population. Due to a lack of definitive SMC subtype-
specific cell surface markers, lineage-specific iPSC-SMCs cannot easily be purified by 
fluorescent or magnetic-activated cell sorting (Kumar et al., 2017). Alternative strategies to 
purify iPSC-SMCs could involve generating iPSC-SMCs in which an antibiotic resistance gene 
is expressed under the control of the MYH11 promoter. This would allow iPSC-SMCs to be 
purified whilst still in the dish, as has been previously demonstrated with iPSC-derived 
cardiomyocytes (Kita-Matsuo et al., 2009; Ma et al., 2011).  
 
Nevertheless, Cheung et al. (2012) showed that more than 86% of LM-iPSC-SMCs expressed 
smooth muscle myosin heavy chain (MYH11), which is considered to be the most robust marker 
of mature SMCs (Owens et al., 2004). The LM-iPSC-SMCs described in this chapter were 
differentiated by following the same protocol described by Cheung et al. (2012) and also stained 
positively for the SMC markers smooth muscle actin (SMA), calponin and MYH11. Together 
with the observation that wild-type C2 LM-iPSC-SMCs displayed contractile responses to 
stimulation with carbachol (300 µM) (see Section 4.3.2), these findings suggest that the 
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4.1 – BMPR2 heterozygosity in iPSC-SMCs is necessary and sufficient to 
recapitulate several PAH-associated SMC phenotypes 
 
Having generated wild-type and BMPR2+/- LM-iPSC-SMCs with an otherwise isogenic 
background and shown that these cells mimic the BMP4 responsiveness of distal PASMCs, my 
next aim was to address the controversial question of whether genetic reduction of BMPR2 
alone is necessary and/or sufficient to establish major PAH-associated PASMC phenotypes in 
these cells. Compared to PASMCs from unaffected donor controls, PASMCs isolated from 
PAH patients have previously been shown to be more proliferative, less susceptible to 
apoptosis, and display increased inner mitochondrial membrane polarisation (Paulin & 
Michelakis, 2014). I therefore investigated whether BMPR2+/- LM-iPSC-SMCs are able to 
recapitulate these PAH-associated cellular phenotypes under basal serum-free, chemically-
defined conditions in the presence or absence of additional extrinsic growth and/or 
inflammatory stimuli such as serum, BMP4 and TNFα.  
 
4.1.1 – BMPR2+/- iPSC-SMCs are more proliferative relative to isogenic wild-type iPSC-
SMCs under serum-free, chemically-defined conditions 
 
Since increased PASMC proliferation is one of the hallmarks of PAH, I first set out to determine 
whether BMPR2 heterozygosity in iPSC-SMCs is sufficient to recapitulate this pro-proliferative 
PASMC phenotype. I initially differentiated C2 and C2 W9X+/- LM-iPSC-SMCs according to 
the standard LM protocol in serum-free, chemically-defined medium (CDM) supplemented 
with PDGF-BB (10 ng/ml) and TGF-b1 (2 ng/ml) (hereafter referred to as ‘PT’) (Figure 4.1 
A). These cells were subsequently cultured for one week in CDM + PT prior to assessing cell 
proliferation by performing cell counts and by measuring cellular DNA content. Under these 
serum-free conditions, cell counts revealed that there was no significant difference (P > 0.05) 
in proliferation between C2 W9X+/- iPSC-SMCs and isogenic wild-type C2 iPSC-SMCs 
(Figure 4.2 A). By contrast, when proliferation in PT was assessed by measuring cellular 
double-stranded DNA content using Vybrant DyeCycle Ruby stain, C2 W9X+/- iPSC-SMCs 
became significantly (1.5-fold, P < 0.001) more proliferative relative to C2 iPSC-SMCs (Figure 









Figure 4.1. Outline of the iPSC-SMC differentiation and culture conditions used when assessing 
cell proliferation. (A and C) Wild-type and BMPR2+/- iPSC-SMCs were initially differentiated via 
lateral plate mesoderm (LM) according to the standard LM protocol (Cheung et al., 2012) in serum-free, 
chemically-defined medium (CDM) supplemented with PDGF-BB (10 ng/ml) and TGF-b1 (2 ng/ml) 
(referred to as ‘PT’). After differentiation, LM-iPSC-SMCs were cultured for 7 days in either CDM + 
PT (A) or DMEM + 5% FBS (C) prior to assessing cell proliferation by measuring cellular DNA content 
and/or performing cell counts. (B and D) Cell proliferation was also assessed after differentiating wild-
type and BMPR2+/- iPSC-SMCs in the presence of a high concentration (50 ng/ml) of exogenous BMP4 
during the 12-day ‘PT’ SMC differentiation phase (referred to as ‘PTB’) and subsequently culturing the 
cells for 7 days in either CDM + PTB (B) or DMEM + 5% FBS (D). In all four protocols (A-D), lateral 
plate mesoderm formation was induced by culturing iPSCs for 1.5 days in CDM supplemented with 
FGF-2 (20 ng/ml), LY294002 (10 ng/ml) and BMP4 (10 ng/ml) (referred to as ‘FLyB’), after which the 
cells were cultured for 3.5 days in CDM supplemented with FGF-2 (20 ng/ml) and BMP4 (50 ng/ml) 














Figure 4.2. Proliferation of C2 and C2 W9X+/- iPSC-SMCs under serum-free conditions. Wild-type 
and BMPR2+/- iPSC-SMCs were differentiated under serum-free conditions in chemically-defined 
medium (CDM) supplemented with either PDGF-BB (10 ng/ml) and TGF-b1 (2 ng/ml) (hereafter 
referred to as ‘PT’) (A and B) or PDGF-BB (10 ng/ml), TGF-b1 (2 ng/ml) and BMP4 (50 ng/ml) 
(hereafter referred to as ‘PTB’) (C and D). iPSC-SMC proliferation was assessed by performing cell 
counts after culturing the differentiated cells for 7 days in CDM + PT (A) or CDM + PTB (C), or by 
measuring cellular DNA content via flow cytometric analysis of Vybrant DyeCycle Ruby staining (B 
and D). Data presented as mean ± s.e.m. of three technical replicates based on cells from the same 
differentiation (A and C), or based on the results from three independent differentiations (B and D) [n.s., 
not significant (P > 0.05), * P < 0.05, ** P < 0.01, *** P < 0.001, unpaired two-tailed Student’s t test].  
 
 
In view of the discrepancy between the findings obtained using these two complementary 
proliferation assays, I investigated whether the LM-iPSC-SMC differentiation protocol could 
be modified to better model distal PASMCs. Since BMP4 is highly expressed in the distal lung 
bud during development (Bellusci et al., 1996; Hogan, 1996), I repeated the iPSC-SMC 
proliferation assays after differentiating C2 and C2 W9X+/- LM-iPSC-SMCs in the presence of 
a high concentration (50 ng/ml) of exogenous BMP4 during the 12-day ‘PT’ SMC 
differentiation phase (hereafter referred to as ‘PTB’) (Figure 4.1 B).  
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After these cells were cultured for 7 days in serum-free PTB conditions, C2 W9X+/- iPSC-SMCs 
were significantly (2.5-fold, P < 0.05) more proliferative compared to isogenic C2 iPSC-SMCs 
(Figure 4.2 C). Consistent with these findings, C2 W9X+/- iPSC-SMCs were also significantly 
(2.2-fold, P < 0.01) more proliferative relative to C2 iPSC-SMCs when the proliferation of 
these cells was assessed by measuring cellular DNA content (Figure 4.2 D). Taken together, 
these results suggest that the pro-proliferative phenotype of C2 W9X+/- iPSC-SMCs was more 
pronounced after iPSC-SMCs were differentiated in PTB rather than in PT.  
 
In support of these observations, after iPSC-SMCs were cultured for one week in DMEM + 5% 
FBS post-differentiation, C2 W9X+/- iPSC-SMCs were 1.4 times more proliferative compared 
to C2 iPSC-SMCs after being differentiated in PT (Figure 4.1 C and Figure 4.3 A) but became 
2.4 times more proliferative after being differentiated in PTB (Figure 4.1 D and Figure 4.3 B). 
 
Since adult PAH patient-derived PASMCs are frequently reported to be at least two times more 
proliferative compared to wild-type PASMCs (Courboulin et al., 2012; Wilson et al., 2015; 
Boucherat et al., 2017), these findings suggest that C2 W9X+/- iPSC-SMCs differentiated in 
PTB recapitulate the pro-proliferative phenotype of distal PASMCs from PAH patients more 
closely and robustly compared to C2 W9X+/- iPSC-SMCs differentiated in PT.  
 
After serum-free differentiation in PTB, additional exposure to serum or other factors was not 
required for C2 W9X+/- iPSC-SMCs to be more proliferative relative to isogenic wild-type C2 
iPSC-SMCs. This suggests that BMPR2 heterozygosity in iPSC-SMCs differentiated in PTB is 


















Figure 4.3. Proliferation of C2 and C2 W9X+/- iPSC-SMCs in serum.  Proliferation of C2 and C2 
W9X+/- iPSC-SMCs was assessed by differentiating the cells in CDM-PVA + PT (A) or CDM-PVA + 
PTB (B), after which all cells were cultured for 7 days in DMEM + 5% FBS, trypsinised and counted 
manually using disposable haemocytometer counting grids. Data presented as mean ± s.e.m. of three 
technical replicates based on cells from the same differentiation [n.s., not significant (P > 0.05), * P < 
0.05, ** P < 0.01, unpaired two-tailed Student’s t test].     
 
 
Next, I performed cell counts to investigate whether the difference in proliferation between C2 
and C2 W9X+/- iPSC-SMCs is representative of the relative levels of cell proliferation observed 
in LM-iPSC-SMCs differentiated from wild-type and patient-derived BMPR2+/- iPSC lines that 
were previously generated by our laboratory (Geti et al., 2012; see Table 2.1 for 
characteristics).  
 
Similar to the difference in proliferation between C2 and C2 W9X+/-  iPSC-SMCs assessed by 
cell counts under serum-free PT conditions (Figure 4.2 A), cell counts revealed that patient-
derived BMPR2+/- iPSC-SMCs assayed under serum-free PT conditions displayed a non-
significant (P > 0.05) trend towards reduced proliferation compared to wild-type iPSC-SMCs 
(Figure 4.4 A). By contrast, patient-derived BMPR2+/- iPSC-SMCs became 1.8 times more 
proliferative compared to wild-type iPSC-SMCs when assayed under serum-free PTB 
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Furthermore, BMPR2+/- iPSC-SMCs differentiated in PT and subsequently cultured for one 
week in DMEM + 5% FBS displayed no significant difference in proliferation (P > 0.05) 
compared to wild-type iPSC-SMCs treated the same way (Figure 4.4 C) but became 
significantly (2.4-fold, P < 0.01) more proliferative in DMEM + 5% FBS after differentiation 
in PTB (Figure 4.4 D).  
 
Taken together, these findings suggest that BMPR2+/- iPSC-SMCs differentiated in PTB 
recapitulate the pro-proliferative phenotype of distal PASMCs from PAH patients more 
robustly compared to BMPR2+/- iPSC-SMCs differentiated in PT, thus validating the findings 




Figure 4.4. Proliferation of wild-type and PAH patient-derived BMPR2+/- iPSC-SMCs under 
serum-free and serum-containing conditions. Proliferation rates of wild-type and patient-derived 
BMPR2+/- iPSC-SMCs were assessed by differentiating cells in CDM-PVA + PT (A and C) or CDM-
PVA + PTB (B and D), after which the cells were cultured for 7 days in CDM-PVA + PT (A), CDM-
PVA + PTB (B) or in DMEM + 5% FBS (C and D). Subsequently, all iPSC-SMCs were trypsinised and 
counted manually using disposable haemocytometer counting grids. Data presented as mean ± s.e.m. of 
three wild-type and two patient-derived BMPR2+/- iPSC-SMC lines (A and B), or two wild-type and two 
patient-derived lines (C and D) based on cells from the same differentiation [n.s., not significant (P > 
0.05), * P < 0.05, ** P < 0.01, unpaired two-tailed Student’s t test].     
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4.1.2 – BMPR2+/- iPSC-SMCs are less apoptotic relative to isogenic wild-type iPSC-SMCs 
under serum-free, chemically-defined conditions 
 
Next, I used two complementary apoptosis assays to determine whether BMPR2 heterozygosity 
in iPSC-SMCs is sufficient to recapitulate the anti-apoptotic phenotype of PASMCs derived 
from PAH patients. First, I differentiated C2 and C2 W9X+/- iPSC-SMCs in PT or PTB and 
assessed apoptosis under basal serum-free conditions using the Caspase-Glo 3/7 Assay 
(Promega). This assay measures the activity of caspase-3 and caspase-7 in terms of their ability 
to cleave a pro-luminescent caspase-3/7 substrate. My analysis revealed that C2 W9X+/- iPSC-
SMCs were significantly (P < 0.01) less apoptotic relative to C2 iPSC-SMCs, regardless of 
whether they were differentiated in PT or PTB (Figures 4.5 A and C). These results were 
confirmed by flow cytometric analysis of isogenic wild-type and BMPR2+/- iPSC-SMCs which 
were positive for annexin-V-FITC staining but negative for propidium iodide (PI) staining 
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Figure 4.5. Serum-free BMPR2+/- iPSC-SMCs are less apoptotic relative to isogenic wild-type 
iPSC-SMCs. LM-iPSC-SMCs with isogenic backgrounds were differentiated in either PT (A and B) or 
PTB (C and D). (A and C):  Basal apoptosis in serum-free PT (A) or PTB (C) conditions was assessed 
using the Caspase Glo-3/7 Assay which provides a luminescent readout of caspase-3/7 activity. (B and 
D): As a complementary assay, iPSC-SMC apoptosis in PT (B) or PTB (D) was also assessed by flow 
cytometric analysis of iPSC-SMCs positive for annexin-V-FITC staining but negative for propidium 
iodide (PI) staining. Data presented as mean ± s.e.m. of the results from three independent 
differentiations, except for annexin-V-FITC/PI staining of C2 ∆Exon1 iPSC-SMCs differentiated in PT 
(B), which were only analysed in a single experiment. (* P < 0.05, ** P < 0.01, *** P < 0.001, unpaired 
two-tailed Student’s t test (A-C), or one-way ANOVA with multiple comparisons being corrected for 
using Dunnett’s post hoc test (D)).        
     
 
Furthermore, similar to the pro-proliferative phenotype of BMPR2+/- iPSC-SMCs, the anti-
apoptotic phenotype of C2 W9X+/- iPSC-SMCs was more pronounced after iPSC-SMCs were 
differentiated in PTB rather than in PT. 
 
In addition to displaying reduced rates of basal apoptosis relative to wild-type PASMCs, 
patient-derived BMPR2+/- PASMCs are also more resistant to apoptosis induction in response 
to extrinsic stimuli (Zhang et al., 2003). Therefore, I also used the Caspase-Glo 3/7 Assay to 
investigate whether C2 W9X+/- iPSC-SMCs are more resistant to apoptosis induction compared 
to C2 iPSC-SMCs in response to treatment for 1 hour with the protein kinase inhibitor 
staurosporine (50 nM). Although the difference in staurosporine-induced apoptosis was not 
statistically significant (P > 0.05), C2 W9X+/- iPSC-SMCs tended to be almost two times more 
resistant to staurosporine-induced apoptosis relative to C2 iPSC-SMCs (Figure 4.6).  
 
The level of apoptosis resistance observed in C2 W9X+/- iPSC-SMCs differentiated in PTB is 
in line with the level of apoptosis resistance observed in BMPR2+/- PASMCs derived from PAH 
patients (Courboulin et al., 2012; Boucherat et al., 2017). Furthermore, apoptosis resistance in 
C2 W9X+/- iPSC-SMCs was more pronounced after differentiation in PTB rather than in PT. 
Taken together, these findings further support the use of the PTB differentiation protocol for 
generating iPSC-SMCs that can be used to model distal PASMCs. In addition, these results also 
suggest that BMPR2 heterozygosity in iPSC-SMCs is necessary and sufficient to recapitulate 
the anti-apoptotic phenotype of distal PASMCs from PAH patients.  
 




Figure 4.6. Staurosporine-induced apoptosis in serum-free C2 and C2 W9X+/- iPSC-SMCs. 
Isogenic C2 and C2 W9X+/- iPSC-SMCs were differentiated in PTB, after which apoptosis was induced 
by culturing the cells for 1 hour in serum-free DMEM in the presence or absence of staurosporine (50 
nM), a broad-spectrum protein kinase inhibitor. Apoptosis was assessed using the Caspase Glo-3/7 
Assay which provides a luminescent readout of caspase-3/7 activity. Data presented as mean ± s.e.m. of 
the results obtained from three independent differentiations and expressed as fold changes in apoptosis 
after 1 hour of exposure to DMEM + staurosporine relative to the level of apoptosis observed after 
exposure to DMEM only [n.s., not significant (P > 0.05), unpaired two-tailed Student’s t test]. 
 
4.1.3 – Isogenic BMPR2+/- iPSC-SMCs display increased IL-6 mRNA expression relative 
to wild-type iPSC-SMCs  
 
In addition to increased proliferation and reduced apoptosis of PAH-derived PASMCs, serum 
levels of the pro-inflammatory cytokine IL-6 are significantly elevated in IPAH patients 
compared to controls (Humbert et al., 1995; Soon et al., 2010). Increased IL-6 expression has 
also been detected in PASMCs isolated from Bmpr2+/- mice with lipopolysaccharide (LPS)-
induced pulmonary hypertension (Soon et al., 2015), as well as in BMPR2+/- PAECs (Diebold 
et al., 2015).  
 
To test whether BMPR2+/- iPSC-SMCs also display increased IL-6 expression, I therefore 
performed qPCR analysis of IL-6 mRNA expression levels in wild-type and isogenic BMPR2+/- 
iPSC-SMCs. C2 W9X+/- iPSC-SMCs differentiated in PT displayed a non-significant trend (P 
> 0.05) towards increased IL-6 expression compared to wild-type C2 iPSC-SMCs (Figure 4.7 
A). However, this difference became statistically significant (P < 0.05) and more pronounced 
after iPSC-SMCs were differentiated in PTB (Figure 4.7 B). Taken together, these findings 
suggest that BMPR2 heterozygosity in iPSC-SMCs differentiated in PTB is sufficient to 
recapitulate the increased IL-6 expression observed in PAH-derived PASMCs. In addition, 
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generates cells that more strongly re-capitulate PAH-associated phenotypes observed in distal 




Figure 4.7. Isogenic BMPR2+/- iPSC-SMCs display increased IL-6 mRNA expression compared to 
wild-type iPSC-SMCs after differentiation in PTB but not after differentiation in PT. Quantitative 
PCR analysis of IL-6 mRNA expression in LM-iPSC-SMCs differentiated in PT (A) or PTB (B) during 
the last 12 days of the LM-iPSC-SMC differentiation protocol. Data presented as mean ± s.e.m. of the 
results from three independent differentiations [n.s., not significant (P > 0.05); * P < 0.05, unpaired two-
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4.2 – BMPR2+/- iPSC-SMCs only recapitulate the mitochondrial 
hyperpolarisation phenotype of patient-derived PASMCs under specific 
conditions  
 
Although I have shown that the iPSC model is able to recapitulate certain PAH-associated 
cellular phenotypes under serum-free conditions, not all phenotypes could be recapitulated 
under these conditions, as described below. 
 
4.2.1 – Inner mitochondrial membrane polarisation in isogenic iPSC-SMCs  
 
Hyperpolarisation of the inner mitochondrial membrane (IMM) is a feature of PASMCs and 
pulmonary artery endothelial cells (PAECs) isolated from patients with end-stage PAH and is 
linked to increased rates of glycolysis, changes in reactive oxygen species (ROS) production 
and vascular remodeling (Pak et al., 2013; Paulin & Michelakis, 2014; Diebold et al., 2015).  
 
First, I determined whether BMPR2 heterozygosity in iPSC-SMCs is sufficient to recapitulate 
IMM hyperpolarisation by performing flow cytometric analysis of isogenic wild-type and 
BMPR2+/- iPSC-SMCs stained with tetramethylrhodamine ethyl ester (TMRE, 30 nM). TMRE 
is a red fluorescent dye that is taken up into mitochondria at a rate that is proportional to the 
charge difference across the IMM, with a higher level of TMRE fluorescence being indicative 
of increased IMM polarisation.  
 
To confirm that changes in TMRE staining intensity in iPSC-SMCs and PASMCs reflect 
changes in mitochondrial membrane potential, I incubated C2 LM-iPSC-SMCs (n=1) and wild-
type PASMCs (n=3) for 20 minutes in the presence or absence of carbonyl cyanide 4-
trifluoromethoxyphenylhydrazone (FCCP, 5 µM), after which the cells were loaded for 30 
minutes with TMRE (30 nM) in the continuing presence or absence of FCCP. FCCP is a 
protonophore which causes mitochondrial uncoupling by dissipating the electrochemical proton 
gradient across the IMM and should hence reduce TMRE fluorescence under non-quenching 
conditions (Brand & Nicholls, 2011). Indeed, FCCP treatment significantly (P < 0.001) reduced 
TMRE fluorescence in wild-type PASMCs (Figure 4.8 A) and also decreased TMRE 
fluorescence in C2 iPSC-SMCs to a similar extent (Figure 4.8 B), confirming that the TMRE 
assay was working as expected. 
 





Figure 4.8. Effect of FCCP on inner mitochondrial membrane polarisation in C2 iPSC-SMCs and 
wild-type PASMCs. The mitochondrial uncoupling agent carbonyl cyanide 4-
trifluoromethoxyphenylhydrazone (FCCP, 5 µM) reduced inner mitochondrial membrane (IMM) 
polarisation in wild-type PASMCs (n=3) (A) and C2 iPSC-SMCs (n=1) (B). IMM polarisation was 
assessed by flow cytometric analysis of cells stained with tetramethylrhodamine ethyl ester (TMRE, 30 
nM), a red fluorescent dye that is taken up into mitochondria at a rate that is proportional to the charge 
difference across the IMM. Data in (A) presented as mean ± s.e.m. of the results obtained from three 





Having validated that changes in TMRE fluorescence reflected changes in mitochondrial 
membrane potential, I used TMRE staining to assess mitochondrial polarisation in isogenic 
iPSC-SMCs that were differentiated in PTB and assayed under serum-free conditions. 
Surprisingly, flow cytometric analysis of TMRE staining in these cells revealed that BMPR2+/- 
iPSC-SMCs had a significantly (P < 0.001) hypopolarised IMM state compared to their 
isogenic wild-type (Figure 4.10 A). I therefore investigated whether serum-free BMPR2+/- 
iPSC-SMCs might require exposure to extrinsic factors such as serum in order to acquire a 
hyperpolarised IMM state (see Figure 4.9 for an outline of these experiments).  
 

































































Figure 4.9. Schematic outline of the culture conditions used to assess inner mitochondrial 
membrane polarisation in iPSC-SMCs. Wild-type and BMPR2+/- iPSC-SMCs were differentiated via 
lateral plate mesoderm (LM) (Cheung et al., 2012) in serum-free, chemically-defined medium 
supplemented with PDGF-BB (10 ng/ml), TGF-b1 (2 ng/ml) and BMP4 (referred to as ‘PTB’). The 
inner mitochondrial membrane polarisation state (∆Ψm) of iPSC-SMCs was assessed by flow cytometric 
analysis of tetramethylrhodamine ethyl ester (TMRE, 30 nM) staining under the following culture 
conditions:  (A) under serum-free conditions after differentiation in PTB; (B) after being cultured for 1 
week post-differentiation in DMEM + 10% FBS; (C) after being cultured for 1 week post-differentiation 
in DMEM + 10% FBS + TNFα (1 ng/ml); (D) after being cultured for 2 weeks post-differentiation in 
DMEM + 10% FBS; (E) after being cultured for 1 week post-differentiation in DMEM + 10% FBS + 
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Whilst isogenic BMPR2+/- iPSC-SMCs remained hypopolarised (P < 0.01) after one week of 
exposure to serum (10% FBS) post-PTB differentiation (Figure 4.10 B), C2 W9X+/- and C2 
ΔExon1 iPSC-SMCs became significantly hyperpolarised (P < 0.01 and P < 0.05, respectively) 
relative to C2 iPSC-SMCs after two weeks of exposure to serum (Figure 4.10 C).  
 
In addition, since TNFα has been shown to increase IMM polarisation (Sutendra et al., 2011) 
and is implicated in pulmonary vascular remodeling (Hurst et al., 2017), I also assessed IMM 
polarisation in isogenic wild-type and BMPR2+/- iPSC-SMCs treated for one week with either 
serum alone, or serum plus TNFα (1 ng/ml). As previously observed (Figure 4.10 B), BMPR2+/- 
iPSC-SMCs exposed to serum for one week maintained a hypopolarised IMM compared to 
isogenic wild-type cells (P < 0.05) (Figure 4.10 D). By contrast, C2 W9X+/- iPSC-SMCs 
exposed to serum plus TNFα for one week acquired a hyperpolarised IMM compared to C2 
iPSC-SMCs (P < 0.05). Taken together, these findings suggest that BMPR2 heterozygosity 
alone is not sufficient for increased IMM polarisation in BMPR2+/- iPSC-SMCs but lowers the 
threshold for hyperpolarisation in response to exogenous factors. 
 
Inflammatory stimuli such as TNFα are one of the proposed “second hits” that are thought to 
be required to trigger PAH establishment and progression (Rabinovitch et al., 2014). However, 
it is unclear whether transient exposure to inflammatory stimuli in susceptible individuals is 
sufficient to drive disease progression, or whether PAH progression can be prevented or even 
reversed following cessation of inflammation. In a preliminary attempt to address this question, 
I therefore assessed whether the TNFα-induced hyperpolarised state in BMPR2+/- iPSC-SMCs 
was reversible following TNFα removal.  
 
After one week of exposure to serum only or to serum plus TNFα (1 ng/ml), all cells were 
cultured for a further week in serum only (Figures 4.9 D and E). In isogenic wild-type cells, 
the trend towards hyperpolarisation after one week of exposure to serum plus TNFα was lost 
(Figure 4.10 E compared to Figure 4.10 D). By contrast, C2 W9X+/- iPSC-SMCs remained 
hyperpolarised (P < 0.001) compared to wild-type C2 iPSC-SMCs exposed to TNFα for one 
week (Figure 4.10 E). This suggests that transient exposure of iPSC-SMCs to inflammatory 









Figure 4.10. Inner mitochondrial membrane polarisation in isogenic wild-type and BMPR2+/- 
iPSC-SMCs assayed under serum-free and serum-containing conditions. Inner mitochondrial 
membrane polarisation in isogenic wild-type and BMPR2+/- iPSC-SMCs differentiated in PTB was 
assessed by flow cytometric analysis of cells stained for 30 minutes with tetramethylrhodamine ethyl 
ester (TMRE, 30 nM). (A) Serum-free BMPR2+/- iPSC-SMCs displayed a significantly hypopolarised 
IMM compared to isogenic wild-type cells. (B) After one week of exposure to serum (10% FBS), 
isogenic BMPR2+/- iPSC-SMCs remained hypopolarised compared to C2 iPSC-SMCs. However, 
BMPR2+/- iPSC-SMCs became hyperpolarised compared to isogenic wild-type cells after two weeks of 
exposure to serum (C) or after one week of exposure to serum and TNFα (1 ng/ml) (D). (E) After one 
week of exposure to serum + TNFα, TNFα was removed and all cells cultured for one further week in 
serum only to see if the polarisation state would recover. The polarisation state of BMPR2+/- iPSC-SMCs 
did not normalise after TNFα removal and was significantly higher compared to the polarisation state 
of BMPR2+/- iPSC-SMCs that were exposed to serum only for 2 weeks and was also significantly higher 
than in isogenic wild-type cells treated the same way. Data presented as mean ± s.e.m. of the results 
from two independent differentiations (A) or three technical replicates based on cells from the same 
differentiation (B-E) [n.s., not significant (P > 0.05), * P < 0.05, ** P < 0.01, *** P < 0.001, one-way 
ANOVA with Dunnett’s post hoc test (A-C) or two-way ANOVA with Sidak’s post hoc test (D and E)]. 
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4.2.2 – Isogenic BMPR2+/- iPSC-SMCs are less glycolytic than wild-type iPSC-SMCs 
under serum-free conditions 
 
As the reduced mitochondrial polarisation state of BMPR2+/- iPSC-SMCs compared to isogenic 
wild-type iPSC-SMCs assayed under serum-free conditions was such an unexpected result, I 
went on to assess phenotypes related to IMM polarisation to see if they were also affected in a 
way that is consistent with a hypopolarised IMM state.   
 
For example, in addition to having a hyperpolarised inner mitochondrial membrane state, PAH 
patient-derived PASMCs have previously been shown to be more glycolytic compared to wild-
type PASMCs (Paulin & Michelakis, 2014). I therefore investigated whether BMPR2+/- iPSC-
SMCs assayed under serum-free conditions are less glycolytic compared to isogenic wild-type 
iPSC-SMCs. To achieve this, glucose-stimulated rates of glycolysis in serum-free isogenic 
wild-type and BMPR2+/- iPSC-SMCs were assessed using a Seahorse extracellular flux analyser 
which measures extracellular acidification rates (ECAR) in cells (Figure 4.11).  
 
This assay revealed that C2 W9X+/- iPSC-SMCs were significantly (P < 0.05) less glycolytic 
compared to C2 iPSC-SMCs under serum-free conditions, with C2 ∆Exon1 iPSC-SMCs also 
displaying a non-significant trend (P > 0.05) towards reduced glycolysis relative to the isogenic 
wild-type (Figure 4.11 B). These results therefore appear to be consistent with the reduced 













Figure 4.11. Serum-free isogenic BMPR2+/- iPSC-SMCs are less glycolytic than wild-type iPSC-
SMCs. (A) Glucose-stimulated glycolytic rates in serum-free wild-type and isogenic BMPR2+/- iPSC-
SMCs differentiated in PTB were assessed using the Seahorse XF Glycolysis Stress Test assay. 
Glycolysis was assessed by measuring the extracellular acidification rate (ECAR) four times for 3 
minutes (with a 3-minute mixing step between each ECAR measurement) both before and after the 
injection of glucose (Port A, 10 mM final concentration) to stimulate glycolysis, oligomycin A (Port B, 
1 µM final concentration) to maximise the glycolytic rate, and 2-deoxy-D-glucose (2-DG) (Port C, 50 
mM final concentration) to inhibit glycolysis. (B) The glycolytic rate of serum-free wild-type and 
isogenic BMPR2+/- iPSC-SMCs was calculated from the ECAR measurements shown in (A) by 
subtracting the last ECAR measurement prior to the injection of glucose from the maximum ECAR 
measurement obtained prior to the injection of oligomycin A. C2 W9X+/-  iPSC-SMCs were significantly 
less glycolytic compared to C2 iPSC-SMCs, with C2 ∆Exon1 iPSC-SMCs also displaying a non-
significant trend towards reduced glycolysis. Data presented as mean ± s.e.m. of the results from n=4 
independent differentiations for C2 and C2 W9X+/- iPSC-SMCs and n=2 independent differentiations 
for C2 ∆Exon1 iPSC-SMCs [n.s., not significant (P > 0.05), * P < 0.05, one-way ANOVA with 




























A: Glucose (10 mM) 
B: Oligomycin A (1 µM)
C: 2-DG (50 mM) C2 ΔExon1
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4.2.3 – Isogenic BMPR2+/- iPSC-SMCs display reduced mitochondrial superoxide 
staining under serum-free conditions 
 
In addition to being linked to increased glycolysis, increased IMM polarisation may under 
certain conditions drive an increase in reactive oxygen species (ROS) production and promote 
vascular remodeling (Pak et al., 2013; Paulin & Michelakis, 2014). I therefore performed a 
preliminary experiment to investigate whether the reduced IMM polarisation state in serum-
free isogenic BMPR2+/- iPSC-SMCs might be associated with reduced ROS production in these 
cells. ROS production in serum-free wild-type and isogenic BMPR2+/- iPSC-SMCs was 
assessed by staining these cells with the mitochondrial superoxide indicator MitoSOX Red (5 
µM) (Figure 4.12). Analysis of MitoSOX fluorescence intensities in these cells revealed that 
C2 W9X+/- iPSC-SMCs displayed less mitochondrial superoxide staining compared to C2 
iPSC-SMCs. This observation therefore appears to be consistent with both reduced glycolysis 
and reduced IMM polarisation in serum-free isogenic BMPR2+/- iPSC-SMCs compared to wild-












Figure 4.12. Serum-free isogenic BMPR2+/- iPSC-SMCs display reduced mitochondrial superoxide 
staining compared to wild-type iPSC-SMCs. Representative fluorescence microscope images of C2 
iPSC-SMCs (A) and C2 W9X+/- iPSC-SMCs (B) incubated for 30 minutes at 37 ºC in HBSS/Ca2+/Mg2+ 
buffer containing MitoSOX Red mitochondrial superoxide indicator (5 µM). (C) Immunofluorescence 
image of C2 iPSC-SMCs incubated in HBSS/Ca2+/Mg2+ buffer only. Scale bars are 250 µm. (D) 
MitoSOX fluorescence intensities in C2 and C2 W9X+/- iPSC-SMCs, assessed by measuring average 
image intensities using ImageJ software. Data in (D) presented as mean ± s.e.m. of the intensities of 
three randomly-selected images for each cell line. All cells analysed originated from the same 
differentiation and the experiment was not repeated, hence no statistical analysis was performed. 
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4.3 – Novel cellular abnormalities in BMPR2+/- iPSC-SMCs  
 
4.3.1 – BMPR2+/- iPSC-SMCs have an altered differentiation state that can be reversed 
by treatment with BMP4 
 
In disease, including PAH, vascular SMCs exhibit phenotypic switching between differentiated 
and de-differentiated states. In vitro, differentiated SMCs are characterised by an elongated 
rather than rounded morphology, low proliferation rate, relatively higher expression of proteins 
required for contraction, and increased contractility compared to de-differentiated SMCs 
(Owens et al., 1997; Mam et al., 2010; Christou et al., 2012; Sahoo et al., 2016). It is also 
recognised in a developmental context that cells have to exit the cell cycle to become terminally 
differentiated. Conversely, for cells to enter a proliferative phase, they first need to de-
differentiate (Owens & Wise, 1997; Owens et al., 2004). Given the increased level of 
proliferation observed in BMPR2+/- iPSC-SMCs, I therefore investigated whether BMPR2+/- 
iPSC-SMCs might have a more de-differentiated state compared to wild-type iPSC-SMCs.  
 
Smooth muscle myosin heavy chain (MYH11) is a major contractile protein which is 
considered to be the most robust SMC-specific marker and is highly expressed in mature, fully 
differentiated SMCs (Owens et al., 2004). I therefore performed immunostaining to assess 
MYH11 expression in C2 and C2 W9X+/- iPSC-SMCs and found that MYH11 expression was 
reduced in C2 W9X+/- iPSC-SMCs compared to their isogenic wild-type (Figure 4.13 A). In 
support of this observation, qPCR analysis of MYH11 mRNA expression revealed that MYH11 
was reduced in C2 W9X+/- iPSC-SMCs compared to C2 iPSC-SMCs (Figure 4.13 B). Taken 
together, these findings support the idea that BMPR2+/- iPSC-SMCs might be more de-
differentiated relative to wild-type iPSC-SMCs.  
 
Given that the only difference between wild-type and BMPR2+/- iPSC-SMCs in the system I 
am using is the presence of a deleterious mutation in the BMPR2 gene, the de-differentiated 
phenotype of C2 W9X+/- iPSC-SMCs might be due to the reduced BMPR2 expression in these 
cells. I therefore investigated whether treating C2 W9X+/- iPSC-SMCs with BMP4 might rescue 
the de-differentiated phenotype. Both immunostaining for MYH11 and qPCR analysis of 
MYH11 mRNA expression revealed that exposure to BMP4 (50 ng/ml) increased MYH11 
expression in C2 W9X+/- iPSC-SMCs to the level of MYH11 expression observed in C2 iPSC-
SMCs (Figures 4.13 A and B). Furthermore, BMP4 treatment increased BMPR2 mRNA 
expression in both C2 iPSC-SMCs and C2 W9X+/- iPSC-SMCs (Figure 4.13 C).  
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Taken together, these observations suggest that isogenic BMPR2+/- iPSC-SMCs have a de-
differentiated phenotype compared to wild-type iPSC-SMCs and that this phenotype can be 




Figure 4.13. Isogenic BMPR2+/- iPSC-SMCs display reduced myosin heavy chain expression which 
can be reversed by treatment with BMP4. (A) Representative immunofluorescence images of C2 and 
C2 W9X+/- iPSC-SMCs cultured in the presence or absence of BMP4 (50 ng/ml) and immunostained 
for smooth muscle myosin heavy chain (MYH11, green). Nuclei were visualised using DAPI staining 
(blue). Scale bars are 10 µm. (B and C) qPCR analysis of MYH11 (B) and BMPR2 (C) mRNA 
expression in these cells showed that C2 W9X+/- iPSC-SMCs displayed reduced MYH11 expression 
relative to C2 iPSC-SMCs. Treatment with BMP4 (50 ng/ml) increased both BMPR2 and MYH11 
mRNA expression in both C2 and C2 W9X+/- iPSC-SMCs, restoring MYH11 expression in C2 W9X+/- 
iPSC-SMCs to the level observed in isogenic wild-type C2 iPSC-SMCs. Data in (B) and (C) presented 
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4.3.2 – BMPR2+/- iPSC-SMCs and PASMCs are less contractile in response to carbachol 
stimulation  
 
To functionally test the hypothesis that BMPR2+/- iPSC-SMCs are de-differentiated compared 
to wild-type iPSC-SMCs, I next went on to test the level of cell contractility in these cells. To 
achieve this, I stimulated wild-type and isogenic BMPR2+/- iPSC-SMCs with carbachol (300 
µM), took time-lapse images of these cells over a 15-minute period and assessed cell 
contraction by calculating percentage changes in the cell surface areas of 10-11 randomly 
sampled cells per cell line between t = 0 and t = 15 minutes (Figure 4.14 A). Consistent with 
the results of a previous study (Cheung et al., 2012), the average cell surface area of wild-type 
C2 iPSC-SMCs decreased by 15% in response to carbachol stimulation. However, the average 
decrease in cell surface area was significantly (P < 0.001) lower in C2 W9X+/- iPSC-SMCs 
relative to C2 iPSC-SMCs (Figure 4.14 B), suggesting that BMPR2+/- iPSC-SMCs are less 
contractile compared to their isogenic wild-type. Since this phenotype has not been previously 
reported in PAH patient-derived PASMCs, I also assessed carbachol-induced contractility in 
PASMCs from PAH patients with BMPR2 mutations and found that BMPR2+/- PASMCs were 
also significantly (P < 0.01) less contractile than wild-type PASMCs (Figures 4.14 C and D). 
Taken together, these data are consistent with the reduced MYH11 expression observed in 
isogenic BMPR2+/- iPSC-SMCs and further suggest that BMPR2 heterozygosity leads to 









Figure 4.14. BMPR2+/- iPSC-SMCs and PASMCs are less contractile. (A) Representative bright field 
images of a wild-type C2 iPSC-derived smooth muscle cell taken immediately prior to and after 15 
minutes of incubation in PBS supplemented with carbachol (300 µM) and bovine serum albumin (0.1 
% w/v). Carbachol-induced cell contraction was assessed by using ImageJ software to measure 
percentage changes in cell surface area between t = 0 and t = 15 minutes. (B-D) Quantitative analysis 
of carbachol-induced contractility of n=10-11 randomly sampled cells per cell line revealed that C2 
W9X+/- iPSC-SMCs were significantly less contractile than wild-type C2 iPSC-SMCs (B) and that 
BMPR2+/- PASMCs derived from PAH patients with BMPR2 mutations were significantly less 
contractile than wild-type PASMCs (C and D). A breakdown of the results for individual wild-type and 
BMPR2+/- PASMC lines is shown in (C), with mean contractile responses of the three wild-type and 
three BMPR2+/- PASMC lines presented in (D). Data presented as mean ± s.e.m. [** P < 0.01, *** P < 
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4.4 – Discussion 
 
4.4.1 – Contributions of BMPR2 mutations and extrinsic factors to cellular phenotypes 
of pulmonary arterial hypertension 
 
The results presented in this chapter suggest that BMPR2 heterozygosity in iPSC-SMCs is 
necessary and sufficient to recapitulate the pro-proliferative and anti-apoptotic phenotype of 
PAH patient-derived PASMCs, but that additional exposure to serum and/or TNFα is required 
to recapitulate the mitochondrial hyperpolarisation phenotype of PAH-derived PASMCs. This 
highlights the utility of iPSC-SMCs with isogenic backgrounds for studying factors affecting 
disease penetrance and supports the hypothesis of this thesis that BMPR2 heterozygosity in 
iPSC-SMCs is necessary and sufficient to recapitulate some but not all PAH-associated cellular 
phenotypes. 
 
Furthermore, this chapter describes the establishment of the first iPSC-SMC model of PAH. 
Previous studies have focussed on using iPSC-derived mesenchymal stromal cells (iPSC-
MSCs) (West et al., 2014) or iPSC-ECs (West et al., 2014; Sa et al., 2017; Gu et al., 2017) to 
study PAH. However, the BMPR2+/- iPSC-MSCs and iPSC-ECs used in these studies were not 
found to be more proliferative compared to their wild-type counterparts, and comparisons were 
predominantly confined to a limited number of patient-derived cell lines which had different 
genetic backgrounds (West et al., 2014; Sa et al., 2017; Gu et al., 2017). The variability between 
different patient-derived cell lines often means that a large number of lines from different 
patients need to be evaluated in order to detect robust differences in the phenotypes being 
studied. This was evident in this thesis investigation, with only non-significant trends usually 
being observed between wild-type and BMPR2+/- patient-derived iPSC lines, in contrast to the 
reduced variability that was present between cells with isogenic backgrounds.    
 
However, it is important to note that whilst BMPR2 heterozygosity in iPSC-SMCs was 
sufficient for the acquisition of a pro-proliferative and anti-apoptotic phenotype, these 
phenotypes might not be present in human BMPR2 mutation carriers who do not have PAH. 
This discrepancy could be due to a lack of exposure of iPSC-SMCs to protective factors that 
might be provided by serum, endothelial cells or other cell types during differentiation 
(Budhiraja et al., 2004). Furthermore, endothelial cells secrete BMP4, pro-inflammatory 
cytokines and other paracrine signals which stimulate SMC proliferation and pulmonary 
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vascular remodelling in PAH (Frank et al., 2005; Eddahibi et al., 2006), and may therefore 
influence PAH-associated SMC phenotypes. 
 
In addition, the results presented in this chapter argue that the acquisition of a hyperpolarised 
inner mitochondrial membrane state in BMPR2+/- iPSC-SMCs in response to serum and/or 
TNFα exposure might represent a transition from a pre-diseased to a diseased state. This is 
consistent with the notion that inflammation is thought to be a potential ‘second hit’ that is 
required for PAH establishment and progression (Rabinovitch et al., 2014) and is further 
supported by the finding that C2 W9X+/- iPSC-SMCs assayed under serum-free conditions were 
less glycolytic and displayed reduced mitochondrial membrane polarisation compared to C2 
iPSC-SMCs.  
 
Furthermore, C2 W9X+/- iPSC-SMCs also displayed slightly lower mitochondrial superoxide 
staining compared to isogenic wild-type cells when assayed under serum-free conditions. 
Whilst several studies suggest that increased IMM polarisation drives an increase in ROS 
production and promotes vascular remodeling (Pak et al., 2013; Paulin & Michelakis, 2014), 
there have also been conflicting reports of reduced ROS production in PAH (Aggarwal et al., 
2013; Bonnet & Boucherat, 2018). This controversy is likely to be due to the existence of 
multiple cellular sources and types of ROS, their highly reactive nature and the different 
methods used to detect ROS production in cells (Bonnet & Boucherat, 2018). As a result, 
further work will be required to determine relative levels of ROS production between wild-type 
and BMPR2+/- iPSC-SMCs under serum-free and serum-containing conditions. Furthermore, 
future studies could focus on investigating the molecular mechanisms linking mitochondrial 
hyperpolarisation, ROS production, glycolysis and mitochondrial function in iPSC-SMCs. 
 
The findings presented in this chapter also suggest that increased proliferation, reduced 
apoptosis and increased IL-6 mRNA expression in BMPR2+/- LM-iPSC-SMCs were more 
pronounced when these cells were differentiated in the presence of a high concentration (50 
ng/ml) of exogenous BMP4 during the 12-day ‘PT’ SMC differentiation phase (herein referred 
to as PTB). This suggests that differentiation in PTB represents a refinement of the LM-iPSC-
SMC differentiation protocol in terms of its ability to generate cells that can be used as 
surrogates for distal PASMCs when studying PAH. Although the reason for this is unclear, the 
observation that BMP4 is highly expressed in the distal region of the lung bud during 
development (Bellusci et al., 1996) suggests that the addition of BMP4 during differentiation 
might promote the acquisition of a distal cell fate in LM-iPSC-SMCs. 
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4.4.2 – Comparisons with iPSC-derived endothelial cell models of PAH 
 
As well as generating lineage-specific iPSC-SMCs which recapitulated key PAH-associated 
cellular phenotypes observed in distal PASMCs, I also contributed to work carried out by Mr 
Christopher JZ Huang and Dr C-Hong Chang in our group which involved generating an iPSC-
derived endothelial cell (iPSC-EC) model of PAH (Kiskin et al., 2018). Using the same patient-
derived and isogenic iPSC lines described in this thesis, wild-type and BMPR2+/- iPSCs were 
differentiated into iPSC-ECs which formed vascular networks and displayed an enhanced 
expression of arterial EC markers (Kiskin et al., 2018). Using these iPSC-ECs, we then 
investigated whether BMPR2 heterozygosity in iPSC-ECs was necessary and/or sufficient to 
recapitulate key PAH-associated phenotypes observed in patient-derived PAECs (Kiskin et al., 
2018). Interestingly, unlike in iPSC-SMCs, we found that BMPR2 heterozygosity in iPSC-ECs 
required additional exposure to serum to manifest increased proliferation and apoptosis (Kiskin 
et al., 2018). Neither iPSC-SMCs or iPSC-ECs displayed hyperpolarised IMMs as they 
emerged from the serum-free iPSC differentiation protocols. However, in contrast to BMPR2+/- 
iPSC-SMCs which required two weeks of exposure to serum to become hyperpolarised, one 
week of exposure to serum was sufficient to induce IMM hyperpolarisation in BMPR2+/- iPSC-
ECs (Kiskin et al., 2018).  
 
Taken together, these findings demonstrate a clear difference in the contribution of BMPR2 
heterozygosity to establishing PAH-associated cellular phenotypes in SMCs and ECs, thus 
highlighting an important difference between these cell types. This suggests that tailored, cell 
type-specific approaches might be required when developing therapies aimed at reversing or 
preventing pulmonary vascular dysfunction in ECs and SMCs. In iPSC-ECs, potential 
therapeutic interventions might include BMP9 treatment which reverses PH in rodent models 
(Long et al., 2015) and prevented IMM hyperpolarisation in BMPR2+/- iPSC-ECs (Kiskin et al., 
2018). In addition, these findings further support the view that therapies aimed at restoring 
BMPR2 signalling could be beneficial in the treatment of PAH. However, whether BMP ligands 
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Previously, iPSC-ECs derived from PAH patients with BMPR2 mutations did not recapitulate 
the hyperpolarised inner mitochondrial membrane state associated with end-stage PAH (Gu et 
al., 2017). This may have been due to the lack of exposure to an environmental stimulus such 
as TNFα or due to the mixed genetic background of the patient-derived iPSC lines used. 
Supporting the importance of environmental stimuli as modifiers of disease penetrance is the 
observation of discordance for disease in monozygotic twins with BMPR2 mutations (Ormiston 
et al., 2013). 
 
In addition to environmental factors, disease penetrance may also be affected by genetic 
modifiers. For example, the lack of response of some PAH-derived PAEC and iPSC-EC lines 
to the immunosuppressant FK506 and the neutrophil elastase inhibitor, elafin, was attributed to 
increased expression of split guidance ligand 3 (SLIT3) (Sa et al., 2017). In a separate study 
from the same group (Gu et al., 2017), baculoviral IAP repeat containing 3 (BIRC3) was 
identified as being responsible for the preserved cell survival in iPSC-ECs derived from 
unaffected BMPR2 mutation carriers and may hence be a protective genetic modifier in PAH. 
However, the precise roles that putative genetic modifiers such as SLIT3 and BIRC3 play in the 
pathogenesis of PAH are yet to be determined. 
 
4.4.3 – BMPR2+/- iPSC-SMCs have an altered differentiation state 
 
Another interesting new finding presented in this chapter is that BMPR2+/- LM-iPSC-SMCs 
displayed reduced smooth muscle myosin heavy chain (MYH11) expression and carbachol-
induced cell contractility compared to wild-type iPSC-SMCs. This dedifferentiated phenotype 
is consistent with the pro-proliferative, ‘synthetic’ phenotype that vascular smooth muscle cells 
acquire due to phenotypic switching in response to vascular injury (Stiemer et al., 1993; Kane 
et al., 2011; Chelladurai et al., 2012).  BMP4 treatment of BMPR2+/- iPSC-SMCs restored 
smooth muscle myosin heavy chain expression in these cells to levels observed in wild-type 
iPSC-SMCs, and also increased BMPR2 mRNA expression.  
 
It remains unclear whether BMP4 treatment improves the SMC differentiation process, acts by 
reducing dedifferentiation, or whether BMP4 mediates both of these effects. Nevertheless, the 
observations described in this chapter suggest that isogenic BMPR2+/- iPSC-SMCs have an 
altered differentiation state compared to wild-type iPSC-SMCs and that this phenotype can be 
reversed by increasing the concentration of BMP4. In support of these findings, previous work 
has shown that BMP4 maintains the expression of smooth muscle actin in cultured PASMCs 
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and reduces the PDGF-BB-induced dedifferentiation of arterial SMCs (Lagna et al., 2007). 
BMP4 treatment has also been shown to promote a contractile phenotype in VSMCs by 
reducing the expression of small non-coding microRNAs such as miR-96 (Kim et al., 2014). It 
would therefore be interesting to test whether BMP4 treatment improves carbachol-induced 
contractility of BMPR2+/- iPSC-SMCs and PASMCs. Alternatively, future studies could also 
explore the effect of other BMP ligands on MYH11 expression in iPSC-SMCs.      
 
A further question is whether the introduction of the BMPR2 mutation impairs iPSC-SMC 
differentiation or promotes the dedifferentiation of mature, contractile iPSC-SMCs. It cannot 
be ruled out that iPSC-SMCs generated in this study might consist of cells with a mixture of 
differentiation states, since a subset of cells may have disproportionately contributed to the 
altered differentiation state of BMPR2+/- iPSC-SMCs. However, a similar state might be present 
in vivo, where both mature, fully differentiated SMCs as well as less terminally differentiated 
‘non-muscle-like’ cells have been reported to exist in close proximity within the arterial media 
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5.1 – Differential RNA-Seq gene expression analysis of wild-type and 
BMPR2+/- iPSC-SMCs  
 
Having demonstrated that the iPSC-SMC model could recapitulate known PASMC cellular 
phenotypes relevant to PAH, my next aim was to identify genes that are differentially expressed 
between wild-type and BMPR2+/- iPSC-SMCs and thus provide further insights into PAH 
pathobiology. I therefore isolated and purified RNA from wild-type and both genome-edited 
and patient-derived BMPR2+/-  iPSC-SMCs and submitted these samples for RNA sequencing.  
RNA-Seq libraries were generated by Dr Mattia Frontini and Dr Frances Burden, with the 
resulting libraries being quantified, pooled and sequenced using paired-end sequencing. 
Subsequently, I enlisted the help of Dr Marta Bleda and Dr Matthias Haimel who processed 

















Figure 5.1. RNA-Seq workflow. After extracting and purifying RNA from wild-type and BMPR2+/- 
iPSC-SMCs, ribosomal RNA (rRNA)-depleted cDNA libraries were generated using a TruSeq Stranded 
Total RNA Library Prep Kit (Illumina). Libraries were quantified, pooled and sequenced using paired-
end 76 bp sequencing on a HiSeq 2000 Sequencing System (Illumina). Raw RNA-Seq data was 
generated in FASTQ format and subjected to quality control using FastQC software before trimming 
PCR and sequencing adapters using Trim Galore. Trimmed reads were then aligned to the human 
transcriptome with Bowtie. MMSEQ was used with default parameters to calculate fragment counts and 
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Transcriptional differences between BMPR2+/- and wild-type iPSC-SMCs were analysed under 
serum-free PTB conditions because both apoptosis resistance and increased proliferation were 
caused by BMPR2 heterozygosity alone and were enhanced after differentiation in PTB 
compared to PT. This analysis revealed that genes encoding somatostatin (SST), dual oxidase 2 
(DUOX2) and mitochondrial uncoupling protein 2 (UCP2) were significantly (Padj < 0.05) 
down-regulated in patient-derived (B3, B4 and B11) and genome-edited (C2 W9X+/- and C2 
ΔExon1) BMPR2+/- iPSC-SMCs compared to wild-type (C2, C6 and C10) iPSC-SMCs. By 
contrast, cytokine receptor-like factor 1 (CRLF1) was significantly (Padj < 0.05) upregulated in 
BMPR2+/- iPSC-SMCs compared to controls (Figure 5.2).  
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Figure 5.2. Differential RNA-Seq gene expression analysis of wild-type and BMPR2+/- iPSC-SMCs 
reveals alterations in genes potentially involved in PAH. Volcano plot (A) and hierarchical clustering 
based on Pearson correlation (B) of differentially expressed genes comparing BMPR2+/-  iPSC-SMC 
lines (B3, B4.11, B11, C2 DExon1, C2 W9X+/-) with wild-type controls (C2, C6, C10) after serum-free 
differentiation in PTB. The heatmap in (B) shows the differentially expressed genes in rows and the 
iPSC-SMC samples in the columns. Samples are annotated according to their genotype at the top of the 
heatmap. Genes with a false discovery rate (FDR) adjusted P value < 0.05 were considered differentially 
expressed. Based on this analysis, somatostatin (SST; Padj = 0.00780), dual oxidase 2 (DUOX2; Padj = 
0.00780), and mitochondrial uncoupling protein 2 (UCP2; Padj = 0.0174) were significantly 
downregulated in BMPR2+/- relative to wild-type iPSC-SMCs, whereas cytokine receptor-like factor 1 





To validate these results, I used quantitative PCR to analyse SST, DUOX2, UCP2 and CRLF1 
mRNA expression in serum-free C2 and C2 W9X+/- iPSC-SMCs differentiated in PTB, which 
confirmed the differential expression of these genes between mutants and controls (Figure 5.3). 
However, after culturing PTB-differentiated iPSC-SMCs for one week in 10% FBS, CRLF1 
mRNA expression became significantly reduced rather than increased in C2 W9X+/- iPSC-
SMCs relative to wild-type C2 iPSC-SMCs, whilst SST, DUOX2 and UCP2 expression 
remained reduced (Figures 5.4 A-D).  
 
To determine whether these findings can be validated in a mouse model of PAH, I collaborated 
with Dr Xudong Yang and Dr Lu Long who isolated lung tissue from knock-in mice which 
harbour a heterozygous R899X mutation in exon 12 of the endogenous Bmpr2 locus 
(Bmpr2+/R899X) and develop increased RVSPs by 6 months of age (Long et al., 2015). qPCR 
analysis revealed that Sst, Duox2, Ucp2 and Crlf1 mRNA expression was reduced in the lungs 
of Bmpr2+/R899X mice compared with wild-type littermates (n=3 per group), although the 
difference in Ucp2 expression between wild-type and Bmpr2+/R899X mouse lungs was not 
statistically significant (P > 0.05) (Figures 5.4 E-H). These findings are consistent with the 
reduced expression of these genes in C2 W9X+/- relative to wild-type C2 iPSC-SMCs after one 
week of serum exposure and suggest that exposure to serum may affect the relative expression 
levels of some genes between wild-type and BMPR2+/- iPSC-SMCs. 
 
 





Figure 5.3. qPCR validation of genes that were differentially expressed between serum-free wild-
type and BMPR2+/- iPSC-SMCs. qPCR analysis confirmed the reduced SST (A), DUOX2 (B) and 
UCP2 (C) mRNA expression, and increased CRLF1 (D) mRNA expression observed in C2 W9X+/- 
relative to isogenic wild-type C2 iPSC-SMCs assayed under serum-free PTB conditions. Data in A and 
B presented as mean ± s.e.m. of the results from two independent qPCR analyses (technical replicates) 
performed on cells from the same differentiation (** P < 0.01, *** P < 0.001, one-way ANOVA with 
Dunnett’s post hoc test). qPCR analysis of UCP2 and CRLF1 mRNA expression (C and D) was only 
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Figure 5.4. qPCR analysis of SST, DUOX2, UCP2 and CRLF1 mRNA expression levels in serum-
matured isogenic iPSC-SMCs and in Bmpr2+/R899X mouse lung tissue. (A-D): Somatostatin (SST) 
(A), dual oxidase 2 (DUOX2) (B), mitochondrial uncoupling protein 2 (UCP2) (C), and cytokine 
receptor like factor 1 (CRLF1) (D) mRNA expression was significantly reduced in C2 W9X+/- relative 
to wild-type C2 iPSC-SMCs cultured for one week in 10% FBS post-differentiation. Furthermore, 
exposure to serum + TNFα (1 ng/ml) for one week significantly decreased SST mRNA expression in C2 
iPSC-SMCs (A). (E-H): Reduced SST (E), DUOX2 (F) and CRLF1 (H) mRNA expression in C2 W9X+/- 
iPSC-SMCs after one week of exposure to serum was further confirmed by qPCR in lung tissue samples 
from wild-type and heterozygous Bmpr2 R899X knock-in (Bmpr2+/R899X) mice (n=3 per group). Ucp2 
expression was also slightly lower in Bmpr2+/R899X mouse lungs compared to wild-type littermates (G), 
but this difference was not statistically significant (P > 0.05, n=3 per group). Data in A-D presented as 
mean ± s.e.m. of the results from three independent qPCR analyses (technical replicates) performed on 
cells from the same differentiation [n.s., not significant (P > 0.05), * P < 0.05, ** P < 0.01, *** P < 
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5.2 – Investigating the effect of somatostatin on iPSC-SMC proliferation  
 
Among the genes that were differentially expressed between wild-type and BMPR2+/- iPSC-
SMCs under serum-free PTB conditions, somatostatin displayed the most significantly reduced 
expression in mutants relative to controls (Padj = 0.0078). Furthermore, since TNFα has 
previously been shown to reduce somatostatin expression in human coronary endothelial cells 
(Yan et al., 2004), I investigated whether TNFα might also reduce SST expression in iPSC-
SMCs. Indeed, I observed that exposure to TNFα (1 ng/ml) for one week significantly (P < 
0.001) decreased SST mRNA expression in C2 iPSC-SMCs, and also reduced SST expression 
in C2 W9X+/- iPSC-SMCs (Figure 5.4 A), suggesting that inflammatory stimuli may reduce 
somatostatin expression.  
 
Somatostatin is a cyclopeptide that broadly inhibits a number of hormones such as growth 
hormone, insulin and glucagon (Brazeau et al., 1973; Reichlin, 1983). In addition, somatostatin 
and its analogues have also been shown to inhibit smooth muscle cell proliferation (Leszczynski 
et al., 1993; Lauder et al., 1997; Zhao & Foegh, 1997), reduce medial pulmonary artery wall 
thickness in MCT rats (Takahashi et al., 1995) and ameliorate chronic hypoxia-induced 
pulmonary hypertension (Tjen et al., 1992), although the latter finding has been disputed 
(Sidney et al., 1996). Taken together, these observations raise the question of whether the 
reduced somatostatin expression observed in BMPR2+/- iPSC-SMCs might contribute to the 
pro-proliferative phenotype of these cells and thus play a role in the pathogenesis of PAH. 
 
I therefore set out to determine whether somatostatin inhibits the proliferation of iPSC-SMCs 
and PASMCs by culturing isogenic C2 and C2 W9X+/- iPSC-SMCs and PAH patient-derived 
BMPR2+/- PASMCs for 7 days in the presence or absence of somatostatin-14 (1 µM), a 
bioactive form of somatostatin which binds with high affinity to all five somatostatin receptor 
subtypes (SSTR1-5) identified to date (Bruns et al., 1994). Cell counts after 7 days in culture 
revealed that somatostatin-14 had no significant effect (P > 0.05) on the proliferation of C2 
W9X+/- iPSC-SMCs (Figure 5.5 A). Similarly, somatostatin-14 also did not affect the 
proliferation of BMPR2+/- PASMCs (Figure 5.5 B).  
 





Figure 5.5. Somatostatin-14 does not significantly affect the proliferation of isogenic iPSC-SMCs 
and BMPR2+/- PASMCs. The effect of somatostatin on the proliferation of isogenic iPSC-SMCs (A) 
and BMPR2+/- PASMCs (B) was assessed by culturing the cells for seven days in CDM-PVA + 5% FBS 
(A) or DMEM + 5% FBS (B) in the presence or absence of somatostatin-14 (SST-14) (1 µM) and 
performing manual cell counts using disposable Haemocytometer counting grids. Data presented as 
mean ± s.e.m. of the results from 2-3 independent differentiations (A) or three different PAH patient-
derived BMPR2+/- PASMC lines (B) and expressed as fold changes in cell number after seven days in 
culture. Statistical analysis was performed using two-way ANOVA with Sidak’s post-hoc test (A) or 
unpaired two-tailed Student’s t test (B). None of the differences in proliferation between treatment 
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While somatostatin-14 may have failed to significantly decrease iPSC-SMC and PASMC 
proliferation due to the large variation in the experimental results and the low number of 
replicates, I wondered whether this lack of an anti-proliferative effect might also partly be due 
to low levels of somatostatin receptor expression in these cells. I therefore performed 
quantitative PCR analysis of SSTR1-5 mRNA expression in isogenic iPSC-SMCs and wild-
type and BMPR2+/- PASMCs, which revealed that the expression of SSTR1, SSTR2, SSTR3 and 
SSTR4 was significantly (P < 0.01) lower in C2 W9X+/- iPSC-SMCs compared to C2 iPSC-
SMCs (Figures 5.6 A-D). Furthermore, C2 W9X+/- iPSC-SMCs displayed a non-significant 
trend (P > 0.05) towards reduced SSTR5 expression (Figure 5.6 E) and BMPR2+/- PASMCs 
also displayed a non-significant trend (P > 0.05) towards reduced SSTR1, SSTR3, SSTR4 and 
SSTR5 expression compared to wild-type PASMCs (Figures 5.6 F and H-J). Taken together, 
these findings raise the possibility that somatostatin-14 may have failed to significantly reduce 
the proliferation of BMPR2+/- iPSC-SMCs and PASMCs due to reduced levels of somatostatin 
receptor expression in these cells. 
 
Possible alternative reasons why somatostatin-14 did not display an anti-proliferative effect 
may be due to its short biological half-life (<3 min) (Patel & Wheatley, 1983) or because it 
might be necessary to target specific somatostatin receptor subtypes to reduce proliferation in 
iPSC-SMCs and PASMCs. I therefore also investigated whether the more stable somatostatin 
analogues octreotide and lanreotide, which preferentially bind to SSTR2 and are clinically 
approved for the treatment of neuroendocrine tumours (Bauer et al., 1982; Caron et al., 1997; 
Murphy et al., 1987; Weckbecker et al., 2003), might be more effective at reducing the 
proliferation of BMPR2+/- iPSC-SMCs and PASMCs. In addition, I also tested whether the 
proliferation of these cells can be reduced by treatment with CH-275, a somatostatin analogue 
that binds with high affinity to SSTR1 (Rivier et al., 2001). However, neither octreotide (100 
nM – 1 µM), lanreotide (1 µM) or CH-275 (100 nM – 1 µM) significantly reduced the 
proliferation of BMPR2+/- iPSC-SMCs or PASMCs (Figure 5.7). Taken together, these 
findings suggest that somatostatin and its analogues do not affect the proliferation of iPSC-
SMCs and PASMCs. Whether somatostatin might have potential other roles in the cellular 
pathogenesis of PAH is yet to be determined. 
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Figure 5.6. Somatostatin receptor mRNA expression levels in iPSC-SMCs and PASMCs. qPCR 
analysis of somatostatin receptor (SSTR1-SSTR5) mRNA expression in isogenic iPSC-SMCs cultured 
for one week in serum after differentiation in PTB (A-E), and in wild-type and BMPR2+/- PASMCs (F-
J). Data presented as mean ± s.e.m. of two independent qPCR analyses performed on the cells from the 
same differentiation (A-E), or three different BMPR2+/- PASMC lines (F-J). [n.s., not significant (P > 









Figure 5.7. The somatostatin analogues lanreotide, octreotide and CH-275 have no significant 
effect on the proliferation of isogenic iPSC-SMCs and BMPR2+/- PASMCs. Isogenic iPSC-SMCs 
(A) and BMPR2+ - PASMCs (B) were cultured for seven days in CDM-PVA + 5% FBS (A) or DMEM 
+ 5% FBS (B) in the presence or absence of lanreotide (1 µM) (A), octreotide (100 nM – 1 µM) (B) or 
CH-275 (100 nM – 1 µM) (A and B). Proliferation was assessed by performing manual cell counts seven 
days after plating the cells. Data presented as mean ± s.e.m. of the results from 2-3 independent 
differentiations (A) or three different BMPR2+/-  PASMC lines (B). Statistical analysis was performed 
using two-way ANOVA with Sidak’s post-hoc test (A) or one-way ANOVA with Dunnett’s post hoc 
test (B). None of the differences in proliferation between treatment groups were deemed statistically 
significant (P > 0.05).  
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5.3 – Discussion 
 
The results presented in this chapter describe the identification of genes that were differentially 
expressed between serum-free wild-type and BMPR2+/-  iPSC-SMCs and may hence provide 
further insights into PAH pathobiology. Genes encoding somatostatin (SST), dual oxidase 2 
(DUOX2) and mitochondrial uncoupling protein 2 (UCP2) were significantly down-regulated 
in BMPR2+/- iPSC-SMCs compared to wild-type iPSC-SMCs under both serum-free conditions 
and after one week of exposure to serum. By contrast, whilst cytokine receptor-like factor 1 
(CRLF1) expression was significantly upregulated in serum-free BMPR2+/- iPSC-SMCs 
compared to controls, CRLF1 mRNA expression became significantly reduced in C2 W9X+/- 
iPSC-SMCs relative to the isogenic wild-type after one week of exposure to serum. Consistent 
with this, reduced CRLF1 expression was also detected in the lungs of Bmpr2+/R899X mice 
compared with wild-type littermates.  
 
Whilst several studies suggest that reduced UCP2 and SST expression might be associated with 
PAH (Tjen et al., 1992; Takahashi et al., 1995; Dromparis et al., 2013; Pak et al. 2013; 
Michelakis et al., 2017), DUOX2 and CRLF1 have not previously been studied in the context 
of PAH. The following sections describe some of the known biological functions of SST, UCP2, 
DUOX2 and CRFL1 and discuss the possible roles that these genes may play in the pathogenesis 
of PAH.  
 
5.3.1. – Somatostatin (SST) 
 
Although somatostatin has previously been reported to inhibit smooth muscle cell proliferation 
(Leszczynski et al., 1993; Lauder et al., 1997; Zhao & Foegh, 1997), somatostatin-14 and the 
somatostatin analogues octreotide, lanreotide and CH-275 did not have any significant effect 
on the proliferation of BMPR2+/- iPSC-SMCs or PASMCs. The lack of a significant effect 
observed in this study may be due to the large variability in the data and the low number of 
experimental replicates (n=2-3) associated with the somatostatin proliferation assays. In some 
of the individual experiments, C2 W9X+/- iPSC-SMCs were not more proliferative compared 
to wild-type C2 iPSC-SMCs under basal conditions (see Figure 5.5 A and Figure 5.7 A), 
suggesting potential issues with cell viability or the iPSC-SMC differentiation process in those 
particular cases. Therefore, these experiments would need to be repeated to increase the number 
of replicates and clarify whether somatostatin and its analogues affect the proliferation of iPSC-
SMCs and PASMCs.      
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Alternatively, it can not be ruled out that somatostatin might play a different yet unknown role 
in the cellular pathogenesis of PAH which might involve other cell types. For example, 
somatostatin and its analogues have been shown to reduce the production of pro-inflammatory 
cytokines in rats (Karalis et al., 2004) and in activated human monocytes (Peluso et al., 1996). 
Furthermore, somatostatin receptor subtype 2 (SSTR2) expression has been linked to apoptosis 
induction in mouse embryonic fibroblasts (Guillermet-Guibert et al., 2007). These observations 
raise the question of whether somatostatin reduces inflammation and promotes apoptosis in 
patient-derived PASMCs.  
 
In addition, somatostatin also inhibits growth hormone, insulin, glucagon and thyroid hormone 
secretion (Brazeau et al., 1973; Burgus et al., 1973; Ahren et al., 1978). The reduced 
somatostatin expression observed in BMPR2+/- iPSC-SMCs might therefore contribute to 
insulin resistance and thyroid dysfunction in these cells. Since both insulin resistance and 
thyroid dysfunction been associated with pulmonary arterial hypertension (Chu et al., 2002; 
Zamanian et al., 2009; Scicchitano et al., 2016), it would therefore be interesting to investigate 
whether somatostatin affects inflammation, apoptosis, insulin signalling and thyroid function 
in PAH.  
 
5.3.2. – Mitochondrial uncoupling protein 2 (UCP2) 
 
UCP2 and other UCPs cause mild mitochondrial uncoupling by dissipating the electrochemical 
proton gradient across the inner mitochondrial membrane, which is generally thought to result 
in decreased production of mitochondrial reactive oxygen species (ROS), thus protecting 
against ROS-related cellular damage (Brand & Esteves, 2005). Consistent with this notion, 
increased mitochondrial ROS production has been reported in Ucp3 knockout mice (Vidal-Puig 
et al., 2000; Brand et al., 2002). By contrast, Ucp2 knockout mouse PASMCs display reduced 
ROS production, mitochondrial hyperpolarisation, normoxic HIF-1a activation, increased 
proliferation and resistance to apoptosis (Dromparis et al., 2013; Pak et al. 2013). In line with 
these findings, BMPR2+/- iPSC-SMCs displayed mitochondrial hyperpolarisation and reduced 
UCP2 expression after exposure to serum and/or TNFα, and ROS production was reduced in 
serum-free BMPR2+/- iPSC-SMCs compared to controls. However, in contrast to IMM 
hyperpolarisation observed in PASMCs from PAH patients and Ucp2-/- mice (Pak et al., 2013; 
Paulin & Michelakis, 2014), BMPR2+/- iPSC-SMCs assayed under serum-free conditions 
displayed reduced IMM polarisation relative to controls. Although the reason for this 
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discrepancy is not known, it is tempting to speculate that reduced UCP2 expression might 
precede the acquisition of a hyperpolarised IMM state in BMPR2+/- iPSC-SMCs.  
 
Recently, further evidence supporting the role of UCP2 in the pathogenesis PAH was provided 
by a phase I clinical trial in which IPAH patients were treated with the pyruvate dehydrogenase 
kinase inhibitor, dichloroacetate (DCA) (Michelakis et al., 2017). In most patients, DCA 
improved functional capacity and reduced both mean pulmonary arterial pressures and 
pulmonary vascular resistance. However, IPAH patients harbouring variants in UCP2 and the 
mitochondrial deacetylase sirtuin-3 (SIRT3) which predicted reduced protein function did not 
respond to DCA treatment (Michelakis et al., 2017), suggesting that UCP2 and SIRT3 might 
act as genetic modifiers in PAH.  
 
DCA has previously been shown to reverse the hyperglycolytic phenotype of PASMCs, 
stimulate mitochondria-dependent PASMC apoptosis, improve RV function and reverse PH in 
rat models (Michelakis et al., 2002; McMurtry et al., 2004, Zhao et al., 2013). Furthermore, 
SIRT3 is thought to reduce mitochondrial membrane potential, inhibit ROS production and thus 
limit oxidative stress (Shi et al., 2005). Sirt3 knockout (Sirt3-/-) mice spontaneously develop 
PH, with Sirt3-/- mouse PASMCs displaying increased glycolysis compared to PASMCs 
isolated from wild-type littermates (Paulin et al., 2014). Given the reduced UCP2 expression 
and IMM hyperpolarisation observed in serum-treated BMPR2+/- iPSC-SMCs, it would 
therefore be interesting to investigate SIRT3 expression and the effect of DCA on glycolysis, 
mitochondrial polarisation and apoptosis in these cells. 
 
Furthermore, reduced UCP2 mRNA expression has been detected in adipose tissue of patients 
with hypothyroidism (Gjedde et al., 2010), suggesting that changes in UCP2 expression might 
partially explain why PAH patients sometimes present with thyroid disorders (Scicchitano et 
al., 2016).  The thyroid hormone triiodothyronine (T3) has been reported to increase UCP2 and 
UCP3 expression in the heart and skeletal muscle of rats (Gong et al., 1997; Lanni et al., 1997; 
Lanni et al., 1999), and also stimulates UCP2 and UCP3 mRNA expression in human adipose 
tissue and skeletal muscle (Barbe et al., 2001). T3 also reduced IMM polarisation, increased 
mitochondrial superoxide dismutase [SOD2, also known as manganese superoxide dismutase 
(MnSOD)] expression and improved mitochondrial Complex V activity in human fibroblasts 
with mitochondrial DNA mutations (Menzies et al., 2009). However, T3 did not affect UCP2 
expression in these cells. Whether thyroid hormone affects UCP2 expression in iPSC-SMCs or 
PASMCs is yet to be determined.  
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5.3.3. – Dual oxidase 2 (DUOX2) 
 
DUOX2 belongs to the large family of NADPH-oxidase enzymes which regulate the synthesis 
of H2O2 and reactive oxygen species and play important roles in modulating immune responses, 
hormone synthesis, cell growth and differentiation (Lambeth, 2004; Sirokmany et al., 2016). 
Among the seven isoforms of NADPH oxidase (NOX), NOX1, NOX2 and NOX4 have been 
implicated in the development of PAH (Mittal et al., 2007; Nisbet et al., 2009; Veit et al., 2013; 
Goncharov et al., 2014; Liu et al., 2014). For example, Nox4 expression has been detected in 
human airways and in PASMCs (Djordjevic et al., 2005) and is upregulated in PASMCs in 
response to hypoxia (Diebold et al., 2010). Increased Nox4 expression has also been detected 
in the lungs of patients with idiopathic pulmonary arterial hypertension (Mittal et al., 2007; 
Goncharov et al., 2014). Furthermore, siRNA-mediated inhibition of Nox4 significantly 
reduced the proliferation of PH-derived PASMCs (Mittal et al., 2007) and decreased the 
expression of smooth muscle cell differentiation markers in rat VSMCs (Clempus et al., 2007).  
 
In contrast to the other NADPH oxidase isoforms, relatively little is known about the functional 
role of DUOX2 (Konior et al., 2014). DUOX2 is required for thyroid hormone biosynthesis 
(Dupuy et al., 1999; De Deken et al., 2000), with DUOX2 mutations being associated with 
congenital hypothyroidism and reduced ROS production (Kizys et al., 2017). Decreased ROS 
levels have been linked to mitochondrial hyperpolarisation and apoptosis resistance in PH 
PASMCs (Sutendra et al., 2011), whilst autoimmune thyroid disorders have also been detected 
in PAH patients (Scicchitano et al., 2016). Interestingly, Nox4 is also expressed in human 
thyrocytes and is thought to be upregulated in human thyroid tumours (Weyemi et al., 2010), 
thus suggesting that aberrant Nox4 expression might promote thyroid dysfunction in PAH.  
Furthermore, Duox2 dysfunction has been reported in inflammatory bowel disease (Hayes et 
al., 2015), suggesting that reduced DUOX2 expression may promote inflammation. Taken 
together, these findings suggest that the reduced DUOX2 expression observed in BMPR2+/- 
iPSC-SMCs in this thesis study may play an important but yet unknown role in the pathogenesis 
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5.3.4 – Cytokine receptor-like factor 1 (CRLF1) 
 
The CRLF1 gene product cytokine-like factor 1 (CLF1) was originally identified as a protein 
that is secreted in a complex with the IL-6 family member cardiotrophin-like cytokine (CLC) 
(Elson et al., 2000), suggesting that CRLF1 plays a role in inflammatory signalling. CRLF1 has 
also been linked to resistance to oxidative stress (Looyenga et al., 2013), making it tempting to 
speculate that the reduction in CRLF1 expression in BMPR2+/- iPSC-SMCs following exposure 
to serum might correlate with the loss of resistance to oxidative stress in these cells. However, 
further work will be required to determine whether this is indeed the case. 
    
Apart from the potential role of CRLF1 in resistance to oxidative stress (Looyenga et al., 2013), 
increased CRLF1 expression has been detected in a mouse model of idiopathic pulmonary 
fibrosis, where it promoted the accumulation of CD4+ T lymphocytes and reduced pulmonary 
fibrosis (Kass et al., 2012). Increased CLF1 gene expression has also been detected in patients 
with osteoarthritis (Tsuritani et al., 2010) and in a mouse model of cardiac fibrosis (Kim et al., 
2016) where it might also play protective roles. For example, increased CLF1 levels have been 
shown to reduce IL-6 expression in a mouse model of arthritis (Nishimoto, 2006; Chao et al., 
2011). However, it is possible that increased CRLF1 expression might also have detrimental 
effects. For example, increased CRLF1 expression has recently been detected in papillary 
thyroid carcinoma (PTC), where it was associated with poor survival (Yu et al., 2018). 
However, the biological role of CRLF1 in PASMCs is yet to be elucidated.  
 
5.3.5 – Thyroid disorders and PAH  
 
Thyroid disorders involving both increased and decreased thyroid function have been detected 
in PAH patients, but the relationship between thyroid function and PAH pathogenesis is poorly 
understood (Chu et al., 2002; Satoh et al., 2010; Scicchitano et al., 2016). The roles of SST, 
UCP2, DUOX2 and CRLF1 in thyroid function described above, together with their differential 
expression between wild-type and BMPR2+/- iPSC-SMCs, therefore raise the intriguing 
question of whether BMPR2 mutations might promote thyroid dysfunction in PAH. Further 




































6.1 – Summary of findings 
 
Reduced BMPR2 signalling is a central finding in PAH, both in patient samples and in 
preclinical models of the disease (Atkinson et al., 2002). However, given the reduced 
penetrance of BMPR2 mutations in affected families (Newman et al., 2001), a major 
outstanding question is the identities of additional factors or pathways that are responsible for 
the manifestation of clinical disease. The use of vascular cell types derived from iPSCs provides 
a system to identify such factors. Patient-specific iPSC-ECs have previously been shown to 
recapitulate some PAH-associated cellular phenotypes observed in patient-derived PAECs (Gu 
et al., 2017; Sa et al., 2017). However, other PAH-associated phenotypes, such as inner 
mitochondrial membrane hyperpolarisation, could not be recapitulated. Furthermore, no iPSC-
SMC model of PAH has previously been described. This thesis study addresses these issues. 
 
This investigation describes the first iPSC-SMC model of PAH associated with BMPR2 
mutations and supports the hypothesis that the introduction of a single BMPR2 mutation is 
necessary and sufficient to establish some but not all PAH-associated cellular phenotypes in 
iPSC-SMCs. By generating wild-type and BMPR2+/- iPSC-SMC lines with isogenic 
backgrounds that could be used as surrogates for distal PASMCs, it was possible to show that 
the introduction of a single BMPR2 mutation in iPSC-SMCs was necessary and sufficient to 
recapitulate the pro-proliferative and anti-apoptotic phenotype of PAH patient-derived 
PASMCs. However, additional exposure to serum and/or TNFα was required to recapitulate 
the mitochondrial hyperpolarisation phenotype of PAH-derived PASMCs, thus suggesting a 
potential mechanism through which inflammatory stimuli such as TNFα might influence 
disease penetrance in BMPR2 mutation carriers. Furthermore, BMPR2+/- iPSC-SMCs cultured 
in serum demonstrated prolonged hyperpolarisation despite withdrawal of TNFα, suggesting 
that transient exposure to an inflammatory stimulus may be sufficient to drive disease 
progression in a BMPR2 mutation carrier.  
 
Another important observation in this study was that increased proliferation, IL-6 mRNA 
expression and reduced apoptosis were more pronounced in BMPR2+/- iPSC-SMCs 
differentiated in the presence of exogenous BMP4 (herein referred to as PTB) compared to 
iPSC-SMCs differentiated according to the protocol described by Cheung et al. (2012). These 
findings suggest that differentiation in PTB represents a refinement of the LM-iPSC-SMC 
differentiation protocol in terms of its ability to generate cells that can be used as surrogates for 
distal PASMCs when studying PAH. Although the reason for this is unclear, the observation 
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that BMP4 is highly expressed in the distal region of the lung bud during development (Bellusci 
et al., 1996) suggests that addition of BMP4 during differentiation might promote the 
acquisition of a distal cell fate in LM-iPSC-SMCs. 
 
In addition, this study also revealed that BMPR2+/- iPSC-SMCs have an altered differentiation 
state and are less contractile compared to wild-type iPSC-SMCs – phenotypes which have not 
previously been observed in PAH-derived PASMCs. Finally, RNA-Seq analysis of wild-type 
and BMPR2+/- iPSC-SMCs identified that genes encoding somatostatin (SST), mitochondrial 
uncoupling protein 2 (UCP2), dual oxidase 2 (DUOX2) and cytokine receptor-like factor 1 
(CRLF1) were differentially expressed between wild-type and BMPR2+/- iPSC-SMCs. 
Although somatostatin has previously been reported to reduce smooth muscle cell proliferation 
(Leszczynski et al., 1993; Lauder et al., 1997; Zhao & Foegh, 1997;), somatostatin and its 
analogues octreotide, lanreotide and CH-275 had no significant effect on the proliferation of 
iPSC-SMCs or PASMCs in this thesis study, possibly due to the large variation in the 
experimental results and the low number of experimental replicates. 
 
6.2 – Advantages and limitations of the iPSC-SMC model to study PAH 
 
An important observation in this study was the reduced variability between experiments in 
isogenic cell lines, which contrasted with the results obtained when comparing wild-type and 
patient-derived BMPR2+/- iPSC-SMCs.  The variability between patient-derived cell lines is 
challenging and would require large numbers of lines from different patients to detect robust 
differences. This might be a possible reason why a previous study using patient-derived iPSC-
ECs (Sa et al., 2017) could not recapitulate all PAH-associated phenotypes, thus highlighting a 
major advantage of using iPSC lines with an isogenic background to determine the impact of 
specific mutations. 
 
Furthermore, the iPSC-SMC model described in this study raises a number of interesting 
questions. For example, we still do not know the precise molecular mechanism through which 
BMPR2 mutations, either alone or via interaction with genetic, epigenetic or environmental 
factors, lead to the acquisition of PAH-associated cellular phenotypes. To this end, RNA-Seq 
differential gene expression analysis of iPSC-SMCs cultured under either serum-free or serum-
containing conditions and in the presence or absence of TNFα may reveal genes and molecular 
pathways implicated in the acquisition of a hyperpolarised IMM state. This analysis, together 
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with RNA-Seq differential gene expression analysis of wild-type and BMPR2+/- PASMCs, is 
currently underway.  
 
In addition, although this study showed that BMPR2+/- iPSC-SMCs display significantly 
increased IL-6 mRNA expression compared to wild-type iPSC-SMCs differentiated in PTB, 
IL-6 expression was not analysed at the protein level. An enzyme-linked immunosorbent assay 
(ELISA) could therefore be performed to determine whether BMPR2+/- iPSC-SMCs also 
display significantly increased IL-6 expression at the protein level. 
 
Similarly, whilst the differential expression of SST, DUOX2, UCP2 and CRLF1 was validated 
by qPCR in both iPSC-SMCs and in the lungs of Bmpr2+/R899X mice, this study did not 
determine whether the differential expression of these genes is reflected at the protein level. 
Furthermore, the low number of iPSC-SMC lines submitted for RNA sequencing meant that 
only a very limited number of genes were found to be differentially expressed after performing 
false discovery rate analysis to adjust for multiple comparisons. Analysis of a larger number of 
different wild-type and BMPR2+/- iPSC-SMCs lines might have uncovered additional 
differentially expressed genes.   
 
Finally, the validity of the findings presented in this study could be strengthened by performing 
the reverse experiment in which genome editing is used to correct a BMPR2 mutation to 
determine whether this reverses PAH-associated cellular phenotypes in iPSC-SMCs. It would 
also have been desirable to introduce the W9X mutation into an additional wild-type iPSC line 
to determine whether the contribution of BMPR2 mutation to PAH-associated phenotypes can 
be replicated in an independent cell line. Alternatively, CRISPR-Cas9 gene editing could be 
used to repair the W9X mutation to determine whether this reverses the PAH-associated cellular 
phenotypes observed in this thesis study. In addition, whilst the W9X mutation results the 
insertion of a premature stop codon and hence the production of a truncated protein, missense 
mutations in BMPR2 (eg C118W) which impair BMPR2 trafficking to the plasma membrane 
(Sobolewski et al., 2008) could be introduced in order to determine whether the findings 
presented in this study apply to different types of BMPR2 mutation. Furthermore, screening for 
potential CRISPR-Cas9-mediated off-target effects or single nucleotide variations which may 
spontaneously occur in culture (reviewed in Musunuru et al., 2018) could also be performed to 
limit the possible number of confounders. 
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6.3 – Conclusions and future directions 
 
In conclusion, this study characterises the first iPSC-SMC model of PAH and elucidates the 
role of BMPR2 in establishing PAH-associated phenotypes in iPSC-derived SMCs. It also 
provides new insights into factors that might influence disease penetrance in BMPR2 mutation 
carriers and the mechanisms by which these influence cell phenotypes, through alterations in 
mitochondrial membrane polarisation. This study also revealed that BMPR2+/- iPSC-SMCs 
have an altered differentiation state and are less contractile compared to wild-type iPSC-SMCs 
– phenotypes which have not previously been observed in PAH-derived PASMCs. 
Furthermore, RNA-Seq analysis of wild-type and BMPR2+/- iPSC-SMCs identified several 
novel genes that are differentially expressed between wild-type and BMPR2+/- iPSC-SMCs. 
 
However, further work will be required to elucidate the precise molecular mechanisms through 
which BMPR2 mutations interact with genetic, epigenetic or environmental factors to cause 
PAH establishment and progression. For example, this study could be extended to investigate 
whether any of the phenotypes described in this study are also present in iPSC-SMCs derived 
from unaffected BMPR2 mutation carriers and idiopathic PAH patients. Furthermore, 
comparisons between male and female BMPR2 mutation carriers with or without PAH could 
also be performed in an attempt to provide insights into why PAH predominantly affects women 
but is associated with reduced survival in male BMPR2 mutation carriers (Hatton & Ryan, 2014; 
Jacobs et al., 2014). Future studies could also focus on developing iPSC-SMC and iPSC-EC 
models of other forms of pulmonary hypertension by examining the role of factors such as 
hypoxia. The importance of this is highlighted by the fact that whilst there are several clinically- 
approved therapies for the management of Group 1 PAH (Lau et al., 2017), there are currently 
no approved drugs for treating most other types of pulmonary hypertension, with Group 2 PH 
being the most common form of pulmonary hypertension worldwide (Lam et al., 2009; Strange 
et al., 2012).  
   
Together with the iPSC-derived endothelial cells generated in our group (Kiskin et al., 2018), 
patient-derived iPSC-SMCs hold great promise for drug screening and precision medicine. For 
example, iPSC disease models might be able to identify drug-responsive patient subgroups 
which should improve the quality of clinical trials (Inoue et al., 2014). Furthermore, patient-
derived iPSC-lines could be used to test the efficacy of several drugs, thus enabling the most 
appropriate medication to be chosen for a particular patient rather than determining the 
effectiveness of prescribed medications in patients by trial and error (Chen et al., 2016). 
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In addition, preclinical studies rely on prospective treatments being tested in animal models 
which do not fully recapitulate the disease pathology observed in humans. By contrast, iPSCs 
are genetically matched to the person from whom they were derived, whilst at the same time 
being stripped of epigenetic changes that are acquired during a person’s lifetime and which 
might confound the phenotypes being studied. This makes iPSC-derived cells especially useful 
for modelling complex diseases such PAH which are caused by a combination of multiple 
genetic and environmental factors.  
 
Wild-type and both patient-derived and isogenic BMPR2+/-  iPSC-SMCs and iPSC-ECs could 
be used to test whether therapeutic interventions aimed at restoring BMPR2 signalling reverse 
the PAH-associated phenotypes described in this study. Such drug screening candidates could 
include (i) the immunosuppressant FK506 (tacrolimus), which activates BMPR2 by binding to 
the BMP inhibitor FK506-binding protein-12 (FKBP12) (Spiekerkoetter et al., 2013), (ii) the 
lysosomal inhibitor hydroxychloroquine, which promotes BMPR2 trafficking to the cell surface 
(Dunmore et al., 2013), and (iii) ataluren, a drug that promotes ribosomal read-through of 
premature stop codons (Drake et al., 2013). The effect of metabolic modulators such as 
dichloroacetate or peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists such 
as rosiglitazone, which reverse PAH in animal models (McMurtry et al., 2004; Nisbet et al., 
2010), could also be tested. However, since PAH is associated with multiple metabolic 
abnormalities beyond aerobic glycolysis (referred to as the ‘Warburg effect’) (D’Alessandro et 
al., 2018), it is likely that multiple signalling pathways might need to be targeted at the same 
time in order to achieve a robust clinical response. 
   
In future studies, iPSC-SMCs could also be generated from PAH patients with mutations in 
other PAH-associated genes, thus extending the study of PAH-associated phenotypes to a 
broader patient population. Furthermore, iPSC-SMCs could be co-cultured with iPSC-ECs or 
combined with adult pulmonary vascular cells in organoid or artery-on-a-chip setups for a more 
comprehensive evaluation of PAH-associated phenotypes in a setting that more closely 
resembles in vivo conditions. In summary, the iPSC-SMC model of PAH described in this study 
will be useful for identifying novel druggable targets that could be used to develop novel 
therapeutic interventions that are desperately needed to treat this devastating and deadly 
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